INDEX TO VOLUME 60—1992

AUTHOR INDEX

Original articles are indicated by (O), editorials (E), correspondence (C), news and notes (N), obituaries (Ob), abstracts (A), book reviews (B), and special section (SS).

Abalos, R. M., (A) 727
Abbot, N. C., (O) 580
Abdel-Hamid, M. E., (A) 500
Abe, C., (A) 330
Abe, H. R., (A) 118
Abe, M., (A) 692
Abebe, M., (A) 129, 499
Abel, K., (A) 715
Abou-Zeid, C., (A) 312, 682
Abraham, I., (A) 502, (O) 549
Abrams, J. S., (A) 137, 680, 725
Abreu, C. M., (A) 504
Abreu, E. G., (A) 508
Abreu, P. R., (A) 504
Acharyulu, G. S., (A) 519
Achenbach, R. E., (A) 124
Adams, E., (A) 136
Adams, L. B., (A) 130, 137
Adeleye, T. A., (A) 679
Agnihotri, N., (A) 511
Aguas, A. P., (A) 152
Aguirre-Negrete, M. G., (A) 119
Ahaley, S. K., (A) 298
Ahrens, P., (A) 315
Aisu, T. O., (A) 325
Al-Majed, S. A., (A) 125
Ala, J., (C) 655
Alberti, K. G. M. M., (A) 158
Alexandrova, A. E., (A) 151
Ali, M. A. M., (A) 297
Alland, D., (A) 305
Allen, B., (A) 709
Allen, S., (A) 696
Almeida, E. C. C., (A) 136
Almeida, J. G., (C) 81, (E) 255
Almodovar, P. I., (A) 147
Altamirano, M., (A) 695
Altamonte, V., (A) 330
Alugupalli, S., (A) 689
Alvardo, M., (A) 298
Alvarenga, A. E., (O) 570
Alvarenga, F. B. F., (A) 681
Ames, E. D., (A) 328
Amicosante, G., (A) 700
Anandan, D., (C) 84, (A) 302, 510
Anantharaman, D. S., (O) 54, 340
Anderson, B., (A) 707
Antia, N. H., (C) 483
Appa Rao, A. V. N., (E) 269
Appelberg, R., (A) 313, 679
Arala-Chaves, M., (A) 155
Arantes, S. C. de F., (O) 273
Aranzazu, N., (O) 189
Arnaud, J. P., (A) 499
Arnoldi, J., (A) 689
Arns, P. A., (A) 676
Arora, S. K., (A) 504
Ashbridge, K. R., (A) 314
Atrat, P., (A) 314
Awofeso, N., (A) 498
Ayliffe, P. R., (E) 451
Azouaou, N., (A) 715

Bachelet, M., (A) 681, 685
Baciewicz, A. M., (A) 295
Backstrom, B. T., (A) 314
Baconcini, C., (A) 125
Baensky, A. V., (A) 131
Baer, H. H., (A) 702
Baganha, M. F., (A) 299
Baigrie, C., (A) 704
Bailey, C. C., (A) 156
Bajardi, A. C., (A) 305
Balakrishnan, S., (A) 503
Balina, L. M., (C) 102, (A) 687
Ball, S. F., (A) 129
Band, H., (A) 140
Banerjee, A., (A) 311
Banerjee, B. R., (A) 123
Banerjee, D. K., (A) 144, (O) 410
Baran, R., (A) 127
Barker, J., (A) 134
Barletta, R. G., (A) 309
Barnard, D. L., (A) 156
Barnes, P. F., (A) 300, 315, 680
Barreau, C., (A) 691
Barrera, L., (A) 702
Barrett, M. S., (A) 315
Barrios, C., (A) 695
Barritault, L., (A) 504
Barry, T., (A) 698
Basak, P., (A) 501
Baslas, R. G., (A) 504
Basten, A., (A) 132, 136, 302, (O) 353
Basu, J., (A) 690
Battesti, J. P., (A) 697
Batungwanayo, J., (A) 696
Baumgart, K., (O) 353

Bech-Nielsen, S., (A) 315
Bechelli, L. M., (A) 132
Beck, J. S., (A) 325, (O) 580
Becx-Bleumink, M., (O) 161, 173, 421, 436
Beer, V., (A) 697
Behrens, R., (A) 141
Bekelie, S., (A) 514, 690
Ben-Zvi, A., (A) 154
Bennett, P. J., (O) 580
Bera, A., (A) 311
Bergeron, C., (A) 125
Berg Jorgensen, J., (A) 315
Berhan, T. Y., (A) 510
Berhe, D., (O) 173
Berlie, H.-C., (A) 153, (O) 208
Bernheimer, H., (A) 301
Bernstein, R. M., (A) 683
Beschorner, W. E., (A) 330
Besra, G. S., (A) 696
Bessis, D., (A) 518
Bessuille, E. T., (A) 695
Bevec, D., (A) 301
Bhardwaj, N., (A) 684
Bhatawdekar, M., (A) 678
Bhatia, V. N., (C) 84, (A) 142, 302, 310
Bhattacharya, S. N., (A) 138
Bhave, A., (A) 678
Bhoopat, L., (A) 510
Bhore, C. P., (A) 294
Bhore, P. D., (A) 294
Bhushnurmath, S. R., (A) 135
Bilbe, G., (A) 125
Biswas, A. N., (A) 296, 513
Black, W. A., (A) 695
Blaih, S. M., (A) 500
Blanchard, D. K., (A) 325, 680
Blanco, M. L., (A) 677
Bliss, L., (A) 307
Bloemhoff, W., (C) 304
Bloom, B. R., (A) 130, 137, 141, 300, 301, 305, 309, 310, 315, 724
Bobbaers, H., (A) 125
Bocart, D., (A) 697
Bocherding, S. M., (A) 295
Boerrigter, G., (C) 656
Bogaerts, J., (A) 696
Bollet, C., (A) 701
Booth, S. A., (A) 294
Bost, S., (A) 697
Bothamley, G., (A) 682
Bottasso, O., (A) 303
Bottger, E. C., (A) 689, 697
Boulouis, H. J., (A) 703
Bourland, J., (A) 502
Boutin, J.-P., (A) 131, (O) 416
Bovin, N. V., (O) 575
Bowden, R. E. M., (A) 506
Braga, F. J. H. N., (A) 504
Bramhne, H. G., (A) 506
Branch, R. A., (A) 676, 676
Brau, N., (A) 324
Breiman, R. F., (A) 694
Brennan, P. J., (C) 96, (A) 130, 143, 159, 300, 305, 315, 317, 317, 319, 328, 680, 696, 715, 723
Brett, S. J., (A) 325
Britton, W. J., (O) 36, (A) 128, 134, 136, (O) 201, (A) 302, 686
Brown, B. A., (A) 316, 707
Brown, E. L., (A) 702
Brown, P., (O) 353
Bruneteau, M., (A) 512
Buck, G. E., (A) 316
Bullington, R. H., (A) 317
Bulmer, K., (A) 312
Burgarelli, M. K. N., (O) 273
Burkhardt, R., (A) 134
Burt, A. D., (A) 699
Buschman, E., (A) 138
Buseva, T. A., (A) 152
Butany, J. W., (A) 125
Butcher, P. D., (A) 144, 327
Butler, B., (A) 309
Butler, R., (A) 679
Butler, W. R., (A) 704
Butlin, C. R., (O) 580
Butlin, R., (A) 301
Byrd, L. T., (A) 703
Byrd, S., (A) 500

Caccamo, F., (A) 699
Cal, S. X., (A) 703
Campbell, G., (A) 680
Camps, I. R., (A) 324
Cant, A. J., (A) 699
Capra, J. D., (A) 684
Carayon, A., (A) 150
Carmargo, E. E., (A) 504
Carrazana Hernandez, G. B., (A) 120
Cartel, J.-L., (A) 131, (O) 416
Cash, R. A., (A) 129
Castano Hernandez, S. T., (A) 120
Castro, A. G., (A) 152
Causey, D. M., (A) 450
Cauthen, G. M., (A) 322
Cave, M. D., (A) 709
Cellona, R. V., (A) 307, 507, 727
Chaicumpar, K., (A) 723
Chaing, T. J., (A) 683
Chakrabarti, P., (A) 690
Chakrabarty, A. K., (O) 404
Chan, G. P., (A) 507, 715, 716
Chan, J., (A) 130, 310
Chandrasekhar, S., (A) 152
Chang, H. R., (A) 697
Chansin, R., (O) 1
Chanteau, S., (O) 1, (A) 131, (O) 416
Charvin, M., (A) 327
Chatterjee, B. R., (C) 82, 271
Chatterjee, D., (A) 300, 317, 317, 319, 680

Chattopadhya, D., (O) 404
Chattopadhyay, R., (A) 690
Chaturvedi, R. M., (A) 294, 677
Chaturvedi, V., (O) 396
Chaudhary, S. D., (A) 138
Chaudhry, A., (A) 138
Chauhan, S. L., (A) 505
Chehl, S. K., (A) 501
Chen, H., (O) 250
Chen, J., (A) 505
Chen, K. T. K., (A) 318
Chen, L.-F., *et al.*, (A) 120
Chen, X.-S., *et al.*, (A) 695
Cheng, K. P., (A) 322
Cheung, W. C., (A) 322
Chevallard, A., (A) 150
Chevret, S., (A) 153
Chiang, T. J., (O) 368
Chin-A-Lien, R., (A) 507
Chiplunkar, S. V., (O) 44, (A) 301
Cho, S.-N., (C) 96, (A) 307, 507, 727
Chopra, I., (A) 700
Chouela, E., (C) 102
Chugh, K. S., (A) 135, (O) 185
Chugh, S., (A) 146
Chujor, C. S. N., (A) 301
Chukanov, V. I., (A) 131
Clark-Curtiss, J. E., (A) 312
Clasper, S., (A) 143
Clavel-Seres, S., (A) 321
Clayberger, C., (A) 137
Clayton, F., (A) 328
Cocito, C., (A) 322, 512
Coddy-Zitsamele, R., (A) 148
Coghill, G., (A) 325
Cohn, Z. A., (A) 131, 134, 134
Cole, S. T., (A) 142, 709
Coleman, M. D., (A) 295, 295
Collins, F. M., (A) 320, 321, 322
Colston, M. J., (A) 309, 511, 513, 679, 690
Colvin, O. M., (A) 330
Comstock, R. D., (A) 683
Content, J., (A) 153
Convit, J., (A) 137, (O) 189, (A) 301, 305
Coombs, D. W., (A) 505
Coppes, M. J., (A) 318
Corcos, M. G., (C) 659
Cordeiro, A. J. A. R., (A) 299
Corio, R. L., (A) 330
Cormican, M. G., (A) 698
Cornelisse, Y. E., (A) 312, 507
Corner, L. A., (A) 319, 708
Cosgriff, L., (A) 156
Costa, M. F. de A., (C) 87, (O) 208
Costantino, P., (A) 695
Costopoulos, C., (A) 319
Cottenot, F., (A) 148
Courtright, P., (A) 504
Cov, J. C., (A) 708
Cox, N. L., (A) 318
Cree, I. A., (A) 680
Crook, N., (A) 147
Cruaud, P., (C) 87, (O) 208, 376
Curtis, J., (A) 512
Cynamon, M. H., (A) 698

D'Hoop, M. H., (A) 159
Daffe, M., (A) 143, (C) 310, (A) 703
Dahl, M. V., (A) 294
Dale, J. W., (A) 312
Damasco, M. H. S., (A) 681
Dandekar, S. R., (C) 488
Dandurand, M., (A) 518
Daniel, T. M., (A) 325
Dann, F. J.. (O) 8
Darvin, A. C., (A) 506
Das, B. N., (A) 311
Das, K. K., (A) 498
Das, M., (A) 311
Das, P. K., (A) 137, 685
Daud, A., (O) 368
Daugelat, S., (A) 698
Dautzenberg, B., (A) 153
Dave, S., (A) 498
Davenport, M. P., (A) 302
David, H. L., (C) 87, (O) 208, (A) 321, 326, (O) 376, (A) 703
David, M., (A) 154
Davidson, S. K., (O) 195
Dayal, R., (A) 693
Dayanghirang, A. J., (A) 722
da Silva e Gonçalves, N. N., (A) 148
Deans, R. J., (A) 140, 141
DeBracco, M. M. D., (A) 687
Debruyn, J., (A) 682, 688
DeFaria, C. R., (A) 125
Degrave, W. M., (A) 691
Delabarrera, S., (A) 687
Delabie, J., (A) 125
Delalla, R., (A) 699
Delamballerie, X., (A) 701
Delaporte, E., (A) 688
Delassence, A., (A) 697
Delgiudice, G., (A) 695
Delisle, G. W., (A) 708
Del Portillo, P., (A) 154
Demicco, P., (A) 701
Deming, A. T., (A) 145, 515
Denis, F., (A) 129
Denis, M., (A) 302, 311, 318
Denner, J. C., (A) 319, 328
Deo, M. G., (O) 44, (A) 301
Deplus, S., (A) 129
Desai, A., (A) 151
Desfontaine, M., (A) 148
Deshpande, R. G., (O) 195, 382
Desikan, K. V., (C) 94, (Ob) 108, (A) 504
Desmet, V. J., (A) 125
Desousa, J. P. C., (A) 681, 685
Despande, R. G., (A) 681

Deusch, K., (A) 307
Devasundaram, J. K., (C) 91
Develoux, M., (A) 688
Dewit, T. F. R., (A) 690
DeWitte, K., (A) 708
de Andrade, A. L. S. S., (O) 335
de Blaquiere, G., (A) 512
De Britto, J., (O) 340
De Bruyn, J., (A) 153
de Chastellier, C., (A) 323
De Cock, M., (A) 159
de Kantor, I. N., (A) 702
De la Cuvellerie, A., (A) 153
De Miranda, A. B., (A) 691
de Rosas, V., (A) 316
de Vries, R. R. P., (A) 131, 133, (C) 304, (A) 312
De Wit, L., (A) 153
De Wolf-Peeters, C., (A) 125
Dhandayuthapani, S., (C) 84, (A) 302
Dhillon, J., (A) 319
Dhople, A. M., (A) 121, (O) 244
Dhote, R., (A) 696
Dieye, A., (O) 225, (A) 305
Diez, A., (A) 124
Dinhxuan, A. T., (A) 705
Dixit, V., (A) 138
Di Fabio, N., (A) 124
Djeu, J. Y., (A) 325, 680
Dockrell, H. M., (O) 368, (A) 683
Dong, L., (A) 505
Dooley, S. W., Jr., (A) 322
Doongaji, D. R., (A) 678
Dorozhkova, I. R., (A) 331
Dorsch, M., (A) 704
dos Santos, R. P., (O) 273
Douglas, J. T., (A) 510
Dovgalyuk, I. F., (A) 329
Drain, V., (A) 145, 515
Drevet, D., (A) 148
Drijfhout, J.-W., (A) 514, 690
Drowart, A., (A) 159, 688
Dubois, R. E. (A) 156
Duchrow, M., (A) 689
Dudeck, U., (A) 126
Durgambal, K., (A) 147
Dutta, A., (A) 127
du Toit, R., (A) 329
Dwyer, B., (A) 157
Dyachina, M. N., (O) 575

Ebiou, D., (A) 327
Eger, A., (A) 329
Ehrenstein, M., (A) 303
Eiglmeier, K., (A) 142
Eisenach, K. D., (A) 709
Ejigu, M., (A) 510
Ekambaram, V., (A) 127
Ekstedt, J., (A) 499
El-Shiemy, S., (N) 110
Elissen, M. C. C. A., (A) 299
Ellis, D. A., (A) 156
Ellner, J. J., (A) 325, 509
Elmets, C. A., (A) 509
Elsaghier, A., (A) 682, 707
Elson, C. J., (A) 327
England, P. M., (A) 142
Englebretsen, D. R., (A) 314
Epstein, M. L., (A) 699
Eriki, P. P., (A) 325
Ernst, M., (A) 689
Erwin, M. E., (A) 315
Esaguy, N., (A) 152
Escanero, J. F., (A) 677
Esparza, J., (O) 18
Espiritu, C. G., (A) 142
Espitia, C., (A) 303
Estrada-G., I. C. E., (O) 18, (A) 690
Estrada-Parra, S., (O) 18
Evans, R., (A) 702

Faber, W. R., (A) 507, 685
Fajardo, T. T., Jr., (A) 307, 507, 727
Falconi, E., (A) 144
Falkinham, J. O., (A) 325
Falkinham, J. O., III, (A) 323
Falla, J. C., (A) 154
Fan, X.-D., (A) 130, 305
Fann, S. A., (A) 156, 320
Farmer, E. R., (A) 330
Fattorini, L., (A) 699, 700
Feige, U., (A) 331
Feld, N. C., (A) 315
Feng, Z. H., (A) 682
Fernandes, R., (A) 678
Ferreira, M. S., (O) 273
Ferreira, P., (A) 155
Fifis, T., (A) 319, 708
Figueiredo, J. F. A., (A) 700
Figueroa, J., (A) 147
Filley, E. A., (A) 132
Fine, P. E. M., (E) 71, (A) 307
Fischer, H. P., (A) 700
Flad, H. D., (A) 689
Flageul, B., (A) 129
Flaherty, D., (A) 156
Fleming, C. M., (A) 676, 676
Flesch, I. E. A., (A) 132
Fleury, R. N., (C) 283
Flomenberg, P., (A) 324
Flory, C. M., (A) 320, 321, 322
Flynn, J., (A) 698
Fong, S.-J., (A) 315
Font, R. L., (A) 317
Forero, J., (A) 154
Forre, O., (A) 684
Forsgren, L., (A) 499
Forster, D. J., (A) 450
Foss, N. T., (A) 132
Fournie, J.-J., (A) 132, (O) 353, (A) 706
Franceschini, N., (A) 700

Francis, B., (A) 708
Franco, L. C., (A) 154
Frankel, R. I., (O) 8
Franzblau, S. G., (A) 130, 137, 296, 513, 715
Frehel, C., (A) 323
Friedericks, R. C., (A) 118
Frist, T. F., (B) 491
Fritschi, E., (Ob) 109
Frommel, D., (A) 129, 313, 515
Fuente, T. G., (A) 324
Fujii, K., (A) 297
Fujiwara, T., (A) 155
Fukasawa, Y., (A) 330
Fukuda, K., (A) 500
Funada, J., (A) 701
Furuta, M., (A) 299

Gaastra, W., (A) 329
Galal, S. M., (A) 500
Gambini, D. J., (A) 504
Ganapati, R., (N) 111, (O) 250, (C) 488, (A) 516
Gangal, S., (O) 44
Gangal, S. G., (A) 301
Ganguly, N. K., (A) 135, 146, 511
Gannon, F., (A) 698
Garbe, T., (A) 312
Garbe, T. R., (A) 145
Gardner, G. D., (A) 121
Garrelts, J. C., (A) 121
Garsia, R. J., (A) 136
Gasser, J., (A) 331
Gatrill, A. J., (A) 133
Gebre-Mariam, A., (A) 499
Gelas, H., (A) 148
Gelber, R. H., (C) 96, (A) 121, 142, (C) 276, (A) 303, (C) 485, (A) 500, 505, 715
Geluk, A., (C) 304
Gerdes, J., (A) 689
Gershon, W., (A) 517
Gevandan, M. J., (A) 701
Ghadirian, E., (A) 318
Gheorghium, M., (A) 323
Gidlund, M., (A) 507
Gidoh, M., (A) 501
Gilbody, J. S., (E) 608
Gillis, T. P., (A) 145, 514, 715, 716
Girdhar, A., (A) 126, 505
Girdhar, B. K., (C) 94, (A) 126, (C) 280, (A) 505, (O) 562
Gittens, C., (A) 499
Glaziou, P., (O) 1, 416
Godfrey, H. P., (A) 682
Gold, R., (A) 318
Goldstein, H., (A) 137
Gomes, H. M., (A) 136
Goncalves, A., (A) 148
Gonzalez, P. C., (A) 708
Gonzalez-Amaro, R., (A) 303
Goodman, D. D., (N) 291, 674
Gordin, F. M., (A) 156
Goren, M. B., (O) 376, (A) 702
Gormus, B. J., (SS) 477
Gosselin, D., (A) 701
Goto, M., (A) 718
Goulart, I. M. B., (O) 273
Grange, J. M., (O) 580
Graninger, W., (A) 126
Grant, A., (A) 325
Grau, G. C., (A) 324
Grau, G. E., (A) 306
Grisso, C. L., (A) 305
Groenen, G., (A) 502
Gros, P., (A) 138
Gros de Beier, A., (A) 499
Grosset, J.-H., (A) 122, 153, 157, 320, (O) 416, 556, (A) 705
Gruer, P. J. K., (A) 307
Gu, D., (A) 505
Gu, Z., (A) 505
Guebre-Xavier, M., (A) 515
Guengerich, F. P., (A) 676
Guerra, H., (A) 144
Guilhou, J. J., (A) 518
Guillot, B., (A) 518
Guitrau, M., (A) 124
Gulle, H., (O) 44, (A) 326, 698
Gupta, A., (O) 185
Gupta, C. K., (A) 138, 138
Gupta, K. L., (O) 185
Gupta, M., (A) 504
Gupta, R. S. (A) 324
Gupta, S. R., (A) 126
Gupte, M. D., (O) 54, 340, (A) 516
Gutierrez, M. C., (O) 18
Guyatt, G., (A) 297
Guzman, F., (A) 154

Haagsma, J., (A) 329
Haanen, J. B. A. G., (A) 133
Hacker, F., (A) 683
Hadley, W. K., (A) 297, 708
Haile-Mariam, H. S., (A) 510, 515
Hajeer, A. H., (A) 683
Halapi, E., (A) 507
Hall, J. J., (C) 655
Hamada, K., (A) 296, 322
Hamada, S., (A) 158
Hambarde, P. S., (A) 151
Hamono, B., (A) 148
Hance, A. J., (A) 697
Hancock, G. E., (A) 134
Handzel, V., (O) 376, (A) 702
Harada, N., (A) 299, 678
Harboe, M., (A) 304, (SS) 470
Harding, D. R. K., (A) 314
Haring, R. M., (A) 329
Harpham, T., (A) 693
Harris, D. P., (A) 707
Harris, E. B., (A) 296, 514, 515
Hartskeerl, R. A., (A) 309

Hasan, R., (A) 683
Hashimoto, K., (A) 719
Hastings, R. C., (A) 124, 145, 145, 150, 501, 515, (B) 664, (N) 673, 674
Hauhnar, C. Z., (O) 390
Havlik, J. A. (A) 156
Havlik, J. A., Jr., (A) 320
Hayman, J., (A) 321
Hebda, C., (A) 143
Heeg, K., (A) 683
Heifets, L. B., (A) 683, 701
Heijbel, J., (A) 499
Hengy, C., (A) 148
Henry, D., (A) 156
Hermans, P. W. M., (A) 312, 514, 690
Hermon Taylor, J., (A) 705
Hernandez-Pando, R., (A) 303
Herrera, T., (A) 159
Herron, M. J., (A) 294
Hess, A. D., (A) 330
Heym, B., (A) 709
Hibbs, J. B., Jr., (A) 130
Hibino, T., (A) 157
Hidaka, T., (A) 297
Hill, D. A., (A) 677
Hinshelwood, S., (A) 311
Hiroshi, I., (A) 299
Hirschel, B., (A) 697
Hoffman, E., (A) 705
Hoffman, S. L., (A) 680
Hollander, D., (A) 707
Hollenstein, U., (A) 126
Holmgren, G., (A) 499
Honore, N., (A) 142
Hopewell, P. C., (A) 156
Horhold, C., (A) 314
Horsburgh, C. R., Jr., (A) 156, 320
Hosel, P., (A) 314
Hosoe, K., (A) 297
Houghten, R. A., (A) 315
Houssaini-Iraqui, M., (A) 321
Howe, R. C., (A) 313
Howes, M., (A) 318
Hsu-Oyama, N. P. S., (A) 157
Hu, C. Q., (A) 699
Hu, L.-F., *et al.*, (A) 121, 676
Huang, Z. H., (A) 157
Hubbard, R. D., (A) 320, 321, 322
Hubner, L., (A) 689
Hunter, S. W., (A) 130, 305, 317
Husain, S., (A) 126, 151
Hussain, R., (O) 368, (A) 683
Husser, J. A., (O) 542
Huygen, K., (A) 159, 682, 688

Ichiyama, S., (A) 331
Ieven, M., (O) 234
Ikeda, T., (A) 701
Inoue, K., (A) 719
Ip, M., (A) 322
Ipe, I. M. (C) 94
Irgens, L. M., (SS) 466
Isaacs, H. D., (A) 118
Isenberg, D., (A) 141, 303
Ishaque, M., (O) 61, (C) 279, (A) 322, (C) 661
Ishida, S., (A) 296, 322
Ishii, N., (C) 658
Isono, K., (A) 519
Isono, S., (A) 519
Isoprodian Study Group, (O) 536
Ito, M., (A) 701
Ito, T., (A) 701
Ivanova, L. A., (A) 323
Ivanyi, J., (A) 325, 682, 683, 707
Izaki, S., (A) 157
Izumi, S., (A) 302, 718, 719, 719
Izzo, A. A., (A) 507

Jabs, D. A., (A) 330
Jackusch, J. D., (A) 703
Jacobs, W. R., Jr., (A) 309
Jacobson, R. R., (A) 124, 124
Jagga, C. R., (A) 123
Jain, N., (A) 151
Jain, S. K., (C) 98, 100
Jain, V. K., (A) 138
Jamet, P., (O) 234, (C) 482, (O) 542
Jamil, S., (A) 683
Janson, A. A. M., (A) 312, 514, 690
Janssens, L., (A) 502
Jawahar, M. S., (A) 707
Jayapal, V., (A) 143
Jeeravipoolvarn, P., (A) 313
Jeevan, A., (A) 702
Jenkins, P. A., (A) 307
Jenner, P. J., (A) 513, 679
Jereb, J. A., (A) 322
Jha, P. K., (A) 501
Ji, B., (A) 122, 157, 320, (O) 542, 556
Ji, Y.-E., (A) 690
Jin, S. H., (A) 699, 700
Jindal, S., (A) 682
Job, C. K., (A) 134, 145, 145, 150, 515, 515
Joffrion, V. C., (A) 129
Johnson, N. M., (A) 326
Jones, P., (O) 353
Jones, R. N., (A) 315
Jones, S. L., (A) 708
Jordaan, A., (A) 329
Joshi, S., (A) 509
Josse, R., (A) 148
Jotimliansky, L., (C) 102

Kalaivani, S., (A) 147
Kaledin, N. A., (A) 709
Kallenius, G., (A) 705
Kanchana, M. A., (A) 304
Kannan, S., (O) 54, 340
Kaplan, G., (A) 131, 134, 134, 681, 686, 719, 722
Kar, H. K., (O) 28, (A) 130

Kar, P. K., (A) 501
Kartikeyan, S., (A) 294, 677
Kashyap, A., (O) 404, (A) 501
Kato, L., (C) 105, 662
Katoch, K., (A) 127, (O) 562
Katoch, V. M., (A) 513
Kaufmann, S. H. E., (O) 44, (A) 132, 133, 139, 312, 326, 508, 698
Kaur, I., (A) 501, 511
Kaur, S., (A) 135, 146, 313, (O) 390, (A) 511
Kawasumi, H., (A) 139
Kawatsu, K., (A) 719
Kazda, J., (C) 277, (A) 704
Kazeze, (A) 502
Kelly, G. D., (A) 322
Kelly, M. T., (A) 695
Kempsell, K. E., (A) 690
Kennedy, E., (A) 156
Kestens, L., (A) 510
Khan, M. B., (O) 195, 382, (A) 681
Kien, M. C., (C) 102
Kiessling, R., (A) 507
Kifayet, A., (O) 368
Kikuchi, S., (A) 513
Kim, D. D., (A) 309
Kim, D. I., (A) 307
Kim, J.-D., (C) 96, (A) 307, 507, 727
Kim, R., (O) 8
Kim, S., (C) 658
Kim, S.-H., (A) 507
Kimura, H., (A) 678
Kimura, T., (A) 719
Kirschner, P., (A) 697
Kirschner, R. A., Jr., (A) 323
Kishimoto, S., (A) 139
Kitamura, K., (A) 157
Kiyoshi, T., (A) 296
Kjeldsen-Kragh, J., (A) 324, 684
Klatser, P. R., (A) 507
Klemens, S. P., (A) 698
Kloehn, G., (A) 118
Knoring, B. E., (A) 323
Kobayashi, S., (A) 296
Kohli, M., (A) 135, 146
Kohsaka, K., (A) 722, 723
Kojiro, N., (A) 701
Kokubu, T., (A) 701
Kolattukudy, P. E., (A) 513
Kolk, A. H. J., (A) 309, 312
Komatsu, A., (A) 721
Konicek, J., (A) 311
Konickova-Radochova, M., (A) 311
Koontz, F. P., (A) 315
Korre, O. T., (A) 324
Koryakin, V. A., (A) 152
Koseki, M., (C) 658
Kotecha, P., (A) 693
Kraakman, E. M., (A) 133
Krahenbuhl, J. L., (A) 130, 137
Kremsner, P. G., (A) 126
Krieg, S., (A) 685
Kripke, M. L., (A) 702
Krishnamoorthy, P., (A) 127
Krishnan, T. R., (A) 502, (O) 549
Krishna Murthy, P., (A) 299
Kromer, S., (A) 307, 683
Kronenberg, M., (A) 726
Kucherov, A. L., (A) 158
Kudalkar, J. L., (A) 301
Kuhn, B., (A) 301
Kuhn, J., (A) 154
Kumar, A., (A) 147
Kumar, V., (A) 305, 519
Kumaresan, J. A., (A) 150
Kundu, M., (A) 690
Kurunov, V. I., (A) 709
Kusumoto, Y., (A) 158
Kuykens, L., (A) 502
Kyriazopoulou, V., (A) 677

Labrousse, V., (A) 691
Lacave, C., (A) 691
Lacroix, C., (A) 320
Laferte, J., (A) 508
Lagranderie, M., (A) 323
Lakshminarayana, C. S., (A) 304
Lalljee, M., (E) 587
Lalwani, A. K., (A) 505
Lambert, P. H., (A) 695
Lamoureux, L. C., (A) 121, (O) 244
Laneelle, G., (A) 691
Laneelle, M. A., (A) 703
Lanier, J. D., (A) 317
Larssen, L., (A) 689
Laszlo, A., (O) 376, (A) 702, 703
Lathigra, R., (A) 309
Launois, P., (O) 225, (A) 305, 688
Lazraq, R., (A) 321
Lebeaut, A., (A) 705
Lecossier, D., (A) 697
Lee, M.-K., (A) 727
Lefford, M. J., (A) 306
Legris, S., (A) 153
Leiker, D. L., (A) 507
Lemassu, A., (A) 703
Lemieux, S., (A) 701
Lemmer, J., (C) 641
Lennon, J. L., (A) 505
Levin, L. S., (A) 330
Levis, W. R., (A) 301
Levitz, R. E., (A) 677
Levy-Frebault, V. V., (A) 153, (C) 310, (A) 703
Lewallen, S., (A) 504
Lewis, I. J., (A) 156
Li, B., *et al.*, (A) 694
Li, F., (A) 505
Li, S.-G., (A) 324, 684
Li, W., (A) 123
Li, X.-Y., *et al.*, (A) 135
Liippo, K., (A) 692

Lima, L. M., (A) 691
Lima Filho, E. C., (A) 132
Lindholm-Levy, P. J., (A) 683, 701
Liomba, N. G., (A) 307
Lipford, G. B., (A) 307
Litvinov, V. I., (A) 131
Liu, H.-X., (A) 314
Lobao, A. S., (A) 681
Locksley, R. M., (A) 715
Locniskar, M., (A) 141
Longo, I. M., (A) 135
Lopes, V. R., (O) 273
Lou, H.-Y., *et al.*, (A) 296
Louis, J. A., (A) 695
Louis, J. P., (A) 148
Lourduraj, R., (O) 340
Lowell, K., (A) 317
Lowrie, D. B., (A) 511
Lu, S. H., (A) 680
Lu, T.-C., *et al.*, (A) 678
Lubinsky-Mink, S., (A) 154
Lucas, S. B., (A) 136, 307
Luesse, H. G., (C) 277
Lukin, Y. V., (O) 575
Lupatkin, H., (A) 324
Luquin, M., (A) 326
Lussow, A. R., (A) 695
Lweno, H., (A) 158

Macedo, P. M., (A) 152
Machado, A. A., (A) 700
MacLaughlin, P., (A) 125
Maddison, M. C., (A) 318
Maddison, P. J., (A) 318
Maeda, Y., (A) 719
Magliozzo, R. S., (A) 310
Mahadevan, P. R., (A) 509
Mahaisavariya, B., (A) 313
Makino, M., (A) 721
Malaviya, G. N., (A) 126, 151, 305, 505
Malefijt, R. de W., (A) 133
Malin, A. S., (A) 126
Mallet, M. N., (A) 701
Malo, D., (A) 138
Malta, A. M., (A) 686
Mancheril, J., (A) 149
Mancilla, R., (A) 303
Mandler, F., (A) 699
Mandy, K., (A) 682
Mandy, S., (A) 682
Manek, K. P., (A) 149
Mann, S. B. S., (O) 390
Marchoux Chemotherapy Study Group, (O) 525
Marin, D., (A) 144
Maroja, M. de F., (O) 208
Marone, P., (A) 699
Marques, M. A. de M., (A) 136
Marques, M. A. T., (A) 299
Martelli, C. M. T., (O) 335
Martin-Casabona, N., (A) 324
Marty, A. M., (A) 119
Mascellino, M. T., (A) 699
Maserati, R., (A) 699
Mastro, T. D., (A) 694
Mates, S. M., (A) 326
Mathur, D., (C) 98
Mathur, D. C., (C) 100
Mathur, N. K., (C) 98, 100
Matsuo, E., (A) 721
Matsuo, K., (A) 330
Matsuoka, M., (A) 722, 723
May, D. G., (A) 676
Mazurek, G. H., (A) 709
McAdam, K. P. W. J., (A) 141
McAuley, P., (A) 125
McClatchy, J. K., (A) 328
McCormick, B. S., (A) 708
McDermott-Lancaster, R. D., (O) 410
McDonough, C. M., (A) 150
McDougall, A. C., (A) 149
McFadden, J., (A) 142, 308, 326
McGeer, E. G., (A) 678
McGeer, P. L., (A) 678
McKenzie, K. R., (A) 136, 302
McLarty, D. G., (A) 158
McMillen, S., (A) 680
McNeil, M. R., (A) 143, 317, 317, 696
Mdjid, B., (A) 719
Mehra, V., (A) 305, 315
Mehra, V. J., (A) 715
Mehrotra, P. K., (A) 707
Mehta, J. M., (A) 506
Mehta, L. N., (A) 308
Mehta, R. D., (C) 100
Mehta, S., (O) 390
Melville, L., (A) 708
Mendes, N. F., (A) 135
Mendoza, M., (A) 154
Menezes, M., (A) 128
Meng, M.-B., *et al.*, (A) 136
Mercat, A., (A) 153
Merlin, M., (A) 148
Metchock, B., (A) 320
Meyer, H. W., (A) 314
Meyers, W. M., (A) 119, (SS) 477
Meyohas, M.-C., (A) 153
Michel, G., (A) 512
Michelini-Norris, M. B., (A) 325
Mielniczuk, Z., (A) 689
Miko, T. L., (A) 136, 514, 690
Mikolich, D. J., (A) 326
Millan, J., (O) 225, (A) 688
Minagawa, F., (A) 692, 723
Minden, P., (A) 315
Minnucci, F., (C) 102, (A) 687
Mirando, W. S., (A) 509
Mirmaladevi, B., (A) 142
Mishra, B., (O) 396
Misra, R. K., (A) 504
Misra, R. S., (O) 13, 28

Mistry, Y., (A) 684
Mita, R. T., (O) 8
Mitchell, D. N., (A) 325
Mitchell, I. C., (A) 325
Mitchison, D. A., (A) 319
Mittal, A., (C) 98, 100
Mizuguchi, Y., (A) 519
Moad, J., (A) 510
Modlin, R. L., (A) 137, 140, 141, 300, 300, 305, 315, 680, 725, 726
Mohagheghpour, N., (A) 715
Mohamed, A. A. F., (C) 277
Molina, J., (A) 301
Molloy, A., (A) 134, 722
Moloney, B., (O) 353
Monpoint, S., (A) 518
Moody, C. E., (A) 294
Moreau, R., (A) 327
Moreira, A. L., (C) 92, (A) 686
Moreno, C., (A) 707
Morgan, K., (A) 138, 683
Mori, Y., (A) 158
Moriarty, K. M., (A) 328
Morita, C. T., (A) 140
Morris, S. L., (A) 603
Morrissey, A. B., (A) 325
Moss, M. T., (A) 705
Motapinto, A., (A) 299
Moudgil, K. D., (A) 514
Moulia-Pelat, J.-P., (O) 416
Moura, N. C., (A) 135
Mputu, L. B., (A) 502
Msosa, R., (A) 307
Mudd, D., (A) 141
Mugusi, F., (A) 158
Mukherjee, A., (O) 28, (A) 130, 308, 686
Mukherjee, R., (O) 28, (A) 130, 140, 141, 146, 306, 308, 684
Mukhija, R. D., (A) 504
Muliyil, J., (A) 122
Mullins, R. J., (A) 132, (O) 353
Munk, M. E., (A) 133
Murillo, L. A., (A) 154
Murphy, D. T., (A) 709
Murray, L. P., (C) 276, (A) 303, (C) 485, (A) 500, 715

Naafs, B., (A) 507
Nade, A. L., (A) 294
Nagai, S., (A) 304, 682
Nagaraju, B., (O) 340
Naik, S. S., (A) 151, (C) 488
Nair, A., (A) 126
Nair, J., (A) 603
Nair, N. G. K., (A) 148
Nakajima, H., (C) 658
Nakanaga, K., (A) 723
Narayanan, R. B., (A) 305
Narita, M., (C) 658
Nassos, P. S., (A) 708
Natu, M. V., (A) 122
Natvig, J. B., (A) 324, 684
Navalkar, R. G., (O) 195, 382, (A) 681
Navalkar, S. R., (O) 382
Ndosi, B. N., (A) 158
Near, K. A., (A) 306
Nebout, M., (C) 653
Neelan, P. N., (A) 299
Nelson, R. D., (A) 294
Neto, J. C. A., (O) 335
Neupane, K. D., (A) 686
Neway, T., (A) 703
Ng, V. L., (A) 297
Niang, M., (O) 225, (A) 305
Nicolin, R., (A) 699
Nigam, P. K., (A) 126
Nightingale, C. H., (A) 677
Nightingale, S. D., (A) 703
Nishioka, S. de A., (O) 273
Nobrega, R. C., (A) 148
Nobuhara, Y., (A) 718
Nomaguchi, H., (A) 723
Noordeen, S. K., (A) 119, 502, 517
Norfolk, D. R., (A) 156
Norman, E., (A) 312
Noronha, D., (A) 158
North, R. J., (A) 507
Nunes-Araujo, F. R. F., (O) 273

O'Hara, L. C., (A) 316
Obara, A., (A) 299
Oftung, E., (A) 684
Oftung, F., (A) 324
Ogawa, T., (A) 158
Ohmen, J. D., (A) 140, 726
Okoro, A. N., (A) 126
Okuma, M., (A) 157
Olivieri, N. F., (A) 318
Onyi, G. O., (A) 316, 707
Oommen, T., (A) 122
Ooms, J., (A) 153
Opromolla, D. V., (A) 148
Opromolla, F., (A) 135
Orefici, G., (A) 699, 700
Orozco, O., (A) 154
Orpiszewski, J., (A) 143
Orrell, J. M., (A) 325
Ortega, A. R., (A) 506
Osland, A., (A) 514, 690
Osterwalder, W., (O) 250
Ostler, H. B., (A) 142
Ottenhoff, T. H. M., (A) 133, (C) 304, (A) 308, 312, 507
Outman, W. R., (A) 677
Ozawa, T., (A) 692

Padilla-Gutierrez, L., (A) 119
Padovani, C. R., (A) 148
Padovani, S. H. P., (A) 148
Pagnano, P. M. G., (A) 132

Pain, S., (A) 311
Palacios, A., (A) 511
Palande, D. D., (A) 506
Pallangyo, K. J., (A) 158
Palmero, M. H. R., (C) 283
Palomino, J. C., (A) 144
Panayi, G. S., (A) 700
Panchamoorthy, G., (A) 140
Pancholi, P., (A) 684
Pandian, T. D., (A) 122
Pandya, S. S., (C) 488
Pang, Y. J., (A) 709
Papa, F., (O) 208, (A) 324, 326, (O) 376, (A) 703
Papgis, M., (A) 503
Paramasivan, C. N., (A) 519
Pardhy, A., (A) 509
Parida, S. K., (A) 306, 308
Park, B. K., (A) 295
Park, J. Y., (A) 307
Parker, B. C., (A) 323
Parra, C. A., (A) 154
Parrot, R., (A) 705
Parums, D. V., (A) 704
Patarroyo, M. E., (A) 154, 154
Patel, B. K. R., (A) 144
Patel, V. K. R., (A) 327
Pathare, S., (A) 678
Patil, S. A., (A) 127, (C) 280, (O) 562
Patki, A. H., (A) 127, 506
Pattyn, S. R., (A) 149, (O) 234, (C) 482, (A) 502, 502
Paul, J., (A) 704
Pavithran, K., (C) 89, 274, 657
Pavlova, M. V., (A) 323
Paz, C. J., (A) 506
Pe-Than-Myint, (A) 688
Pearson, C. A., (A) 325
Pedrosa, J., (A) 313
Pego, M. A., (A) 299
Peng, J., (A) 505
Peralta, J. M., (A) 136
Perani, E. G., (O) 556
Perez-Stable, E. J., (A) 156
Perez Gallardo, L., (A) 677
Perret, J., (A) 512
Perumal, V. K., (A) 152
Pessolani, M. C. V., (A) 136, 723
Petinon, C., (O) 556
Pfeffer, K., (A) 307, 683
Pilet, C., (A) 703
Pinardi, M. E., (A) 301
Pitout, J., (A) 329
Pitulle, C., (A) 704
Pla, R. V., (A) 324
Plata, J., (A) 301
Plesnila, N., (A) 307
Plichart, R., (O) 416
Plikaytis, B. B., (A) 704
Plikaytis, B. D., (A) 704
Ponnighaus, J. M., (A) 307
Popova, A. G., (A) 709
Porichha, D., (A) 506
Porter, J., (A) 676
Porto, J. A., (A) 681
Possani, L. D., (O) 18
Powar, S., (A) 294
Powls, R., (A) 143
Prabhakar, M. C., (E) 269
Prabhakar, R., (A) 519, 707
Prabhakaran, K., (A) 514
Pradhan, H. M., (A) 134
Prantera, C., (A) 682
Premkumar, R., (A) 498
Prestidge, R. L., (O) 201
Pretet, S., (A) 705
Prowse, M. V., (A) 318
Prussick, R., (A) 297
Pusic, M., (A) 318
Puzo, G., (A) 706

Quayle, A. J., (A) 324, 684
Quemard, A., (A) 691
Quesada-Pascual, F., (O) 18

Rada S., E. M., (O) 189
Radhakrishna, S., (A) 148
Radotra, B. D., (O) 390
Radzioch, D., (A) 138
Raes, V., (O) 234, (C) 482
Rainwater, D. L., (A) 513
Ramakrishnan, R., (A) 148
Ramanathan, U., (A) 151
Ramanathan, V. D., (A) 509
Ramasesh, N., (A) 137
Ramasubban, R., (A) 147
Rambukkana, A., (A) 137, 685
Ramesh, V., (O) 13
Ramirez, M. M., (A) 299
Ramirez-Soltero, S., (A) 119
Ramu, G., (A) 304, 503
Randhawa, B., (A) 514
Rani, R., (A) 308
Rao, N. A., (A) 450
Rao, P. S., (A) 127, 299
Rappuoli, R., (A) 695
Rasouli, I., (A) 308
Rastogi, N., (A) 308, 321, 681, 685, 691
Rathinavel, L., (A) 310
Ratledge, C., (A) 144, 312, 330
Rea, T. H., (A) 140, 141, 300, 305, 500, 725, 726
Redd, S. C., (A) 694
Reddy, B. M., (E) 269
Reddy, B. N., (A) 127, 299
Ree, G. H., (A) 149
Rees, H. H., (A) 143
Rees, R. J. W., (A) 516
Reetha, A. M., (A) 707
Reeve, P. A., (C) 655
Rehman, F., (A) 519
Reid, M., (A) 156
Res, P. C. M., (A) 133

Richards, W. O., (A) 676
Richardson, S. E., (A) 318
Richardus, J. H., (A) 128
Richter, W., (A) 314
Rigoli, R., (A) 699
Rinke de Wit, T. B., (A) 514
Ripper, J. L., (A) 708
Rivier, F., (O) 225
Riviere, M., (A) 706
Rivitti, M. C. M., (A) 504
Rivoire, B., (A) 315, 317, 715
Robaina, R., (A) 508
Roberts, M. M., (A) 126
Robinson, P., (A) 509
Roche, P. W., (O) 36, (A) 128, 134, (O) 201, (A) 686
Rodde, C., (C) 277
Rodrigo, G., (A) 705
Rodrigues, M. L. O., (O) 335
Roman, E., (A) 707
Rook, G. A. W., (A) 132, 327
Rosa, M. A. S., (A) 299
Rosankaimer, F., (A) 681
Rosel, A. S., (A) 506
Rosenthal, D., (A) 297
Ross, B. C., (A) 157
Rothel, J. S., (A) 708
Rotter, J. I., (A) 707
Rouse, D. A., (A) 603
Roux, J.-F., (A) 131, (O) 416
Rumjanek, F. D., (A) 136
Rusch Gerdes, S., (A) 706
Russell, R. M., (A) 295
Ryan, T. J., (A) 708
Ryder, D., (A) 676

Saad, M. H. F., (A) 136
Saboor, S. A., (A) 326
Sabuka, S. R., (A) 158
Sada, E., (A) 159
Saha, K., (A) 123, (O) 404, (A) 501, 686
Saha, S. P., (A) 498
Sahasrabudhe, R. V., (C) 488
Sahu, A., (A) 123, (O) 404, (A) 501, 686
Saito, H., (A) 146, 297, 723
Sakhuja, V., (O) 185
Salafia, A., (A) 128, 129
Salem, J. I., (C) 87, (O) 208
Salfinger, M., (A) 692
Salgado, A., (A) 301
Salgado, J. L., (C) 92
Salgame, P., (A) 137, 300, 724
Samal, R. C., (A) 506
Sambuc, R., (A) 701
Sampaio, E. P., (A) 686
Sampson, C., (A) 301
Samson, P. D., (A) 298, 301, (O) 580
Samy, A. A., (A) 147, 149
Sanchez, R. M., (A) 145, 145, 515
Sanchez-Garcia, J., (A) 688
Sanders, C. A., (A) 708
Sanderson, J. D., (A) 705
Sandler, E. D., (A) 297
Sangal, B. C., (C) 100
Sankaran, K., (A) 707
Santaella, C., (O) 189
Santoro, C., (A) 699
Santos, A. R., (A) 691
Santos, D. O., (C) 92
Santos, G. W., (A) 330
Sardeshmukh, A. S., (A) 298
Sarno, E. N., (C) 92, (A) 136, 681, 686
Sarthou, J.-L., (O) 225, (A) 305
Sasaki, D. T., (A) 715
Sasaki, N., (A) 721
Sasiain, M. del C., (C) 102, (A) 687
Sato, E., (A) 718
Sato, K., (A) 146, 297, 723
Saul, A., (A) 298
Savariar, L. S., (O) 382
Saxena, U., (O) 13
Saylan, T., (A) 126
Scardaci, G., (A) 700
Scarpellini, P., (A) 699
Schaper, K. J., (A) 706
Schecter, G., (A) 156
Scheepers, A., (C) 641
Schluter, C., (A) 689
Schoel, B., (O) 44, (A) 139, 307, 326, 698
Schoningh, R., (A) 312, 514, 690
Schuitema, A., (A) 309
Schulzer, M., (A) 678
Schurr, E., (A) 138
Schwerer, B., (A) 301
Sciutto, E., (A) 303
Scollard, D. M., (A) 510
Sehgal, B. N., (A) 138
Sehgal, P. K., (A) 138
Sehgal, V. N., (A) 123, 138, 501, 686
Seino, M., (A) 296, 322
Sekar, B., (A) 510
Self, T. H., (A) 295
Selvakumar, N., (A) 519
Selvibai, G., (A) 143
Sen, P., (A) 138
Sengupta, U., (A) 127, (C) 280, (A) 304, (O) 340, 396, 562
Sequeira, A., (C) 488
Seydel, J. K., (A) 706
Shah, A., (O) 250
Shah, D. H., (C) 488
Shah, J. K., (A) 129
Shah, Y., (A) 138
Shanmugasundaram, N., (A) 143
Shannon, E. J., (A) 510, 515
Sharma, A. K., (O) 28, (A) 130
Sharma, V. K., (A) 135, 138, 138, 146, 313, (O) 390, (A) 501, 511
Sharmila, K. M., (A) 143
Sharrock, C. E. M., (A) 700
Shchegoleva, R. A., (A) 151

Shcherbakova, N. M., (A) 151
Shehade, S. A., (A) 126
Shen, Y., (A) 324
Shereef, P. H., (A) 511
Sheth, A., (A) 678
Shetty, P. C., (C) 483
Shi, M., (A) 123
Shimoda, H., (A) 157
Shimokata, K., (A) 331
Shinnick, T. M., (A) 684, 704
Shiratsuchi, H., (A) 509
Shivraj, L., (C) 280
Shu, H.-W., *et al.,* (A) 139, 687
Sibille, G., (A) 499
Siddhartha, S., (A) 678
Sieling, P. A., (A) 305, 725
Sikka, R., (A) 138
Silcox, V. A., (A) 704
Silva, C. L., (A) 511
Silva, I. M., (A) 125
Silva, J., (A) 301
Silva, M. T., (A) 152
Silva, S. A., (O) 335
Sima, A., (A) 148
Simberkoff, M. S., (A) 324
Singh, B., (A) 147
Singh, I. G., (A) 146
Singh, N., (A) 327
Singh, U., (A) 138
Sinha, S., (A) 304, (O) 396, (A) 515
Sioud, M., (A) 684
Sirichativapee, V., (A) 313
Sirumban, P., (A) 147
Siu, P., (C) 276, (A) 303, (C) 485, (A) 500, 715
Skamene, E., (A) 138
Skinsnes, O. K., (A) 721
Skurnik, M., (A) 692
Slosarek, M., (A) 311
Small, K., (A) 708
Smid, I., (A) 692
Smith, J. A., (A) 695
Smith, K. A., (A) 134
Smith, K. D., (A) 722
Smith, P. G., (A) 301, 517
Smith, T. C., (A) 128
Snapper, S. B., (A) 309
Snehi, P. S., (A) 501
Snider, D. E., Jr., (A) 322
Soares, R., (A) 155
Soini, H., (A) 692
Sokai, K., (A) 299
Soria, H., (A) 677
Southern, P. M., (A) 703
Spindler, E., (A) 129
Spits, H., (A) 133
Sramek, H. A., (A) 330, 707
Sreenivas, V., (A) 148
Sreevatsa, (C) 94, (A) 126, 127
Srinivasan, G. R., (A) 517
Saheer, S. A., (O) 28, (A) 130, 141, 306, 308
Stackebrandt, E., (A) 704
Stanford, J. L., (A) 327, 688
Stead, W. W., (A) 706
Steingrube, V. A., (A) 298
Steinhoff, U., (A) 139
Steinman, R. M., (A) 684
Sterne, J. A. C., (A) 307
Sticht-Groh, V., (O) 570
Stoker, N. G., (A) 311, (O) 368, (A) 688
Storrs, E. E., (O) 244
Strobel, M., (A) 499
Subramanian, M., (A) 299
Subramanian, S., (A) 143
Suffys, P. N., (A) 691
Sugita, Y., (C) 658
Suissa, M., (A) 154
Suite, M., (A) 499
Sumiishi, A., (A) 721
Summersgill, J. T., (A) 316
Sun, H.-T., *et al.,* (A) 150
Suresh, N. R., (A) 130, 141, 308
Suresh Kumar, S. K., (A) 127
Suri, S., (A) 313
Suryakar, A. N., (A) 298
Sussman, G., (A) 512
Suzuki, Y., (A) 721
Svenson, S. B., (A) 705
Swai, A. B. M., (A) 158
Swart, K. J., (A) 503
Szejtli, J., (C) 105
Szente, L., (C) 105
Szykula, J., (A) 143

Tadesse, G., (A) 510
Tadesse, T., (A) 129
Taelman, H., (A) 696
Takahashi, M., (A) 330
Takatsu, A., (A) 721
Tala, E., (A) 692
Taljaard, B., (A) 329
Talwar, G. P., (O) 28, (A) 130, 141, 146, 308
Tami, T. A., (A) 505
Tang, Q.-C., *et al.,* (A) 694
Tanji, O., (A) 157
Tare, S. P., (N) 113
Tasaka, H., (A) 682
Tedesco-Marchesi, L. C. M., (A) 504
Tekle-Haimanot, R., (A) 129, 499
Terpstra, W. J., (A) 499
Teske, A., (A) 689, 697
Thappa, D. M., (A) 313
Theuvenet, W. J., (O) 36, (A) 128, 134
Thibault, D., (A) 703
Thole, J. E. R., (A) 312, 312, 514, 690
Thomas, L., (A) 699
Thompson, S. E., (A) 156
Thompson, S. E., III, (A) 320
Thompson, S. J., (A) 327
Thomsen, R. J., (A) 120
Thorel, M. F., (A) 327

Thyagarajan, S. P., (A) 143
Tin-Shwe, (A) 688
Tingle, M. D., (A) 295, 295
Tizard, M. L. V., (A) 705
Toba, H., (A) 509
Tolson, J., (A) 708
Tomioka, H., (A) 146, 297, 723
Torlakovic, E., (A) 328
Torres, M., (A) 159
Trad, E. S., (C) 283
Traore, I., (O) 542
Trebucq, A., (A) 148
Truffot, C., (A) 153, 705
Truffot-Pernot, C., (A) 157, 320
Truman, R. W., (A) 145, 150, 515
Tsang, A. Y., (A) 319, 328, 699
Tsang, M., (C) 276, (A) 303, (C) 485, (A) 500, 715
Tsukamura, M., (A) 331
Tsutsumi, S., (A) 501
Tsuyuguchi, I., (A) 139
Tubesing, K., (A) 509
Tukhtayev, M. T., (A) 131
Turcotte, R., (A) 701
Turk, J. L., (A) 325, 512
Turner, S. J., (A) 158
Tyagi, P., (A) 127, (O) 562

Uchida, H., (A) 158
Ueta, C., (A) 139
Ulitzur, S., (A) 154
Uplekar, M. W., (A) 129
Urgell, J. R., (A) 324
Ursi, D., (O) 234
Uyemura, K., (A) 140, 141, 726

Vadheim, C. M., (A) 707
Vadher, A., (E) 587
Vagenakis, A. G., (A) 677
Vaishnavi, C., (A) 146, 511
Valcke, C., (A) 159
Valdez, R., (A) 687
Valencia, L. B., (A) 506
Valentin-Weigand, P., (A) 328
Valeyre, D., (A) 697
Vallishayee, R. S., (O) 54, 340
Vandeperre, P., (A) 696
Vandergiessen, J. W. B., (A) 329
Vanderzee, R., (A) 695
Vanderzeijst, B. A. M., (A) 329
Vanham, G., (A) 510
Vanlinden, F., (A) 512
van Beers, S., (A) 719
Van Der Zee, R., (A) 327
van Eden, W., (A) 308
Van Embden, J., (A) 695
van Helden, P. D., (A) 329
Van Onckelen, A., (A) 159
van Rens, M. M., (A) 507
van Scoy, R. E., (A) 329
van Soolingen, D., (A) 514, 690
Van Vooren, J. P., (A) 159, 688
Vargha Butler, E. I., (A) 502
Varnerot, A., (C) 310
Vasilyev, A. V., (A) 329
Vavrin, Z., (A) 130
Vellut, C., (A) 122
Vemuri, N., (A) 140
Venkataramana, D., (E) 269
Venkatesan, K., (A) 505
Venkateswarlu, B., (E) 269
Ventura, E. R., (A) 506
Verbon, A., (A) 309
Vercellone, A., (A) 706
Verdier, M., (A) 129
Verez, V., (A) 508
Vermani, M., (A) 509
Vettom, L., (O) 570
Victor, T., (A) 329
Vijayan, V. K., (A) 707
Vikerfors, T., (A) 314
Viljanen, M. K., (A) 692
Villarreal-Ramos, B., (A) 688
Vipulakorn, K., (A) 313
Voegtline, M. S., (A) 315
Vogelsang, G. B., (A) 330
von Ballestrem, W., (O) 570
Vordermeier, H. M., (A) 707
Vreeburg, A. E. M., (A) 506
Vugman, I., (C) 283
Vurmarapp, U., (A) 692

Wada, M., (A) 330
Wadee, A. A., (A) 512
Wagner, H., (A) 307, 683
Walia, R., (A) 308
Walker, K. B., (A) 309
Walker, R. C., (A) 123
Wall, S., (A) 142
Wallace, R. J., (A) 707, 709
Wallace, R. J., III, (A) 316
Wallace, R. J., Jr., (A) 298, 316
Walsh, G. P., (A) 307, (SS) 477, (A) 507, 727
Walton, R. C., (A) 129
Wang, E., (A) 680
Wang, H., (A) 123
Wang, X.-H., (A) 726
Wang, Z., (A) 505
Waters, M. F. R., (A) 126
Watson, J. D., (O) 201, (A) 314, (O) 368
Wayne, L. G., (A) 330, 707
Weinberg, K., (A) 141
Weiss, M. G., (A) 678
Weng, S.-M., *et al.*, (A) 679
Westmacott, K., (O) 250
Wheeldon, J., (A) 156
Wheeler, P. R., (A) 144, 312, 330, (E) 445
Wigzell, H., (A) 507
Wiker, H. G., (A) 304, 682
Wilfred, D., (A) 122
Wilkins, E., (A) 682

Wilkinson, G. R., (A) 676, 676
Wilkowske, C. J., (A) 329
Williams, D. L., (A) 145, 514, 715, 716
Williams, P. P., (A) 320
Williams, W., (A) 141
Wilson, K. B., (A) 684
Wilson, R. J., (A) 307
Windebank, K. P., (A) 699
Wingard, J. R., (A) 330
Wolinsky, E., (A) 708
Wolters, J., (A) 704
Wong, A., (A) 695
Wood, P. R., (A) 319, 708
Wood, S. R., (A) 120
Woodley, C. L., (A) 704
Worthington, J., (A) 683
Wright, A. J., (A) 123
Wu, Q.-X., *et al.*, (A) 140
Wynne, B. A., (A) 703
Wypij, D., (A) 678

Xabier, M. G., (A) 313
Xing, Y., (A) 310

Yadava, A., (A) 141
Yagi, K., (A) 296
Yagi, S., (A) 322
Yajko, D. M., (A) 708
Yakrus, M. A., (A) 704
Yamada, T., (A) 519
Yamaguchi, R., (A) 330
Yamamura, M., (A) 141, 680, 725
Yamamura, Y., (A) 158
Yamane, T., (A) 297
Yamashita, K., (A) 297
Yamazaki, A., (A) 330
Yamori, S., (A) 331
Yan, L.-B., (O) 250
Yan, L.-B., *et al.*, (A) 151
Yang, X.-D., (A) 331
Yano, I., (A) 139
Yawalkar, S., (O) 250
Ye, F., *et al.*, (A) 689
Ye, G., (A) 123
Ye, G.-Y., (N) 110, (B) 493
Yernault, J. C., (A) 159, 688
Yoder, L. J., (A) 124, 124, (B) 491, 664
Yokota, S., (A) 723
Yong, S., (A) 137
Yoon, K.-H., (A) 727
Yoshino, Y., (A) 692
Youn, J. K., (A) 307
Young, D., (A) 709
Young, D. B., (A) 145, 309, 312, 508, 684
Yu, L., (A) 123
Yu, N., (A) 709
Yu, V. L., (A) 327

Zabolothykh, N. V., (A) 151
Zemskova, Z. S., (A) 331
Zhang, G.-C., (O) 250
Zhang, G.-C., *et al.*, (A) 151
Zhang, J., (A) 505
Zhang, S. K., (A) 298
Zhang, Y., (A) 709
Zhang, Y. S., (A) 709
Zhou, D.-H., *et al.*, (A) 124
Zicker, F., (O) 335
Zubov, V. P., (O) 575
Zucoloto, S., (C) 283
Zumla, A., (A) 141
Zuniga, M., (A) 301

SUBJECT INDEX

Original articles are indicated by (O), editorials (E), correspondence (C), news and notes (N), obituaries (Ob), reprinted article (R), special section (SS), abstracts (A), and book reviews (B).

Acid, fatty,
Purification and characterization of an unusually large fatty acid synthase from *M. tuberculosis* var. *bovis* BCG. Kikuchi, S., *et al.* ..... (A) 513

Acquired immunodeficiency syndrome (AIDS),
Absence of *M. avium* complex disease in patients with AIDS in Uganda. Morrissey, A. B., *et al.* ..... (A) 325
Activity of antimicrobial agents against *M. avium intracellulare* complex (MAC) strains isolated in Italy from AIDS patients. Fattorini, L., *et al.* ..... (A) 699
Activity of clarithromycin against *M. avium* infection in patients with the acquired immune deficiency syndrome; a controlled clinical trial. Dautzenberg, B., *et al.* ..... (A) 153
Clarithromycin-ciprofloxacin-amikacin for therapy of *M. avium-M. intracellulare* bacteremia in patients with AIDS. Delalla, R., *et al.* ..... (A) 699
Clofazimine crystals in alveolar macrophages from a patient with the acquired immunodeficiency syndrome. Sandler, E. D., *et al.* ..... (A) 297
Disseminated "*Mycobacterium genavense*" infection in patients with AIDS. Bottger, E. C., *et al.* ..... (A) 697
Immunophenotypic analysis of histiocytes involved in AIDS-associated *M. scrofulaceum* infection: similarities with lepromatous lepra. Delabie, J., *et al.* ..... (A) 125
Reduced anti-*M. tuberculosis* antibody response in tuberculosis patients with acquired immunodeficiency syndrome. Figueiredo, J. F. A. and Machado, A. A. ..... (A) 700
Survival of patients with acquired immune deficiency syndrome and disseminated *M. avium* complex infection with and without antimycobacterial chemotherapy. Horsburgh, C. R., Jr., *et al.* ..... (A) 156
Time course of anti-SL-IV immunoglobulin-G antibodies in patients with tuberculosis and tuberculosis-associated AIDS. Martin-Casabona, N., *et al.* ..... (A) 324
Tuberculous abscesses in patients with AIDS. Lupatkin, H., *et al.* ..... (A) 324

Africa,
Duration of multidrug therapy in paucibacillary leprosy patients; experience in the leprosy control program of the All Africa Leprosy and Rehabilitation Training Center (ALERT) in Ethiopia. Becx-Bleumink, M. ..... (O) 436
Evolution of the leprosy problem in some African areas during the 1980-89 decade. Pattyn, S. R. ..... (A) 149
Leprosy treatment in Africa with the Flying Doctor Service of East Africa. Kloehn, G. (A) 118
Occurrence of reactions, their diagnosis and management in leprosy patients treated with multidrug therapy; experience in the leprosy control program of the All Africa Leprosy and Rehabilitation Training Center (ALERT) in Ethiopia. Becx-Bleumink, M. and Berhe, D. ..... (O) 173
Relapses among leprosy patients treated with multidrug therapy: experience in the leprosy control program of the All Africa Leprosy and Rehabilitation Training Center (ALERT) in Ethiopia; practical difficulties with diagnosing relapses; operational procedures and criteria for diagnosing relapses. Becx-Bleumink, M. ..... (O) 465
Relapses in leprosy patients after release from dapsone monotherapy; experience in the leprosy control program of the All Africa Leprosy and Rehabilitation Training Center (ALERT) in Ethiopia. Becx-Bleumink, M. ..... (O) 161
[Surveys of prevalence of leprosy in 5 countries of Central Africa.] Louis, J. P., *et al.* ..... (A) 148

Albania,
Albanian Dermatological Association founded. ..... (N) 493

Allergy(ies),
[A thermoindicative nasal test for detecting allergy to antituberculosis drugs.] Buseva, T. A. and Koryakin, V. A. ..... (A) 152

Amikacin,
Clarithromycin-ciprofloxacin-amikacin for therapy of *M. avium–M. intracellulare* bacteremia in patients with AIDS. Delalla, R., *et al.* ....(A) 699

Amoxicillin,
The activity of amoxicillin plus clavulanic acid against *M. leprae* in mice. Gelber, R. H. ....(A) 121

Antibody,
Antibody responses to the 18-kDa protein of *M. leprae* in leprosy and tuberculosis patients. Roche, P. W., *et al.* ....(O) 201
[Antituberculous antibodies in enzyme immunoassay in relation to the efficacy of tuberculosis chemotherapy.] Chukanov, V. I., *et al.* ....(A) 131
[Autoantibodies in lepromatous leprosy.] Graninger, W., *et al.* ....(A) 126
Central nervous system lesions in leprosy—immunohistochemical study using anti-PGL-I antibody. Goto, M., *et al.* ....(A) 718
Detection of antibodies to human nerve antigens in sera from leprosy patients by ELISA. Park, J. Y., *et al.* ....(A) 307
Detection of high titres of *Toxoplasma gondii* antibodies in sera of patients with leprosy in Pakistan. Hussain, R., *et al.* ....(A) 683
Disease association of antibodies to human and mycobacterial hsp70 and hsp60 stress proteins. Elsaghier, A., *et al.* ....(A) 682
Distribution of anti-PGL-I and anti-LAM-B antibodies among inhabitants of leprosy-endemic villages in South Sulawesi, Indonesia. Izumi, S., *et al.* ....(A) 719
[Evaluation of MLPA for determination of antibody to PG-1 of MB leprosy.] Meng, M.-B., *et al.* ....(A) 136
Evaluation of gelatin particle agglutination assay for the detection of anti-PGL-I antibodies. Comparison with ELISA method and applicability on a large scale study using blood collected on filter paper. Chanteau, S., *et al.* ....(A) 131
[GPAT with dried blood specimens for detection of antibody to PGI of *M. leprae.*] Weng, S.-M., *et al.* ....(A) 679
High antibody levels to the mycobacterial fibronectin-binding antigen of 30-31 kD in tuberculosis and lepromatous leprosy. Espitia, C., *et al.* ....(A) 303
Immune complexes and antibody levels in blisters over human leprosy skin lesions with or without erythema nodosum leprosum. Scollard, D. M., *et al.* ....(A) 510
Immunoglobulin-A (IgA) and IgG serum antibodies to mycobacterial antigens in Crohn's disease patients and their relatives. Wayne, L. G., *et al.* ....(A) 707
Major proteins of mycobacterial strain ICRC and *M. leprae* identified by antibodies in sera from leprosy patients and their contacts. Chiplunkar, S. V., *et al.* ....(A) 301
Mapping of T helper cell epitopes by using peptides spanning the 19-kDa protein of *M. tuberculosis*: evidence for unique and shared epitopes in the stimulation of antibody and delayed-type hypersensitivity. Ashbridge, K. R., *et al.* ....(A) 314
Prevalence of IgM antibodies to phenolic glycolipid-I among household contacts and controls in Korea and The Philippines. Cho, S.-N., *et al.* ....(A) 507
Reduced anti-*M. tuberculosis* antibody response in tuberculosis patients with acquired immunodeficiency syndrome. Figueiredo, J. F. A. and Machado, A. A. ....(A) 700
Relationships between titers of antibodies immunoreacting against glycolipid antigens from *M. leprae* and *M. tuberculosis*, the Mitsuda and Mantoux reactions, and bacteriological loads: implications in the pathogenesis, epidemiology and serodiagnosis of leprosy and tuberculosis. David, H. L., *et al.* ....(O) 208
Serology and leprosy: immunoassays comparing immunoglobulin G antibody responses to 28- and 30-kilodalton proteins purified from *M. bovis*. Pessolani, M. C. V., *et al.* (A) 136
Specific binding of phenolic glycolipid antigens from *M. bovis* BCG with antibodies. Vercellone, A., *et al.* ....(A) 706
Specificity of IgG subclass antibodies in different clinical manifestations of leprosy. Dhandayuthanpani, S., *et al.* ....(A) 302
Susceptibility to infection with *M. avium* is paradoxically correlated with increased synthesis of specific anti-bacterial antibodies. Ferreira, P., *et al.* ....(A) 155
The antibody repertoire to proteins of *M. leprae*: genetic influences at the antigen and epitope level. Adeleye, T. A., *et al.* ....(A) 679

The pathogenesis of leprosy in the nine-banded armadillo and the significance of IgM antibodies in PGL-I. Job, C. K., *et al.* ....(A) 515
Time course of anti-SL-IV immunoglobulin-G antibodies in patients with tuberculosis and tuberculosis-associated AIDS. Martin-Casabona, N., *et al.* ....(A) 324
[UltramicroELISA assay for the detection of human IgM antibodies to *M. leprae*.] Laferte, J., *et al.* ....(A) 508
Use of serum antibody and lysozyme levels for diagnosis of leprosy and tuberculosis. Near, K. A. and Lefford, M. J. ....(A) 306

Antibodies, monoclonal,
Characterization of circulating lymphocytes by monoclonal antibodies in childhood and adult leprosy. Sehgal, V. N., *et al.* ....(A) 138
Isolation and structural characteristics of monoclonal antibody-defined cross-reactive phospholipid antigen from *M. tuberculosis* and *M. leprae*. Fournie, J. J., *et al.* ....(A) 132
Monoclonal antibody epitopes of mycobacterial 65-kD heat-shock protein defined by epitope scanning. Hajeer, A. H., *et al.* ....(A) 683

Antigen(s),
[A comparison of serological activities of synthetic leprosy antigens—F/NT, ND and NT.] Wu, Q.-X., *et al.* ....(A) 140
A major T cell antigen of *M. leprae* is a 10-kD heat-shock cognate protein. Mehra, V., *et al.* ....(A) 305
[A preliminary analysis of antigen components of *M. leprae* with SDS-PAGE.] Li, X.-Y., *et al.* ....(A) 135
Analysis of circulating immune complexes from leprosy patients for *M. leprae* antigens. Sinha, S., *et al.* ....(O) 396
Antigens of *M. leprae* in the cerebrospinal fluid of leprosy patients: detection by monoclonal-antibody-based sandwich immunoradiometric assay and avidin/biotin immunoblotting. Patil, S. A., *et al.* ....(A) 127
Assessment of the diagnostic value of the native PGLTB1, its synthetic neoglycoconjugate PGLTB0 and the sulfolipid IV antigens for the serodiagnosis of tuberculosis. Chanteau, S., *et al.* ....(O) 1
Association of HLA antigens with differential responsiveness to *Mycobacterium w* vaccine in multibacillary leprosy patients. Rani, R., *et al.* ....(A) 308
Avidin-biotin immunoblotting studies on reactivity of leprosy sera with *M. leprae* antigen. Patil, S. A., *et al.* ....(C) 280
Characterization of the specific antigenicity of *M. fortuitum*. Besra, G. S., *et al.* ....(A) 696
Cloning and expression of the gene for the Avi-3 antigen of *M. avium* and mapping of its epitopes. Yamaguchi, R., *et al.* ....(A) 330
Comparison of bis-di-octadecylamide of trehalose dicarboxylic acid (BDA.TDA) with glycolipid SL-IV as ELISA antigens for the serodiagnosis of leprosy. Laszlo, A., *et al.* (O) 376
Composition and immunogenicity of the polysaccharide components of the thermostable macromolecular antigen group of mycobacterial antigens. Bruneteau, M., *et al.* ....(A) 512
Dendritic cells efficiently immunoselect mycobacterial-reactive T-cells in human blood, including clonable antigen-reactive precursors. Pancholi, P., *et al.* ....(A) 684
Detection of a *M. leprae* cell wall antigen in the urine of untreated and treated patients. Sharma, V. K., *et al.* ....(A) 511
Detection of antibodies to human nerve antigens in sera from leprosy patients by ELISA. Park, J. Y., *et al.* ....(A) 307
Does previous BCG vaccination interfere with the serodiagnosis of tuberculosis using *M. tuberculosis*-specific glycolipid antigens?. Salem, J. I., *et al.* ....(C) 87
Dot-ELISA for detection of phenolic glycolipid PGL-Tb1 and diacyl-trehalose antigens of *M. tuberculosis*. Papa, F., *et al.* ....(A) 326
Effect of skin test with *M. leprae* soluble antigen on reaction to a subsequent test with the same antigen. Gupte, M. D., *et al.* ....(O) 54
Heat shock proteins and antigens of *M. tuberculosis*. Young, D. B. and Garbe, T. R. ..(A) 145
Heterogeneity of the repertoire of T cells of tuberculosis patients and healthy contacts to *M. tuberculosis* antigens separated by high-resolution techniques. Schoel, B., *et al.* (A) 326
High antibody levels to the mycobacterial fibronectin-binding antigen of 30-31 kD in tuberculosis and lepromatous leprosy. Espitia, C., *et al.* ....(A) 303

Humoral response to nerve glycolipid antigen in sera of leprosy patients. Sahasrabudhe, R. V., *et al.* ..... (C) 488
Humoral responses against the 85A and 85B antigens of *M. bovis* BCG in patients with leprosy and tuberculosis. Van Vooren, J. P., *et al.* ..... (A) 688
IA antigen-positive epithelioid cells in experimentally induced granulomatous inflammations. Izaki, S., *et al.* ..... (A) 157
Immunization of mice with the antigen A60 of *M. bovis* BCG. Hubbard, R. D., *et al.* (A) 322
Immunoglobulin-A (IgA) and IgG serum antibodies to mycobacterial antigens in Crohn's disease patients and their relatives. Wayne, L. G., *et al.* ..... (A) 707
Immunoreactivity of a 120-kDa antigen of *M. tuberculosis.* Barnes, P. F., *et al.* ..... (A) 315
Immunoreactivity of nerve lipid antigens in leprosy. Vemuri, N. and Mukherjee, R. .. (A) 140
Isolation and structural characteristics of monoclonal antibody-defined cross-reactive phospholipid antigen from *M. tuberculosis* and *M. leprae.* Fournie, J. J., *et al.* ..... (A) 132
M. leprae 65hsp antigen expressed from a retroviral vector in a macrophage cell line is presented to T cells in association with MHC class II in addition to MHC class I. Silva, C. L., *et al.* ..... (A) 511
M. leprae express extracellular homologs of the antigen 85 complex. Pessolani, M. C. V. and Brennan, P. J. ..... (A) 723
Modulation of expression of delayed hypersensitivity by mycobacterial antigen-85 fibronectin-binding proteins. Godfrey, H. P., *et al.* ..... (A) 682
Modulation of pristane-induced arthritis by mycobacterial antigens. Thompson, S. J., *et al.* ..... (A) 327
Molecular and immunological analysis of a fibronectin-binding protein antigen secreted by *M. leprae.* Thole, J. E. R., *et al.* ..... (A) 312
Molecular cloning of the alpha-antigen gene from *M. leprae* and its application to serodiagnosis of leprosy. Makino, M. and Suzuki, Y. ..... (A) 721
Mycobacterial protein antigens: a compilation. Young, D. B., *et al.* ..... (A) 312
Nucleotide sequence analysis and serologic characterization of the *M. intracellulare* homologue of the *M. tuberculosis* 19-kDa antigen. Nair, J., *et al.* ..... (A) 603
Protein antigens of mycobacteria studied by quantitative immunologic techniques. Harboe, M., *et al.* ..... (A) 304
Relationships between titers of antibodies immunoreacting against glycolipid antigens from *M. leprae* and *M. tuberculosis,* the Mitsuda and Mantoux reactions, and bacteriological loads: implications in the pathogenesis, epidemiology and serodiagnosis of leprosy and tuberculosis. David, H. L., *et al.* ..... (O) 208
Secreted antigens of Mycobacterium tuberculosis and Mycobacterium bovis BCG by H. G. Wiker. ..... (B) 665
Secreted antigens of *M. tuberculosis*—characterization with lymphocytes-T from patients and contacts after two-dimensional separation. Daugelat, S., *et al.* ..... (A) 698
Sero-Immunoreactivity of cloned protein antigens of *M. leprae.* Khan, M. B., *et al.* ...(O) 195
Serological reactivity to *M. bovis* protein antigens in cattle. Fifis, T., *et al.* ..... (A) 319
Soluble CD4 suppress the antigen driven proliferative response of certain T cell clones specific for mycobacteria and for peptides by monoclonal heat shock proteins. Gidlund, M., *et al.* ..... (A) 507
Specific binding of phenolic glycolipid antigens from *M. bovis* BCG with antibodies. Vercellone, A., *et al.* ..... (A) 706
Specific inhibition of mRNA accumulation for lymphokines in human T cell line Jurkat by mycobacterial lipoarabinomannan antigen. Chujor, C. S. N., *et al.* ..... (A) 301
T-cell mediated cytotoxicity against mycobacterium antigen-pulsed autologous macrophages in leprosy patients. Sasiain, M. D., *et al.* ..... (A) 687
T-cell responses of leprosy patients and healthy contacts toward separated protein antigens of *M. leprae.* Gulle, H., *et al.* ..... (O) 44
T-cell responses to fractionated antigens of *Mycobacterium w,* a candidate anti-leprosy vaccine, in leprosy patients. Yadava, A., *et al.* ..... (A) 141
The 14,000-molecular-weight antigen of *M. tuberculosis* is related to the alpha-crystallin family of low-molecular-weight heat shock proteins. Verbon, A., *et al.* ..... (A) 309
The antibody repertoire to proteins of *M. leprae*: genetic influences at the antigen and epitope level. Adeleye, T. A., *et al.* ..... (A) 679
The genes coding for the antigen 85 complexes of *M. bovis* BCG are members of a gene family: cloning, sequence determination, and genomic organization of the gene coding for antigen 85-C of *M. tuberculosis.* Content, J., *et al.* ..... (A) 153

Armadillo(s),
An attempt to produce experimental tuberculoid leprosy in the nine-banded armadillo. Job, C. K., *et al.* ..... (A) 145
Comparison of polymerase chain reaction technique with other methods for detection of *M. leprae* in tissues of wild nine-banded armadillos. Job, C. K., *et al.* ..... (A) 145
Improved method for purification of *M. leprae* from armadillo tissues. Rodde, C., *et al.* ..... (C) 277
Isolation of cultivable mycobacteria from feces and lungs of armadillos infected with *M. leprae.* Dhople, A. M., *et al.* ..... (O) 244
Nine-banded armadillo (*Dasypus novemcinctus*) as an animal model for leprosy. Job, C. K. ..... (A) 515
Phospholipase activity of *M. leprae* harvested from experimentally infected armadillo tissue. Wheeler, P. R. and Ratledge, C. ..... (A) 144
Seasonal and spatial trends in the detectibility of leprosy in wild armadillos. Truman, R. W., *et al.* ..... (A) 150
The pathogenesis of leprosy in the nine-banded armadillo and the significance of IgM antibodies in PGL-I. Job, C. K., *et al.* ..... (A) 515

Arthritis,
Modulation of pristane-induced arthritis by mycobacterial antigens. Thompson, S. J., *et al.* ..... (A) 327
Prevention of adjuvant arthritis in rats by a nonapeptide from the 65-kDa mycobacterial heat shock protein: specificity and mechanism. Yang, X.-D., *et al.* ..... (A) 331
Treatment of early rheumatoid arthritis with rifampicin. Cox, N. L., *et al.* ..... (A) 318

Asia,
Third Asian Dermatological Congress 1993 in Hong Kong. ..... (N) 111

Assay(s) (see also **ELISA),**
Antigens of *M. leprae* in the cerebrospinal fluid of leprosy patients: detection by monoclonal-antibody-based sandwich immunoradiometric assay and avidin/biotin immunoblotting. Patil, S. A., *et al.* ..... (A) 127
[Antituberculous antibodies in enzyme immunoassay in relation to the efficacy of tuberculosis chemotherapy.] Chukanov, V. I., *et al.* ..... (A) 131
Diagnostic accuracy of a *M. phlei*-absorbed serum enzyme-linked immunosorbent assay for diagnosis of bovine paratuberculosis in dairy cows. Bech-Nielsen, S., *et al.* ..... (A) 315
Double-blind evaluation of BACTEC and Buddemeyer-type radiorespirometric assays for *in vitro* screening of antileprosy agents. Franzblau, S. G., *et al.* ..... (A) 513
Evaluation of gelatin particle agglutination assay for the detection of anti-PGL-I antibodies. Comparison with ELISA method and applicability on a large scale study using blood collected on filter paper. Chanteau, S., *et al.* ..... (A) 131
Serology and leprosy: immunoassays comparing immunoglobulin G antibody responses to 28- and 30-kilodalton proteins purified from *M. bovis.* Pessolani, M. C. V., *et al.* (A) 136

Australia,
Pattern of leprosy in Queensland, Australia, 1865–1990. Ree, G. H. ..... (A) 149

Bacilli,
Significance of neither green nor red (NGR) bacilli in FDA-EB staining. Bhatia, V. N. and Mirmaladevi, B. ..... (A) 142

Bacilli, ICRC,
Major proteins of mycobacterial strain ICRC and *M. leprae* identified by antibodies in sera from leprosy patients and their contacts. Chiplunkar, S. V., *et al.* ..... (A) 301

Bacterial index (BI),
BI of patient vs BI of individual sites. Porichha, D., *et al.* ..... (A) 506

Bacteremia,
Clarithromycin-ciprofloxacin-amikacin for therapy of *M. avium-M. intracellulare* bacteremia in patients with AIDS. Delalla, R., *et al.* ..... (A) 699
Incidence of *M. avium intracellulare* complex bacteremia in human immunodeficiency virus positive patients. Nightingale, S. D., *et al.* ..... (A) 703

Bacteriology,
Is bacteriological examination by skin smear necessary in all paucibacillary leprosy patients in mass control programmes? Rao, P. S., *et al.* ..... (A) 127
Relationships between titers of antibodies immunoreacting against glycolipid antigens from *M. leprae* and *M. tuberculosis,* the Mitsuda and Mantoux reactions, and bacteriological loads: implications in the pathogenesis, epidemiology and serodiagnosis of leprosy and tuberculosis. David, H. L., *et al.* ..... (O) 208

Bacteriophage,
Identification of expression signals of the mycobacteriophages Bxb1, L1 and TM4 using the *Escherichia-Mycobacterium* shuttle plasmids pYUB75 and pYUB76 designed to create translational fusions to the lacZ gene. Barletta, R. G., *et al.* ..... (A) 309
[Pathomorphological evaluation of therapeutic effect of mycobacteriophages in tuberculosis.] Zemskova, Z. S. and Dorozhkova, I. R. ..... (A) 331

BCG (bacille Calmette-Guérin),
Cellular oxidative responses and mycobacterial growth inhibition in aerosol and intradermal BCG-immunized guinea-pigs. Lagranderie, M., *et al.* ..... (A) 323
Does Convit vaccine (BCG + *M. leprae*) afford protection against biochemical changes in renal brush border membrane in experimental leprosy? Kohli, M., *et al.* ..... (A) 135
Does previous BCG vaccination interfere with the serodiagnosis of tuberculosis using *M. tuberculosis*-specific glycolipid antigens? Salem, J. I., *et al.* ..... (C) 87
Effect of local ultraviolet irradiation on infections of mice with *Candida albicans, M. bovis* BCG, and *Schistosoma mansoni.* Jeevan, A., *et al.* ..... (A) 702
Efficacy of BCG vaccine against leprosy and tuberculosis in Malawi. Ponnighaus, J. M., *et al.* ..... (A) 307
Evidence for an alpha/beta T cell-independent mechanism of resistance to mycobacteria. Bacillus Calmette-Guérin causes progressive infection in severe combined immunodeficient mice, but not in nude mice or in mice depleted of CD4+ and CD8+ T cells. Izzo, A. A. and North, R. J. ..... (A) 507
Human phagocyte respiratory burst by *M. bovis* BCG and *M. leprae*: functional activation by BCG is mediated by complement and its receptors on monocytes. Launois, P., *et al.* ..... (O) 225
Humoral immune response of tuberculous patients against the three components of the *M. bovis* BCG 85 complex separated by isolectric focusing. Van Vooren, J. P., *et al.* (A) 159
Humoral responses against the 85A and 85B antigens of *M. bovis* BCG in patients with leprosy and tuberculosis. Van Vooren, J. P., *et al.* ..... (A) 688
Immunization of mice with the antigen A60 of *M. bovis* BCG. Hubbard, R. D., *et al.* (A) 322
Immunoprophylactic trial with combined *M. leprae*/BCG vaccine against leprosy: preliminary results. Convit, J., *et al.* ..... (A) 301
Improving on BCG. Stanford, J. L. ..... (A) 688
Mycobacterial brain abscess possibly due to bacille Calmette-Guérin in an immunocompromised child. Coppes, M. J., *et al.* ..... (A) 318
Mycobacterial heat-shock proteins as carrier molecules. 2. The use of the 70-kDa mycobacterial heat-shock protein as carrier for conjugated vaccines can circumvent the need for adjuvants and bacillis-Calmette-Guérin priming. Barrios, C., *et al.* ..... (A) 695
Protective effect of intradermal BCG against leprosy; a case-control study in central Brazil. Rodrigues, M. L. O., *et al.* ..... (O) 335
Purification and characterization of an unusually large fatty acid synthase from *M. tuberculosis* var. *bovis* BCG. Kikuchi. S. *et al.* ..... (A) 513
Secreted antigens of Mycobacterium tuberculosis and Mycobacterium bovis BCG by H. G. Wiker. ..... (B) 665
Sensitization potential and reactogenicity of BCG with and without various doses of killed *M. leprae.* Gupte, M. D., *et al.* ..... (O) 340
Specific binding of phenolic glycolipid antigens from *M. bovis* BCG with antibodies. Vercellone, A., *et al.* ..... (A) 706
The genes coding for the antigen 85 complexes of *M. bovis* BCG are members of a gene family: cloning, sequence determination, and genomic organization of the gene coding for antigen 85-C of *M. tuberculosis.* Content, J., *et al.* ..... (A) 153
Thin-layer chromatography systems for the identification of *M. tuberculosis, M. bovis* BCG, *M. kansasii, M. gastri,* and *M. marinum.* Laszlo, A., *et al.* ..... (A) 703

Beta-glucuronidase,
On the cross-immunoreactivity of the receptor for beta-glucuronidase (BGR) of *M. leprae* with the extracts of beans. Matsuo, E., *et al.* ..... (A) 721

Biopsy,
Detection of *M. leprae* in biopsy specimens from leprosy patients by polymerase chain reaction. Yoon, K.-H., *et al.* ..... (A) 727
Polymerase chain reaction applied to biopsies from paucibacillary leprosy. Pattyn, S. R., *et al.* ..... (C) 482
Species-specific assessment of *M. leprae* in skin biopsies by *in situ* hybridization and polymerase chain reaction. Arnoldi, J., *et al.* ..... (A) 689
Suggested new technique for skin biopsy under field conditions. Chaturvedi, R. M. and Kartikeyan, S. ..... (A) 677

Blood,
Comparison of a urine spot test and blood tests as indicators of patient compliance. Yoder, L. J., *et al.* ..... (A) 124
Dendritic cells efficiently immunoselect mycobacterial-reactive T-cells in human blood, including clonable antigen-reactive precursors. Pancholi, P., *et al.* ..... (A) 684
Evaluation of *M. leprae* particle agglutination test, using eluates of filter paper blood spots. Sekar, B. and Anadan, D. ..... (A) 510
Evaluation of gelatin particle agglutination assay for the detection of anti-PGL-I antibodies. Comparison with ELISA method and applicability on a large scale study using blood collected on filter paper. Chanteau, S., *et al.* ..... (A) 131
[GPAT with dried blood specimens for detection of antibody to PGI of *M. leprae*.] Weng, S.-M., *et al.* ..... (A) 679
Isolation of a DOPA positive rapid growing mycobacterium from blood of a leprosy patient. Bhatia, V. N. and Rathinavel, L. ..... (A) 310
Thalidomide's effectiveness in erythema nodosum leprosum is associated with a decrease in CD4+ cells in the peripheral blood. Shannon, E. J., *et al.* ..... (A) 510

Bone,
[Analysis of roetgenograms of bones and joints in leprosy.] Lu, T.-C., *et al.* ..... (A) 678
Skin, soft tissue, and bone infections due to *M. chelonae chelonae*—importance of prior corticosteroid therapy, frequency of disseminated infections, and resistance to oral antimicrobials other than clarithromycin. Wallace, R. J., *et al.* ..... (A) 707

Book reviews,
A Fresh Look at Hansen's Disease by M. J. de Mallac. Yoder, L. J. ..... (B) 491
An Epidemiological Review of Pune Urban Leprosy Investigation Centre by J. M. Mehta, M. P. Dandare and D. G. Jogaikar ..... (B) 491
Leprosy Diagnosis and Management by C. K. Job, A. J. Selvapandian, and D. K. Rao. Yoder, L. J. ..... (B) 664
Leprosy in India; a Compendium of Statistics, 1992. Hastings, R. C. ..... (B) 664
Secreted Antigens of Mycobacterium tuberculosis and Mycobacterium bovis BCG by H. G. Wiker ..... (B) 665
Social Sciences Research and Social Action for Better Leprosy Control edited by H. Srinivasan. Frist, T. F. ..... (B) 491
WHO Model Prescribing Information; Drugs Used in Mycobacterial Diseases. ..... (B) 117

Borderline leprosy,
Risk factors for type-1 reactions in borderline leprosy patients. Roche, P. W., *et al.* ..... (A) 128

Brazil,
Protective effect of intradermal BCG against leprosy; a case-control study in central Brazil. Rodrigues, M. L. O., *et al.* ..... (O) 335

Burma (see Myanmar),

Catalase,
The catalase peroxidase gene and isoniazid resistance of *M. tuberculosis.* Zhang, Y., *et al.* ..... (A) 709

Cell(s),
Autoradiographic evidence of reduced epidermal cell proliferation in leprosy patients. Palmero, M. H. R., *et al.* ..... (C) 283
Cellular immune response to the cell walls of *M. leprae* in leprosy patients and healthy subjects exposed to leprosy. Roche, P. W., *et al.* ..... (A) 686
Cellular oxidative responses and mycobacterial growth inhibition in aerosol and intradermal BCG-immunized guinea-pigs. Lagranderie, M., *et al.* ..... (A) 323
Comparison of the intracellular activities of clarithromycin and erythromycin against *M. avium* complex strains in J774 cells and in alveolar macrophages from human immunodeficiency virus type 1-infected individuals. Yajko, D. M., *et al.* ..... (A) 708
Cyclophosphamide treatment antagonizes the *in vitro* development of *M. lepraemurium*-induced suppressor cell precursors. Gosselin, D., *et al.* ..... (A) 701
Delipidified cell components of *M. leprae* and its applications. Mahadevan, P. R., *et al.* (A) 509
Dendritic cells efficiently immunoselect mycobacterial-reactive T-cells in human blood, including clonable antigen-reactive precursors. Pancholi, P., *et al.* ..... (A) 684
Detection of a *M. leprae* cell wall antigen in the urine of untreated and treated patients. Sharma, V. K., *et al.* ..... (A) 511
Extracellular and intracellular activities of sparfloxacin against *M. avium* complex and *M. xenopi.* Gevandan, M. J., *et al.* ..... (A) 701
Fusidic acid is highly active against extracellular and intracellular *M. leprae.* Franzblau, S. G., *et al.* ..... (A) 296
Giant cell myocarditis and myositis associated with thymoma and leprosy. Butany, J. W., *et al.* ..... (A) 125
Increase in tumor necrosis factor alpha- and interleukin-6-secreting cells in peripheral blood mononuclear cells from subjects infected with *M. tuberculosis.* Ogawa, T., *et al.* ..... (A) 158
Intracellular growth of *M. avium* in human macrophages is linked to the increase synthesis of prostaglandin E2 and inhibition of the phagosome-lysosome fusions. Rastogi, N., *et al.* ..... (A) 685
Location of the mycolyl ester substituents in the cell walls of mycobacteria. McNeil, M., *et al.* ..... (A) 143
M. leprae express extracellular homologs of the antigen 85 complex. Pessolani, M. C. V. and Brennan, P. J. ..... (A) 723
Mycobacterial spindle cell pseudotumor of lymph nodes. Chen, K. T. K. ..... (A) 318
On structural aspects of peptidoglycan of bacterial cell wall with special attention on mycobacteria by computer modeling. Pain, S., *et al.* ..... (A) 311
Squamous cell carcinoma in chronic ulcers in leprosy: a review of 38 consecutive cases. Richardus, J. H. and Smith, T. C. ..... (A) 128
Thalidomide's effectiveness in erythema nodosum leprosum is associated with a decrease in CD4+ cells in the peripheral blood. Shannon, E. J., *et al.* ..... (A) 510
Unusual cell of leprous neuritis. Shetty, P. C. and Antia, N. H. ..... (C) 483

Cells, B,
Characterization of the B-cell epitope on hsp65 in the immunized mice and autoimmune patients. Nomaguchi, H., *et al.* ..... (A) 723
Identification of a novel B-cell epitope of restricted specificity on the hsp 65-kDa protein of *M. tuberculosis.* Rambukkana, A., *et al.* ..... (A) 137

Cells, epithelioid,
IA antigen-positive epithelioid cells in experimentally induced granulomatous inflammations. Izaki, S., *et al.* ..... (A) 157
Macrophage and epithelioid cell nuclear morphology in leprosy. Campbell, G. and Cree, I. A. ..... (A) 680

Cells, mononuclear,
Increase in tumor necrosis factor alpha- and interleukin-6-secreting cells in peripheral blood mononuclear cells from subjects infected with *M. tuberculosis.* Ogawa, T., *et al.* ..... (A) 158
TNF-alpha failed to reverse the *M. leprae*-induced defective chemiluminescence response of human mononuclear cells. Launois, P., *et al.* ..... (A) 305

Cells, Schwann,
An ultrastructural study of Schwann cells in peripheral nerves of leprosy patients. Kumar, V., *et al.* ..... (A) 305
Hsp 70 synthesis in Schwann cells in response to heat shock and infection with *M. leprae*. Mistry, Y., *et al.* ..... (A) 684
Lysis of interferon-gamma activated Schwann cell by cross-reactive CD8 + alpha/beta T cells with specificity for the mycobacterial 65 kd heat shock protein. Steinhoff, U., *et al.* ..... (A) 139

Cells, T,
A lectin-binding, protease-resistant mycobacterial ligand specifically activates Vgamma9+ and human gamma/delta T cells. Pfeffer, K., *et al.* ..... (A) 307
A major T cell antigen of *M. leprae* is a 10-kD heat-shock cognate protein. Mehra, V., *et al.* ..... (A) 305
Binding of a major T-cell epitope of mycobacteria to a specific pocket within HLA-DRw17 (DR3) molecules. Geluk, A., *et al.* ..... (C) 304
Dendritic cells efficiently immunoselect mycobacterial-reactive T-cells in human blood, including clonable antigen-reactive precursors. Pancholi, P., *et al.* ..... (A) 684
Differing lymphokine profiles of functional subsets of human CD4 and CD8 T cell clones. Salgame, P., *et al.* ..... (A) 137
Evidence for an alpha/beta T cell-independent mechanism of resistance to mycobacteria. Bacillus Calmette-Guérin causes progressive infection in severe combined immunodeficient mice, but not in nude mice or in mice depleted of CD4+ and CD8+ T cells. Izzo, A. A. and North, R. J. ..... (A) 507
Evidence for clonal selection of gamma/delta T cells in response to a human pathogen. Uyemura, K., *et al.* ..... (A) 140
Gamma-Delta T cells and bacteria. Gatrill, A. J., *et al.* ..... (A) 133
Heterogeneity of the repertoire of T cells of tuberculosis patients and healthy contacts to *M. tuberculosis* antigens separated by high-resolution techniques. Schoel, B., *et al.* (A) 326
Human T-cell subsets in leprosy. Salgame, P. and Bloom, B. R. ..... (A) 724
Identification of B- and T-cell epitopes within the MTP40 protein of *M. tuberculosis* and their correlation with the disease course. Falla, J. C., *et al.* ..... (A) 154
Increase of T-cell receptor gamma/delta-bearing T cells in cord blood of newborn babies obtained by *in vitro* stimulation with mycobacterial cord factor. Tsuyuguchi, I., *et al.* (A) 139
Increased proportions of peripheral blood gamma/delta T cells in patients with pulmonary tuberculosis. Ito, M., *et al.* ..... (A) 701
Induction and expression of protective T cells during *M. avium* infections in mice. Appelberg, R. and Pedrosa, J. ..... (A) 313
Interferon-gamma and macrophage inflammatory proteins (MIP)-1 and (MIP)-2 are involved in the regulation of the T-cell-dependent chronic peritoneal neutrophilia of mice infected with mycobacteria. Appelberg, R. ..... (A) 679
Limited T-cell receptor repertoire in the delayed-type hypersensitivity response to *M. leprae*. Wang, X.-H., *et al.* ..... (A) 726
Lysis of interferon-gamma activated Schwann cell by cross-reactive CD8 + alpha/beta T cells with specificity for the mycobacterial 65 kd heat shock protein. Steinhoff, U., *et al.* ..... (A) 139
M. leprae 65hsp antigen expressed from a retroviral vector in a macrophage cell line is presented to T cells in association with MHC class II in addition to MHC class I. Silva, C. L., *et al.* ..... (A) 511
M. tuberculosis-complex specific T-cell stimulation and DTH reactions induced with a peptide from the 38-kDa protein. Vordermeier, H. M., *et al.* ..... (A) 707
Mouse T cell clones against *M. avium*: identification of clones that modify resistance against atypical mycobacteria infection. Denis, M. ..... (A) 302
Peptide recognition, T-cell receptor usage and HLA restriction elements of human heat-shock protein (hsp)-60 and mycobacterial 65-kDa hsp-reactive T-cell clones from rheumatoid synovial fluid. Quayle, A. J., *et al.* ..... (A) 684
Protection of mice from *M. leprae* infection by T cells and protein vaccines. Gelber, R. H., *et al.* ..... (A) 715
Screening gene expression libraries for epitopes recognized in *M. leprae* by mouse T cells. Villarreal-Ramos, B., *et al.* ..... (A) 688

Selection of a human T helper type 1-like T cell subset by mycobacteria. Haanen, J. B. A. G., *et al.* ..... (A) 133
Soluble CD4 suppress the antigen driven proliferative response of certain T cell clones specific for mycobacteria and for peptides by monoclonal heat shock proteins. Gidlund, M., *et al.* ..... (A) 507
Specific inhibition of mRNA accumulation for lymphokines in human T cell line Jurkat by mycobacterial lipoarabinomannan antigen. Chujor, C. S. N., *et al.* ..... (A) 301
Stigma variations—observations on suppressor T cells and leprosy. Bloom, B. R., *et al.* (A) 300
T-cell mediated cytotoxicity against mycobacterium antigen-pulsed autologous macrophages in leprosy patients. Sasiain, M. D., *et al.* ..... (A) 687
T-cell responses of leprosy patients and healthy contracts toward separated protein antigens of *M. leprae.* Gulle, H., *et al.* ..... (O) 44
T-cell responses to fractionated antigens of *Mycobacterium w,* a candidate anti-leprosy vaccine, in leprosy patients. Yadava, A., *et al.* ..... (A) 141

Cell-mediated immunity (CMI),
Cell-mediated immunity to mycobacteria: the effect of cytolysis on parasite viability. Molloy, A., *et al.* ..... (A) 722
Hansen's disease, cell-mediated immunity, and recombinant lymphokines. Cohn, Z. A. and Kaplan, G. ..... (A) 131
Leprosy and cell-mediated immunity. Kaplan, G. and Cohn, Z. A. ..... (A) 134
Preliminary study of cellular immunity to *M. leprae* protein in contacts and leprosy patients. Rada S., E. M., *et al.* ..... (O) 189

Chemotherapy (see also **Therapy**),
A quantitative basis for sustainable anti-*M. leprae* chemotherapy in leprosy control programs. Almeida, J. G. ..... (E) 255
Ambulatory treatment of multibacillary leprosy with a regimen of 8 months duration. Pattyn, S. R., *et al.* ..... (A) 502
[Antituberculous antibodies in enzyme immunoassay in relation to the efficacy of tuberculosis chemotherapy.]. Chukanov, V. I., *et al.* ..... (A) 131
Chemotherapeutic efficacy of a newly synthesized benzoxazinorifamycin, KRM-1648, against *M. avium* complex infection induced in mice. Tomioka, H., *et al.* ..... (A) 297
Chemotherapy of leprosy in multibacillary nude mice. Hastings, R. C. and Chehl, S. K. (A) 501
Combined chemotherapy including rifabutin for rifampicin and isoniazid resistant pulmonary tuberculosis. Pretet, S., *et al.* ..... (A) 705
Consensus Development Statement on the Chemotherapy of Leprosy ..... (SS) 644
Current concepts in the pathogenesis of leprosy; clinical, pathological, immunological and chemotherapeutic aspects. Meyers, W. M. and Marty, A. M. ..... (A) 119
Immunological upgrading with combined immunotherapy and chemotherapy in a lepromatous leprosy patient: a case report. Zaheer, S. A., *et al.* ..... (A) 130
Patient treatment compliance in leprosy; a critical review. Vadher, A. and Lalljee, M. (E) 587
Survival of patients with acquired immune deficiency syndrome and disseminated *M. avium* complex infection with and without antimycobacterial chemotherapy. Horsburgh, C. R., Jr., *et al.* ..... (A) 156
Treatment of multibacillary leprosy with a regimen of 13 weeks duration. Pattyn, S. R., *et al.* ..... (A) 502

Children,
Early detection of leprosy in children. Dayal, R. ..... (A) 693
Immunoepidemiological studies on subclinical infection in leprosy. I. Clinical and immunological findings in schoolchildren and adults in Okinawa. Abe, M., *et al.* ..... (A) 692
[Immunogenetic grounds for the development of local forms of primary tuberculosis in children.] Vasilyev, A. V. and Dovgalyuk, I. F. ..... (A) 329
Increase of T-cell receptor gamma/delta-bearing T cells in cord blood of newborn babies obtained by *in vitro* stimulation with mycobacterial cord factor. Tsuyuguchi, I., *et al.* (A) 139

China, People's Republic of,
[An observation of multibacillary cases of leprosy the second year after stopping MDT in Xichang City, Sichuan Province.] Hu, L.-F., *et al.* ..... (A) 676
[Analysis of 335 new outpatient cases of leprosy.] Sun, H.-T., *et al.* ..... (A) 150
[Analysis of 545 active cases of leprosy in Shandong.] Li, B., *et al.* ..... (A) 694

[Effects of MDT on leprosy in Wuhan area.] Chen, L.-F., *et al.* ..... (A) 120
Meeting of Editorial Board of "China Leprosy Journal" held in Dalian. Ye, G.-Y. .... (N) 493
National conference on MDT held in Hangzhou. Ye, G.-Y. ..... (N) 110
[Observation on retreatment with MDT in 657 cases of MB leprosy cured with DDS.] Zhou, D.-H., *et al.* ..... (A) 124
[Observations on two-year therapeutic effect of leprosy MDT of 1482 cases in Jiangsu Province (China).] Lou, H.-Y., *et al.* ..... (A) 296
[Results of monitoring 657 ex-patients with MB leprosy in the first year after stop of MDT.] Hu, L.-F., *et al.* ..... (A) 121

Chromatography,
Gas chromatography-mass spectrometry methods for analysis of secondary alcohols present in the *M. avium* complex. Alugupalli, S., *et al.* ..... (A) 689
Thin-layer chromatography systems for the identification of *M. tuberculosis, M. bovis* BCG, *M. kansasii, M. gastri,* and *M. marinum.* Laszlo, A., *et al.* ..... (A) 703

Chromosome(s),
Towards the integration of foreign DNA into the chromosome of *M. leprae.* Eiglmeier, K., *et al.* ..... (A) 142

Cimetidine,
Inhibition of dapsone-induced methaemoglobinaemia by cimetidine in the presence of thrimethoprim in the rat. Coleman, M. D., *et al.* ..... (A) 295

Ciprofloxacin,
Clarithromycin-ciprofloxacin-amikacin for therapy of *M. avium-M. intracellulare* bacteremia in patients with AIDS. Delalla, R., *et al.* ..... (A) 699

Classification,
Clinico-pathological correlation in Indian Consensus Classification. Desikan, K. V. ... (A) 504

Clinic(s),
Attitudes towards leprosy in the outpatient population of dermatology clinics in Trinidad. Suite, M. and Gittens, C. ..... (A) 499

Clinical,
[A study of subclinical infection with *M. leprae,* the factors influencing the subclinical infection.] Shu, H.-W., *et al.* ..... (A) 139
CI-960 (PD127391 or AM-1091), sparfloxacin, WIN57273, and isepamicin activity against clinical isolates of *M. avium-intracellulare* complex, *M. chelonae,* and *M. fortuitum.* Barrett, M. S., *et al.* ..... (A) 315
Characterization of a DNA probe for detection of *M. tuberculosis* complex in clinical samples by polymerase chain reaction. Altamirano, M., *et al.* ..... (A) 695
Clinical and epidemiological importance of typing of *M. avium* complex isolates. Tsang, A. Y., *et al.* ..... (A) 328
[Clinical application of Modulan in leprosy.] Yan, L.-B., *et al.* ..... (A) 151
Clinical biochemical studies in leprosy. Balakrishnan, S. ..... (A) 503
Clinical observations on leprosy patients with HIV-1 infection in Zambia. Vreeburg, A. E. M. ..... (A) 506
Comparison of PCR with different clinical forms of leprosy and with multibacillary patients on MDT. Gillis, T. P., *et al.* ..... (A) 716
Current concepts in the pathogenesis of leprosy; clinical, pathological, immunological and chemotherapeutic aspects. Meyers, W. M. and Marty, A. M. ..... (A) 119
Disseminated *M. avium* complex infection: clinical identification and epidemiologic trends. Havlik, J. A., Jr., *et al.* ..... (A) 320
Electromyographic diagnosis of leprosy. DeFaria, C. R. and Silva, I. M. ..... (A) 125
Immunoepidemiological studies on subclinical infection in leprosy. I. Clinical and immunological findings in schoolchildren and adults in Okinawa. Abe, M., *et al.* ..... (A) 692
Maxillary antrum involvement in multibacillary leprosy: a radiologic, sinuscopic, and histologic assessment. Hauhnar, C. Z., *et al.* ..... (O) 390
Pre-emptive diagnosis of leprosy. Okoro, A. N. ..... (A) 126
Pulmonary tuberculosis in Kigali, Rwanda—impact of human immunodeficiency virus infection on clinical and radiographic presentation. Batungwanayo, J., *et al.* ..... (A) 696

Rapid, simple method for treating clinical specimens containing *M. tuberculosis* to remove DNA for polymerase chain reaction. Buck, G. E., *et al.* ....(A) 316
Significance of nail changes in leprosy; a clinical review. Patki, A. H. and Baran, R. ....(A) 127
Specificity of IgG subclass antibodies in different clinical manifestations of leprosy. Dhandayuthanpani, S., *et al.* ....(A) 302

Clofazimine,
A rapid and sensitive high performance liquid chromatographic analysis of clofazimine in plasma. Krishnan, T. R. and Abraham, I. ....(O) 549
Bull's eye retinopathy and clofazimine. Forster, D. J., *et al.* ....(A) 450
CIBA-GEIGY combination capsules postponed. ....(N) 292
Clofazimine crystals in alveolar macrophages from a patient with the acquired immunodeficiency syndrome. Sandler, E. D., *et al.* ....(A) 297
Clofazimine: a review of its use in leprosy and *M. avium* complex infection. Garrelts, J. C. ....(A) 121
Comment: clofazimine-induced lymphoedema. Oommen, T., *et al.* ....(A) 122
Effect of antileprosy drugs on superoxide anion production by rat peritoneal macrophage with special reference to light exposed clofazimine. Sahu, A., *et al.* ....(A) 123
Red discoloration of the sputum by clofazimine simulating haemoptysis. Girdhar, A., *et al.* ....(A) 505
Role of rifampin and clofazimine ointments in the treatment of leprosy. Venkateswarlu, B., *et al.* ....(E) 269
Short-term trial of clofazimine in previously untreated lepromatous leprosy. Jamet, P., *et al.* ....(O) 542
Wettability study of clofazimine and poly (vinyl methyl ether/maleic anhydride) copolymer coevaporates. Krishnan, T. R., *et al.* ....(A) 502

Cloning,
Citrate synthase from *M. smegmatis*; cloning, sequence determination and expression in *Escherichia coli*. David, M., *et al.* ....(A) 154
Cloning and expression of *M. aurum* carotenogenesis genes in *M. smegmatis*. Houssaini-Iraqui, M., *et al.* ....(A) 321
Cloning and expression of the gene for the Avi-3 antigen of *M. avium* and mapping of its epitopes. Yamaguchi, R., *et al.* ....(A) 330
Dendritic cells efficiently immunoselect mycobacterial-reactive T-cells in human blood, including clonable antigen-reactive precursors. Pancholi, P., *et al.* ....(A) 684
Differing lymphokine profiles of functional subsets of human CD4 and CD8 T cell clones. Salgame, P., *et al.* ....(A) 137
Evidence for clonal selection of gamma/delta T cells in response to a human pathogen. Uyemura, K., *et al.* ....(A) 140
Molecular cloning of the alpha-antigen gene from *M. leprae* and its application to serodiagnosis of leprosy. Makino, M. and Suzuki, Y. ....(A) 721
Mouse T cell clones against *M. avium*: identification of clones that modify resistance against atypical mycobacteria infection. Denis, M. ....(A) 302
Peptide recognition, T-cell receptor usage and HLA restriction elements of human heat-shock protein (hsp)-60 and mycobacterial 65-kDa hsp-reactive T-cell clones from rheumatoid synovial fluid. Quayle, A. J., *et al.* ....(A) 684
Sero-Immunoreactivity of cloned protein antigens of *M. leprae*. Khan, M. B., *et al.* ....(O) 195
Soluble CD4 suppress the antigen driven proliferative response of certain T cell clones specific for mycobacteria and for peptides by monoclonal heat shock proteins. Gidlund, M., *et al.* ....(A) 507
The genes coding for the antigen 85 complexes of *M. bovis* BCG are members of a gene family: cloning, sequence determination, and genomic organization of the gene coding for antigen 85-C of *M. tuberculosis*. Content, J., *et al.* ....(A) 153

Commonwealth of Independent States, (formerly **U.S.S.R.**),
Leprosy in southern Russia. ....(N) 292

Complement,
Anti-leprosy drugs inhibit the complement-mediated solubilization of pre-formed immune complexes *in vitro*. Kashyap, A., *et al.* ....(A) 501

Human phagocyte respiratory burst by *M. bovis* BCG and *M. leprae*: functional activation by BCG is mediated by complement and its receptors on monocytes. Launois, P., *et al.* ..... (O) 225
The pathophysiology of the complement system in leprosy. Ramanathan, V. D. ..... (A) 509

Congresses,
First International Conference on the Pathogenesis of Mycobacterial Infections: a summary. Rastogi, N., *et al.* ..... (A) 308
International Leprosy Seminar, Istanbul, Turkey. ..... (N) 495
The International Conference of Leprosy 1992 in Egypt. El-Shiemy, S. ..... (N) 110
Third Asian Dermatological Congress 1993 in Hong Kong. ..... (N) 111
Twenty-Seventh Joint Leprosy Research Conference, U.S.-Japan Cooperative Medical Science Program, Matsue, Japan, 4–7 August 1992. ..... (–) 710
XVII Biennial Conference of the Indian Association of Leprologists (IAL). ..... (B) 493

Control of leprosy,
A quantitative basis for sustainable anti-*M. leprae* chemotherapy in leprosy control programs. Almeida, J. G. ..... (E) 255
ALERT-India 1981–89: nine years' experience in leprosy control in the slums of Bombay. Samy, A. A., *et al.* ..... (A) 149
An educational approach to leprosy control: an evaluation of knowledge, attitudes and practice in two poor localities in Bombay, India. Crook, N., *et al.* ..... (A) 147
Child-to-parent education: a pilot study. Bhore, P. D., *et al.* ..... (A) 294
Control of leprosy in India in the background of urbanization. Ganapati, R. ..... (A) 516
Impact of multidrug therapy on the treatment and control of leprosy. Chatterjee, B. R. (C) 271
Leprosy control through multidrug therapy (MDT). Noordeen, S. K. ..... (A) 119
Recent developments in leprosy control. Noordeen, S. K. ..... (A) 502
Report of the First Meeting of the WHO Working Group on Leprosy Control. ..... (N) 114
Social Sciences Research and Social Action for Better Leprosy Control edited by H. Srinivasan. Frist, T. F. ..... (B) 491
Some indices pertaining to the leprosy control programme in Tamil Nadu (India), based on data from the random sample of 14 governmental control units. Nair, N. G. K., *et al.* ..... (A) 148
Time lag between case registration and commencement of treatment in a leprosy control unit. Krishna Murthy, P., *et al.* ..... (A) 299

Corticosteriods,
Skin, soft tissue, and bone infections due to *M. chelonae chelonae*—importance of prior corticosteroid therapy, frequency of disseminated infections, and resistance to oral antimicrobials other than clarithromycin. Wallace, R. J., *et al.* ..... (A) 707

Cuba,
International course in Cuba. ..... (N) 667

Cultivation,
[Energy production in *M. lepraemurium* cultivated *in vitro.*] Ishaque, M. ..... (A) 322
Water-soluble complexes of palmitic acid and palmitates for metabolic studies and cultivation trials of *M. leprae.* Kato, L., *et al.* ..... (C) 105

Cutaneous,
Association of the mycobacterial 30-kDa region proteins with the cutaneous infiltrates of leprosy lesions—evidence for the involvement of the major mycobacterial secreted proteins in the local immune response of leprosy. Rambukkana, A., *et al.* ..... (A) 685
[Contribution to the study of two infectious granulomatous diseases (leprosy and cutaneous and mucous leishmaniasis) by scintigraphic methods.] Braga, F. J. H. N., *et al.* ..... (A) 504
Effect of cutaneous cell-mediated immune response to rIFNgamma on *M. leprae* viability in the lesions of lepromatous leprosy. Damasco, M. H. S., *et al.* ..... (A) 681

Cyclosporine,
Resolution of type 1 reaction in multibacillary Hansen's disease as a result of treatment with cyclosporine. Frankel, R. I., *et al.* ..... (O) 8

Dapsone (DDS),
Anticonvulsive effect of dapsone (4, 4′-diaminodiphenyl sulfone) on amygdala-kindled seizures in rats and cats. Hamada, K., *et al.* ..... (A) 296
Comparing the anticonvulsive effects of dapsone on amygdala-kindled seizures and hippocampal-kindled seizures in rats. Ishida, S., *et al.* ..... (A) 322
Dapsone suppresses integrin-mediated neutrophil adherence function. Booth, S. A., *et al.* ..... (A) 294
Does isoniazid increase the hepatotoxicity of the combination prothionamide-dapsone? Isoprodian Study Group. ..... (O) 536
Human liver microsomal N-hydroxylation of dapsone by cytochrome-P-4503A. Fleming, C. M., *et al.* ..... (A) 676
Inhibition of dapsone-induced methaemoglobinaemia by cimetidine in the presence of trimethoprim in the rat. Coleman, M. D., *et al.* ..... (A) 295
[Observation on retreatment with MDT in 657 cases of MB leprosy cured with DDS.] Zhou, D.-H., *et al.* ..... (A) 124
Relapses in leprosy patients after release from dapsone monotherapy; experience in the leprosy control program of the All Africa Leprosy and Rehabilitation Training Center (ALERT) in Ethiopia. Becx-Bleumink, M. ..... (O) 161
Risk of relapse among non-lepromatous patients released from treatment after dapsone monotherapy. Pandian, T. D., *et al.* ..... (A) 122
The disposition of dapsone in cirrhosis. May, D. G., *et al.* ..... (A) 676
The protective effect of vitamin E on the hemolysis associated with dapsone treatment in patients with dermatitis herpetiformis. Prussick, R., *et al.* ..... (A) 297
Use of a metabolic inhibitor to reduce dapsone-dependent haemotological toxicity. Coleman, M. D. and Tingle, M. D. ..... (A) 295

Deformity, disability,
[A sociomedical investigation on leprosy disability—a survey of marriage in patients with leprosy disability.] Chen, X.-S., *et al.* ..... (A) 695
[Epidemiological investigation of disability in leprosy. (II) Analysis of disability.] Zhang, G.-C., *et al.* ..... (A) 151
Psychosocial aspects of deformed leprosy patients undergoing surgical correction. Ramanathan, U., *et al.* ..... (A) 151
Shrinkage of the below-knee stump in leprosy. Mahaisavariya, B., *et al.* ..... (A) 313

Dermal,
Autoradiographic evidence of reduced epidermal cell proliferation in leprosy patients. Palmero, M. H. R., *et al.* ..... (C) 283
Cellular oxidative responses and mycobacterial growth inhibition in aerosol and intradermal BCG-immunized guinea-pigs. Lagranderie, M., *et al.* ..... (A) 323
Protective effect of intradermal BCG against leprosy; a case-control study in central Brazil. Rodrigues, M. L. O., *et al.* ..... (O) 335

Dermatology,
Attitudes towards leprosy in the outpatient population of dermatology clinics in Trinidad. Suite, M. and Gittens, C. ..... (A) 499

DNA,
A search for mycobacterial DNA in graulomatous tissues from patients with sarcoidosis using the polymerase chain reaction. Bocart, D., *et al.* ..... (A) 697
Amplification of a species-specific DNA fragment of *M. tuberculosis* and its possible use in diagnosis. Del Portillo, P., *et al.* ..... (A) 154
Characterization of a DNA probe for detection of *M. tuberculosis* complex in clinical samples by polymerase chain reaction. Altamirano, M., *et al.* ..... (A) 695
DNA hybridization analysis of mycobacterial DNA using the 18-kDa protein gene of *M. leprae.* Moudgil, K. D., *et al.* ..... (A) 514
DNA polymorphisms in strains of *M. tuberculosis* analyzed by pulsed-field gel electrophoresis—a tool for epidemiology. Zhang, Y. S., *et al.* ..... (A) 709
Detection of mycobacterial DNA in sarcoidosis and tuberculosis with polymerase chain reaction. Saboor, S. A., *et al.* ..... (A) 326
Identification of *M. kansasii* by DNA hybridization. Huang, Z. H., *et al.* ..... (A) 157
M. paratuberculosis DNA in Crohn's disease tissue. Sanderson, J. D., *et al.* ..... (A) 705

Polymerase chain reaction amplifying DNA coding to species-specific rRNA of *M. leprae*. Pattyn, S. R., *et al.* ..... (O) 234
Rapid, simple method for treating clinical specimens containing *M. tuberculosis* to remove DNA for polymerase chain reaction. Buck, G. E., *et al.* ..... (A) 316
Towards the integration of foreign DNA into the chromosome of *M. leprae*. Eiglmeier, K., *et al.* ..... (A) 142

Drugs (see also specific drugs),
[A thermoindicative nasal test for detecting allergy to antituberculosis drugs.] Buseva, T. A. and Koryakin, V. A. ..... (A) 152
Anti-leprosy drugs inhibit the complement-mediated solubilization of pre-formed immune complexes *in vitro*. Kashyap, A., *et al.* ..... (A) 501
Bactericidal activities of single or multiple doses of various combinations of new antileprosy drugs and/or rifampin against *M. leprae* in mice. Ji, B., *et al.* ..... (O) 556
Bacteriostatic and bactericidal activity of anti-tuberculosis drugs against *M. tuberculosis, M. avium, M. intracellular* complex and *M. kansasii* in different growth phases. Yamori, S., *et al.* ..... (A) 331
Delayed clearance of circulating immune complexes in mice following administration of antileprosy drugs. Kashyap, A., *et al.* ..... (O) 404
Development of effective drug combinations for the inhibition of multiply resistant mycobacteria, especially of the *M. avium* complex. Seydel, J. K., *et al.* ..... (A) 706
Effect of antileprosy drugs on superoxide anion production by rat peritoneal macrophage with special reference to light exposed clofazimine. Sahu, A., *et al.* ..... (A) 123
Impact of multidrug therapy on the treatment and control of leprosy. Chatterjee, B. R. (C) 271
In vivo effects of anti-leprosy drugs on the rat peritoneal macrophages and lymphocyte subpopulations. Sahu, A., *et al.* ..... (A) 686
Prevalence of dementia amongst elderly Japanese with leprosy—apparent effect of chronic drug therapy. McGeer, P. L., *et al.* ..... (A) 678
Reactive oxygen intermediates in the phagocytes from leprosy patients: correlation with reactional states and variation drug treatment. Santos, D. O., *et al.* ..... (C) 92
The fluoroquinolones. Walker, R. C. and Wright, A. J. ..... (A) 123
Update on rifampin drug interactions. Bocherding, S. M., *et al.* ..... (A) 295
WHO Model Prescribing Information; Drugs Used in Mycobacterial Diseases. ..... (B) 117

Edema,
Comment: clofazimine-induced lymphoedema. Oommen, T., *et al.* ..... (A) 122

Egypt,
The International Conference of Leprosy 1992 in Egypt. El-Shiemy, S. ..... (N) 110

ELISA (enzyme-linked immunosorbent assay),
[A comparison between agglutination test with gelatin particles sensitized by NT-P-BSA and ELISA.] Tang, Q.-C., *et al.* ..... (A) 694
An appraisal of enzyme linked immunosorbent assay (ELISA) and serum antibody competition test (SACT) in leprosy. Kanchana, M. A., *et al.* ..... (A) 304
Comparison of bis-di-octadecylamide of trehalose dicarboxylic acid (BDA.TDA) with glycolipid SL-IV as ELISA antigens for the serodiagnosis of leprosy. Laszlo, A., *et al.* (O) 376
Detection of antibodies to human nerve antigens in sera from leprosy patients by ELISA. Park, J. Y., *et al.* ..... (A) 307
Dot-ELISA for detection of phenolic glycolipid PGL-Tb1 and diacyl-trehalose antigens of *M. tuberculosis*. Papa, F., *et al.* ..... (A) 326
Enzyme linked immunosorbent assay of a 12-kDa protein of *M. leprae* with sera from leprosy patients. Navalkar, R. G., *et al.* ..... (O) 382
Evaluation of gelatin particle agglutination assay for the detection of anti-PGL-I antibodies. Comparison with ELISA method and applicability on a large scale study using blood collected on filter paper. Chanteau, S., *et al.* ..... (A) 131
Follow-up of multibacillary leprosy patients using a phenolic glycolipid-I-based ELISA. Do increasing ELISA-values after discontinuation of treatment indicate relapse? Chin-A-Lien, R., *et al.* ..... (A) 507
[UltramicroELISA assay for the detection of human IgM antibodies to *M. leprae*.] Laferte, J., *et al.* ..... (A) 508

Use of a different buffer system in the phenolic glycolipid-I ELISA. Sticht-Groh, V., *et al.* ..... (O) 570

Enzyme(s),
[Antituberculous antibodies in enzyme immunoassay in relation to the efficacy of tuberculosis chemotherapy.] Chukanov, V. I., *et al.* ..... (A) 131
Diagnosis of mycobacterial infections by PCR and restriction enzyme digestion. Rodrigo, G., *et al.* ..... (A) 705
Renal brushborder membrane vesicle study of marker enzymes and uptake of nutrients in *M. leprae* infected mice. Kohli, M., *et al.* ..... (A) 146

Epidemiology,
An Epidemiological Review of Pune Urban Leprosy Investigation Centre by J. M. Mehta, M. P. Dandare and D. G. Jogaikar. ..... (B) 491
[An estimate of the prevalence of hanseniasis by means of investigation into nonspecific demand for health services.] Opromolla, D. V., *et al.* ..... (A) 148
Clinical and epidemiological importance of typing of *M. avium* complex isolates. Tsang, A. Y., *et al.* ..... (A) 328
DNA polymorphisms in strains of *M. tuberculosis* analyzed by pulsed-field gel electrophoresis—a tool for epidemiology. Zhang, Y. S., *et al.* ..... (A) 709
Disseminated *M. avium* complex infection: clinical identification and epidemiologic trends. Havlik, J. A., Jr. *et al.* ..... (A) 320
Elimination of leprosy as a public health problem. Noordeen, S. K. ..... (A) 517
[Epidemiological investigation of disability in leprosy. (II) Analysis of disability.] Zhang, G.-C., *et al.* ..... (A) 151
Epidemiology of infection by nontuberculosis mycobacteria; *M. avium, M. intracellulare,* and *M. scrofulaceum* in acid, brown-water swamps of the Southeastern United States and their association with environmental variables. Kirschner, R. A., Jr., *et al.* ..... (A) 323
Immunoepidemiological studies on subclinical infection in leprosy. I. Clinical and immunological findings in schoolchildren and adults in Okinawa. Abe, M., *et al.* ..... (A) 692
Imported leprosy in the United States, 1987 through 1988—an epidemic without secondary transmission. Mastro, T. D., *et al.* ..... (A) 694
On reflections on the elimination of leprosy. Boerrigter, G. ..... (C) 656
Postulated epidemiology of *M. ulcerans* infection. Hayman, J. ..... (A) 321
Recent advances in the development of techniques for diagnosis and epidemiology of leprosy. Katoch, V. M. ..... (A) 513
Recent trends in the epidemiology of tuberculosis and leprosy. Smith, P. G. ..... (A) 517
Reflections on the elimination of leprosy. Fine, P. E. M. ..... (E) 71
Relationships between titers of antibodies immunoreacting against glycolipid antigens from *M. leprae* and *M. tuberculosis,* the Mitsuda and Mantoux reactions, and bacteriological loads: implications in the pathogenesis, epidemiology and serodiagnosis of leprosy and tuberculosis. David, H. L., *et al.* ..... (O) 208

Erythema nodosum leprosum (ENL),
ENL quantification—a proposal. Salafia, A. and Shah, J. K. ..... (A) 129
Erythema nodosum leprosum: a possible cause of oral destruction in leprosy. Scheepers, A. and Lemmer, J. ..... (C) 641
Immune complexes and antibody levels in blisters over human leprosy skin lesions with or without erythema nodosum leprosum. Scollard, D. M., *et al.* ..... (A) 510
Prolonged treatment with recombinant interferon-gamma induces erythema nodosum leprosum in lepromatous leprosy patients. Sampaio, E. P., *et al.* ..... (A) 686
Soluble interleukin-2 receptors: levels in leprosy, and during and after type 1 (lepra) and type 2 (ENL) reactions. Sehgal, B. N., *et al.* ..... (A) 138
Thalidomide's effectiveness in erythema nodosum leprosum is associated with a decrease in CD4+ cells in the peripheral blood. Shannon, E. J., *et al.* ..... (A) 510

Erythromycin,
Comparison of the intracellular activities of clarithromycin and erythromycin against *M. avium* complex strains in J774 cells and in alveolar macrophages from human immunodeficiency virus type 1-infected individuals. Yajko, D. M., *et al.* ..... (A) 708

Escherichia coli,
An *Escherichia coli-Mycobacterium* shuttle cosmic vector. Hinshelwood, S. and Stoker, N. G. ..... (A) 311
Citrate synthase from *M. smegmatis*; cloning, sequence determination and expression in *Escherichia coli*. David, M., *et al.* ..... (A) 154
Fluorescein diacetate and ethidium bromide staining to determine the viability of *M. smegmatis* and *Escherichia coli*. Jayapal, V., *et al.* ..... (A) 143

Ethionamide,
Mycolic acid synthesis—a target for ethionamide in mycobacteria. Quemard, A., *et al.* (A) 691

Ethiopia,
A survey of HTLV-I and HIVs in Ethiopian leprosy patients. Tekle-Haimanot, R., *et al.* ..... (A) 129
ALERT seeks candidates for two positions. ..... (N) 667
Attitudes of rural people in central Ethiopia towards leprosy and a brief comparison with observations on epilepsy. Tekle-Haimanot, R., *et al.* ..... (A) 499

Experimental leprosy,
Does Convit vaccine (BCG + *M. leprae*) afford protection against biochemical changes in renal brush border membrane in experimental leprosy? Kohli, M., *et al.* ..... (A) 135
Evolution and contribution of animal models in leprosy. Rees, R. J. W. ..... (A) 516
Nonhuman sources of leprosy. Meyers, W. M., *et al.* ..... (SS) 477

Eye(s),
[Acute uveitis in the course of reversal reactions.] Spindler, E., *et al.* ..... (A) 129
Bull's eye retinopathy and clofazimine. Forster, D. J., *et al.* ..... (A) 450
Chronic anterior uveitis in leprosy: insidious cause of blindness. Espiritu, C. G., *et al.* (A) 142
Considerations in the integration of eye care into leprosy care services. Courtright, P. and Lewallen, S. ..... (A) 504
Glaucoma in Hansen's disease. Walton, R. C., *et al.* ..... (A) 129
Intraocular penetration of rifampin in humans. Outman, W. R., *et al.* ..... (A) 677
Subcorneal pustular dermatosis in type 1 lepra reaction. Pavithran, K. ..... (C) 89

Finger(s),
Cold fingers in leprosy. Abbot, N. C., *et al.* ..... (O) 580

Foot,
IAL-sponsored 1991 training workshop on foot care. ..... (N) 112
[Progressive dislocations of the foot joints in leprosy.] Carayon, A. and Chevallard, A. (A) 150
Radiological changes in hands and feet in disabled leprosy patients: a clinico-radiological correlation. Thappa, D. M., *et al.* ..... (A) 313

Foot pad(s),
Activity of sparfloxacin against *M. leprae* inoculated into foot pads of nude mice. Gidoh, M. and Tsutsumi, S. ..... (A) 501
Comparison of PGL-I level with AFB numbers in foot pad suspension. Cho, S.-N., *et al.* ..... (C) 96
Inoculation of foot pads of severe combined immunodeficient mice with *M. leprae*. Ishaque, M. ..... (C) 661

Genetics,
Genetic and biochemical analysis of ribosomal proteins of minocycline-susceptible and -resistant *M. smegmatis*. Yamada, T., *et al.* ..... (A) 519
Genetic control of innate resistance to mycobacterial infections. Schurr, E., *et al.* ..... (A) 138
Genetic vaccines against genetically infective macromolecules? Corcos, M. G. ..... (C) 659
Genetics and resistance to tuberculosis—could resistance be enhanced by genetic engineering. Stead, W. W. ..... (A) 706
[Immunogenetic grounds for the development of local forms of primary tuberculosis in children.] Vasilyev, A. V. and Dovgalyuk, I. F. ..... (A) 329
Morphometric analysis of *M. tuberculosis* infection in mice suggests a genetic influence on the generation of the granulomatous inflammatory response. Orrell, J. M., *et al.* (A) 325
The antibody repertoire to proteins of *M. leprae*: genetic influences at the antigen and epitope level. Adeleye, T. A., *et al.* ..... (A) 679

The genes coding for the antigen 85 complexes of *M. bovis* BCG are members of a gene family: cloning, sequence determination, and genomic organization of the gene coding for antigen 85-C of *M. tuberculosis*. Content, J., *et al.* ..... (A) 153
[Use of dimephosphone in a pathogenetic therapy of experimental tuberculosis.] Alexandrova, A. E., *et al.* ..... (A) 151

Genome,
The genes coding for the antigen 85 complexes of *M. bovis* BCG are members of a gene family: cloning, sequence determination, and genomic organization of the gene coding for antigen 85-C of *M. tuberculosis*. Content, J., *et al.* ..... (A) 153

Granuloma(s),
A search for mycobacterial DNA in granulomatous tissues from patients with sarcoidosis using the polymerase chain reaction. Bocart, D., *et al.* ..... (A) 697
[Contribution to the study of two infectious granulomatous diseases (leprosy and cutaneous and mucous leishmaniasis) by scintigraphic methods.] Braga, F. J. H. N., *et al.* ..... (A) 504
Granulomatous prostatitis due to *M. avium* complex. Mikolich, D. J. and Mates, S. M. (A) 326
Ia antigen-positive epithelioid cells in experimentally induced granulomatous inflammations. Izaki, S., *et al.* ..... (A) 157
Morphometric analysis of *M. tuberculosis* infection in mice suggests a genetic influence on the generation of the granulomatous inflammatory response. Orrell, J. M., *et al.* (A) 325

Guadeloupe,
[Leprosy in Guadeloupe (FWI) 1980–1990: evolution and management in a general hospital.] Strobel, M., *et al.* ..... (A) 499

Hand(s),
Palmar involvement in histoid leprosy. Baslas, R. G., *et al.* ..... (A) 504
Radiological changes in hands and feet in disabled leprosy patients: a clinico-radiological correlation. Thappa, D. M., *et al.* ..... (A) 313

Hepatotoxicity,
Does isoniazid increase the hepatotoxicity of the combination prothionamide-dapsone? Isoprodian Study Group. ..... (O) 536

Histoid leprosy,
Giant histoid tumor. Pavithran, K. ..... (C) 274
Palmar involvement in histoid leprosy. Baslas, R. G., *et al.* ..... (A) 504

Histology,
Intralesional variation in histology. Chatterjee, B. R. ..... (C) 82

Histopathology,
Histopathological monitoring of an immunotherapeutic trial with *Mycobacterium w.* Mukherjee, A., *et al.* ..... (O) 28
Hypopigmented macules in leprosy—a histopathological and histochemical study of melanocytes. Shereef, P. H. ..... (A) 511

History of leprosy,
A contribution to the history of tuberculosis and leprosy in 19th century Norway. Wood, S. R. ..... (A) 120
Armauer Hansen Jubilee Symposium, October 1992, Bergen, Norway. ..... (SS) 465
Hansen, 150 years after his birth, the context of a medical discovery. Irgens, L. M. .. (SS) 466
How leprosy is depicted in Ben-Hur. Thomsen, R. J. ..... (A) 120
In memorium to Armauer Hansen (1841–1912). ..... (SS) 481
Text and documents; a medieval Arab medical certificate. Isaacs, H. D. ..... (A) 118
[To the history of leprosy in Erfurt.] Abe, H. R. ..... (A) 118

HLA (see also Genetics),
Association of HLA antigens with differential responsiveness to *Mycobacterium w* vaccine in multibacillary leprosy patients. Rani, R., *et al.* ..... (A) 308
Binding of a major T-cell epitope of mycobacteria to a specific pocket within HLA-DRw17 (DR3) molecules. Geluk, A., *et al.* ..... (C) 304

Peptide recognition, T-cell receptor usage and HLA restriction elements of human heat-shock protein (hsp)-60 and mycobacterial 65-kDa hsp-reactive T-cell clones from rheumatoid synovial fluid. Quayle, A. J., *et al.* ..... (A) 684

ILEP (International Federation of Anti-Leprosy Associations),
First elected President of ILEP. ..... (N) 674

Immune complexes,
Analysis of circulating immune complexes from leprosy patients for *M. leprae* antigens. Sinha, S., *et al.* ..... (O) 396
Anti-leprosy drugs inhibit the complement-mediated solubilization of pre-formed immune complexes *in vitro*. Kashyap, A., *et al.* ..... (A) 501
Delayed clearance of circulating immune complexes in mice following administration of antileprosy drugs. Kashyap, A., *et al.* ..... (O) 404
Immune complexes and antibody levels in blisters over human leprosy skin lesions with or without erythema nodosum leprosum. Scollard, D. M., *et al.* ..... (A) 510
Suppressive effect of circulating immune complexes from leprosy patients on the lymphocyte proliferation induced by *M. leprae* antigens in healthy responders. Tyagi, P., *et al.* ..... (O) 562

Immune responses,
Association of the mycobacterial 30-kDa region proteins with the cutaneous infiltrates of leprosy lesions—evidence for the involvement of the major mycobacterial secreted proteins in the local immune response of leprosy. Rambukkana, A., *et al.* ..... (A) 685
Cellular immune response to the cell walls of *M. leprae* in leprosy patients and healthy subjects exposed to leprosy. Roche, P. W., *et al.* ..... (A) 686
Cellular immune responses of mycobacterial heat shock proteins in Nepali leprosy patients and controls. Roche, P. W., *et al.* ..... (O) 36
Effect of cutaneous cell-mediated immune response to rIFNgamma on *M. leprae* viability in the lesions of lepromatous leprosy. Damasco, M. H. S., *et al.* ..... (A) 681
Humoral immune response of tuberculous patients against the three components of the *M. bovis* BCG 85 complex separated by isolectric focusing. Van Vooren, J. P., *et al.* (A) 159
The variable C-terminal region of the *M. leprae* 70-kilodalton heat shock protein is the target for humoral immune responses. Davenport, M. P., *et al.* ..... (A) 302

Immunoglobulins,
Immunoglobulin-A (IgA) and IgG serum antibodies to mycobacterial antigens in Crohn's disease patients and their relatives. Wayne, L. G., *et al.* ..... (A) 707
Prevalence of IgM antibodies to phenolic glycolipid-I among household contacts and controls in Korea and The Philippines. Cho, S.-N., *et al.* ..... (A) 507
Serology and leprosy: immunoassays comparing immunoglobulin G antibody responses to 28- and 30-kilodalton proteins purified from *M. bovis*. Pessolani, M. C. V., *et al.* (A) 136
Specificity of IgG subclass antibodies in different clinical manifestations of leprosy. Dhandayuthanpani, S., *et al.* ..... (A) 302
The pathogenesis of leprosy in the nine-banded armadillo and the significance of IgM antibodies in PGL-I. Job, C. K., *et al.* ..... (A) 515
Time course of anti-SL-IV immunoglobulin-G antibodies in patients with tuberculosis and tuberculosis-associated AIDS. Martin-Casabona, N., *et al.* ..... (A) 324
[UltramicroELISA assay for the detection of human IgM antibodies to *M. leprae*.] Laferte, J., *et al.* ..... (A) 508

Immunology,
Autoimmunity associated with infection: leprosy, acute rheumatic fever and Lyme disease. Ehrenstein, M. and Isenberg, D. ..... (A) 303
Current concepts in the pathogenesis of leprosy; clinical, pathological, immunological and chemotherapeutic aspects. Meyers, W. M. and Marty, A. M. ..... (A) 119
Immunoepidemiological studies on subclinical infection in leprosy. I. Clinical and immunological findings in schoolchildren and adults in Okinawa. Abe, M., *et al.* ..... (A) 692
Immunological upgrading with combined immunotherapy and chemotherapy in a lepromatous leprosy patient: a case report. Zaheer, S. A., *et al.* ..... (A) 130
Immunology of a burnt-out lepromatous leprosy patient. Balina, L. N., *et al.* ..... (C) 102

[Influence of tuberculin therapy on the immunologic parameters in adolescents with pulmonary tuberculosis.] Knoring, B. E., *et al.* ....(A) 323
Molecular and immunological analysis of a fibronectin-binding protein antigen secreted by *M. leprae.* Thole, J. E. R., *et al.* ....(A) 312
Protein antigens of mycobacteria studied by quantitative immunologic techniques. Harboe, M., *et al.* ....(A) 304
Tumor necrosis factor production in patients with leprosy. Barnes, P. F., *et al.* ....(A) 300

Immunotherapy,
Immunological upgrading with combined immunotherapy and chemotherapy in a lepromatous leprosy patient: a case report. Zaheer, S. A., *et al.* ....(A) 130

Indeterminate leprosy,
Indeterminate leprosy; a therapeutic evaluation. Kar, P. K., *et al.* ....(A) 501

India,
1990–1991 Annual Report of the ICMR Director-General. ....(N) 668
1991 Workshop of Voluntary Leprosy Institutions of Andhra Pradesh. Tare, S. P. ....(N) 113
ALERT-India 1981–89: nine years' experience in leprosy control in the slums of Bombay. Samy, A. A., *et al.* ....(A) 149
An educational approach to leprosy control: an evaluation of knowledge, attitudes and practice in two poor localities in Bombay, India. Crook, N., *et al.* ....(A) 147
Bombay Leprosy Project completed 15 years. Ganapati, R. ....(N) 111
Can leprosy be eradicated from India? Kotecha, P. and Harpham, T. ....(A) 693
Central Leprosy Teaching and Research Institute (CLTRI) staff changes. ....(N) 493
Clinico-pathological correlation in Indian Consensus Classification. Desikan, K. V. ....(A) 504
Control of leprosy in India in the background of urbanization. Ganapati, R. ....(A) 516
GLRA takes active part in National Leprosy Eradication Program (NLEP) of Indian government. ....(N) 112
IAL-sponsored 1991 training workshop on foot care. ....(N) 112
ICMR awards for leprosy scientists. ....(N) 113
Leprosy in India; a Compendium of Statistics, 1992. Hastings, R. C. ....(B) 664
Mycobacterium w vaccine being tried in New Delhi, India. ....(N) 113
Problems and needs of women leprosy patients in Bombay and Goa—a preliminary report. Naik, S. S., *et al.* ....(A) 151
Some indices pertaining to the leprosy control programme in Tamil Nadu (India), based on data from the random sample of 14 governmental control units. Nair, N. G. K., *et al.* ....(A) 148
Susceptibility of south Indian strains of *M. tuberculosis* to tuberactinomycin. Selvakumar, N., *et al.* ....(A) 519
The factors influencing the operational efficiency of leprosy case detection programme. Kumar, A., *et al.* ....(A) 147
XVII All India Leprosy Workers Conference. ....(N) 114
XVII Biennial Conference of the Indian Association of Leprologists (IAL). ....(B) 493

Indonesia,
Beliefs of leprosy patients about their illness—a study in the province of South Sulawesi, Indonesia. Elissen, M. C. C. A. ....(A) 299
Distribution of anti-PGL-I and anti-LAM-B antibodies among inhabitants of leprosy-endemic villages in South Sulawesi, Indonesia. Izumi, S., *et al.* ....(A) 719

Indomethacin,
Effect of indomethacin on the modulation of *M. avium* growth in human macrophages by interferon gamma, retinoic acid and 1,25(OH)2-vitamin-D3. DeSousa, J. P. C., *et al.* ....(A) 681

Inoculation,
Activity of sparfloxacin against *M. leprae* inoculated into foot pads of nude mice. Gidoh, M. and Tsutsumi, S. ....(A) 501
Inoculation of foot pads of severe combined immunodeficient mice with *M. leprae.* Ishaque, M. ....(C) 661
Resistance to intravenous inoculation of *M. tuberculosis* H37Rv in mice of different inbred strains following immunization with a leprosy vaccine based on *Mycobacterium w.* Singh, I. G., *et al.* ....(A) 146

Interferon,
Effect of indomethacin on the modulation of *M. avium* growth in human macrophages by interferon gamma, retinoic acid and 1,25(OH)2-vitamin-D3. DeSousa, J. P. C., *et al.* ..... (A) 681
Interferon-gamma and macrophage inflammatory proteins (MIP)-1 and (MIP)-2 are involved in the regulation of the T-cell-dependent chronic peritoneal neutrophilia of mice infected with mycobacteria. Appelberg, R. ..... (A) 679
Long-term follow up of lepromatous leprosy patients receiving intralesional recombinant gamma-interferon. Mathur, N. K., *et al.* ..... (C) 98
Lysis of interferon-gamma activated Schwann cell by cross-reactive CD8 + alpha/beta T cells with specificity for the mycobacterial 65 kd heat shock protein. Steinhoff, U., *et al.* ..... (A) 139
Mechanisms involved in mycobacterial growth inhibition by gamma interferon-activated bone marrow macrophages: role of reactive nitrogen intermediates. Flesch, I. E. A. and Kaufmann, S. H. E. ..... (A) 132
Prolonged treatment with recombinant interferon-gamma induces erythema nodosum leprosum in lepromatous leprosy patients. Sampaio, E. P., *et al.* ..... (A) 686

Interleukin(s),
Differential release of interleukin (IL-)-1 alpha, IL-1 beta, and IL-6 from normal human monocytes stimulated with a virulent and an avirulent isogenic variant of *M. avium-intracellulare* complex. Michelini-Norris, M. B., *et al.* ..... (A) 325
Increase in tumor necrosis factor alpha- and interleukin-6-secreting cells in peripheral blood mononuclear cells from subjects infected with *M. tuberculosis.* Ogawa, T., *et al.* ..... (A) 158
Interleukin-10 production in response to *M. leprae*: evidence for an immunosuppressive role in leprosy. Sieling, P. A., *et al.* ..... (A) 725
Interleukin-6 is used as a growth factor by virulent *M. avium*: presence of specific receptors. Denis, M. ..... (A) 311
Mycobacterial induction of activated killer cells—possible role of tyrosine kinase activity in interleukin-2 receptor alpha expression. Blanchard, D. K., *et al.* ..... (A) 680
Serum tumor necrosis factor and interleukin 1 in leprosy and during lepra reactions. Parida, S. K., *et al.* ..... (A) 306
Soluble interleukin-2 receptors: levels in leprosy, and during and after type 1 (lepra) and type 2 (ENL) reactions. Sehgal, B. N., *et al.* ..... (A) 138
Supernatants derived from CD8+ lymphocytes activated by mycobacterial fractions inhibit cytokine production; the role of interleukin-6. Sussman, G. and Wadee, A. A. (A) 512
The systemic influence of recombinant interleukin 2 on the manifestations of lepromatous leprosy. Kaplan, G., *et al.* ..... (A) 134

International Journal of Leprosy (IJL),
Index to Volume 60 ..... (–) 733
Reviewers ..... (–) 730
Statement of Financial Condition ..... (–) 521
Statement of Ownership, Management, and Circulation ..... (–) 731

Isoniazid,
Antagonism between isoniazid and the combination pyrazinamide-rifampin against tuberculosis infection in mice. Grosset, J., *et al.* ..... (A) 320
Combined chemotherapy including rifabutin for rifampicin and isoniazid resistant pulmonary tuberculosis. Pretet, S., *et al.* ..... (A) 705
Does isoniazid increase the hepatotoxicity of the combination prothionamide-dapsone? Isoprodian Study Group. ..... (O) 536
The catalase peroxidase gene and isoniazid resistance of *M. tuberculosis.* Zhang, Y., *et al.* ..... (A) 709

Italy,
Activity of antimicrobial agents against *M. avium intracellulare* complex (MAC) strains isolated in Italy from AIDS patients. Fattorini, L., *et al.* ..... (A) 699

Japan,
Leprosy situation in selected countries: abstracts from the 64th General Meeting of the Japanese Leprosy Association held in March 1991. ..... (A) 693

Prevalence of dementia amongst elderly Japanese with leprosy—apparent effect of chronic drug therapy. McGeer, P. L., *et al.* ..... (A) 678
Twenty-Seventh Joint Leprosy Research Conference, U.S.-Japan Cooperative Medical Science Program, Matsue, Japan, 4–7 August 1992. ..... (–) 710

Kidney(s),
Does Convit vaccine (BCG + *M. leprae*) afford protection against biochemical changes in renal brush border membrane in experimental leprosy? Kohli, M., *et al.* ..... (A) 135
Hypoadrenalism in patients with pulmonary tuberculosis in Tanzania: an undiagnosed complication? Mugusi, F., *et al.* ..... (A) 158
Intravascular hemolysis and acute renal failure following intermittent rifampin therapy. Gupta, A., *et al.* ..... (O) 185
Renal brushborder membrane vesicle study of marker enzymes and uptake of nutrients in *M. leprae* infected mice. Kohli, M., *et al.* ..... (A) 146

Korea,
"Leprosy in Korea, Past and Present" by Joon Lew. Goodman, D. D. ..... (N) 291
Prevalence of IgM antibodies to phenolic glycolipid-I among household contacts and controls in Korea and The Philippines. Cho, S.-N., *et al.* ..... (A) 507

Larynx,
[A leprosy reaction involving the esophagus and the larynx.] Alvardo, M. and Saul, A. (A) 298

Leishmaniasis,
[Contribution to the study of two infectious granulomatous diseases (leprosy and cutaneous and mucous leishmaniasis) by scintigraphic methods.] Braga, F. J. H. N., *et al.* ..... (A) 504

Lepromatous leprosy,
A clinical trial of minocycline in lepromatous leprosy. Gelber, R. H., *et al.* ..... (A) 500
[Autoantibodies in lepromatous leprosy.] Graninger, W., *et al.* ..... (A) 126
Effect of cutaneous cell-mediated immune response to rIFNgamma on *M. leprae* viability in the lesions of lepromatous leprosy. Damasco, M. H. S., *et al.* ..... (A) 681
High antibody levels to the mycobacterial fibronectin-binding antigen of 30-31 kD in tuberculosis and lepromatous leprosy. Espitia, C., *et al.* ..... (A) 303
Immunological upgrading with combined immunotherapy and chemotherapy in a lepromatous leprosy patient: a case report. Zaheer, S. A., *et al.* ..... (A) 130
Immunology of a burnt-out lepromatous leprosy patient. Balina, L. N., *et al.* ..... (C) 102
Lepromatous leprosy in a Saudi female from central region. Al-Majed, S. A. ..... (A) 125
Lepromatous leprosy: nasal manifestations and treatment with minocycline. Lalwani, A. K., *et al.* ..... (A) 505
[Lepromatous leprosy; an unusual form of presentation.] Achenbach, R. E., *et al.* ..... (A) 124
Long-term follow up of lepromatous leprosy patients receiving intralesional recombinant gamma-interferon. Mathur, N. K., *et al.* ..... (C) 98
Prolonged treatment with recombinant interferon-gamma induces erythema nodosum leprosum in lepromatous leprosy patients. Sampaio, E. P., *et al.* ..... (A) 686
Short-term trial of clofazimine in previously untreated lepromatous leprosy. Jamet, P., *et al.* ..... (O) 542
Subgroups among lepromatous leprosy—a viewpoint. Mathur, N. K., *et al.* ..... (C) 100
The systemic influence of recombinant interleukin 2 on the manifestations of lepromatous leprosy. Kaplan, G., *et al.* ..... (A) 134

Lepromin,
Lepromin reaction in patients with falciparum malaria. Tin-Shwe and Pe-Than-Myint. (A) 688

Lesion(s),
Association of the mycobacterial 30-kDa region proteins with the cutaneous infiltrates of leprosy lesions—evidence for the involvement of the major mycobacterial secreted proteins in the local immune response of leprosy. Rambukkana, A., *et al.* ..... (A) 685
Central nervous system lesions in leprosy—immunohistochemical study using anti-PGL-I antibody. Goto, M., *et al.* ..... (A) 718
Cryptococcus neoformans can be misidentified as a microsporidian: studies of lung lesions in leprosy patients. Furuta, M., *et al.* ..... (A) 299
Defining protective responses to pathogens: cytokine profiles in leprosy lesions. Yamamura, M., *et al.* ..... (A) 141

Effect of cutaneous cell-mediated immune response to rIFNgamma on *M. leprae* viability in the lesions of lepromatous leprosy. Damasco, M. H. S., *et al.* ..... (A) 681
Hyperkeratotic and verrucous skin lesions on lower extremities of leprosy patients. Patki, A. H. and Mehta, J. M. ..... (A) 506
Immune complexes and antibody levels in blisters over human leprosy skin lesions with or without erythema nodosum leprosum. Scollard, D. M., *et al.* ..... (A) 510
[Immunohistochemical study of leprosy skin lesions using S-100 protein and alpha-antichymotrypsin.] Ye, F., *et al.* ..... (A) 689
Intralesional variation in histology. Chatterjee, B. R. ..... (C) 82
Long-term follow up of lepromatous leprosy patients receiving intralesional recombinant gamma-interferon. Mathur, N. K., *et al.* ..... (C) 98

Levamisole,
Displacement of rifampicin bound to serum proteins by addition of levamisole. Perez Gallardo, L., *et al.* ..... (A) 677

Lipid(s),
[Activities of polar glycopeptidolipids from *M. chelonae* in the reversal of a chemically induced leucopenia.] Neway, T., *et al.* ..... (A) 703
Assessment of the diagnostic value of the native PGLTB1, its synthetic neoglycoconjugate PGLTB0 and the sulfolipid IV antigens for the serodiagnosis of tuberculosis. Chanteau, S., *et al.* ..... (O) 1
Comparison of bis-di-octadecylamide of trehalose dicarboxylic acid (BDA.TDA) with glycolipid SL-IV as ELISA antigens for the serodiagnosis of leprosy. Laszlo, A., *et al.* (O) 376
Correlation of serum lipids and lipoproteins in leprosy. Ahaley, S. K., *et al.* ..... (A) 298
Does previous BCG vaccination interfere with the serodiagnosis of tuberculosis using *M. tuberculosis*-specific glycolipid antigens? Salem, J. I., *et al.* ..... (C) 87
Evaluation of synthetic pseudo cord-factor-like glycolipids for the serodiagnosis of tuberculosis. Laszlo, A., *et al.* ..... (A) 702
Humoral response to nerve glycolipid antigen in sera of leprosy patients. Sahasrabudhe, R. V., *et al.* ..... (C) 488
Immunoreactivity of nerve lipid antigens in leprosy. Vemuri, N. and Mukherjee, R. ..(A) 140
Isolation and structural characteristics of monoclonal antibody-defined cross-reactive phospholipid antigen from *M. tuberculosis* and *M. leprae.* Fournie, J. J., *et al.* .....(A) 132
Lipid-laden macrophages in bone marrow of leprosy patients. Sen, P., *et al.* ..... (A) 138
Relationships between titers of antibodies immunoreacting against glycolipid antigens from *M. leprae* and *M. tuberculosis,* the Mitsuda and Mantoux reactions, and bacteriological loads: implications in the pathogenesis, epidemiology and serodiagnosis of leprosy and tuberculosis. David, H. L., *et al.* ..... (O) 208

Lipoarabinomannan (LAM),
Cytokine production induced by *M. tuberculosis* lipoarabinomannan—relationship to chemical structure. Barnes, P. F., *et al.* ..... (A) 680
Distribution of anti-PGL-I and anti-LAM-B antibodies among inhabitants of leprosy-endemic villages in South Sulawesi, Indonesia. Izumi, S., *et al.* ..... (A) 719
Evaluation of lipoarabinomannan for the serological diagnosis of tuberculosis. Sada, E., *et al.* ..... (A) 159
Lipoarabinomannan of *M. tuberculosis*; capping with mannosyl residues in some strains. Chatterjee, D., *et al.* ..... (A) 317
Lipoarabinomannan, a possible virulence factor involved in persistence of *M. tuberculosis* within macrophages. Chan, J., *et al.* ..... (A) 130
Lipoarabinomannan; multiglycosylated form of the mycobacterial mannosylphophosphatidylinositols. Chatterjee, D., *et al.* ..... (A) 317
Specific inhibition of mRNA accumulation for lymphokines in human T cell line Jurkat by mycobacterial lipoarabinomannan antigen. Chujor, C. S. N., *et al.* ..... (A) 301

Lipoprotein,
Correlation of serum lipids and lipoproteins in leprosy. Ahaley, S. K., *et al.* ..... (A) 298

Liver,
CD30 expression by peripheral blood monocytes and hepatic macrophages in a child with miliary tuberculosis. Epstein, M. L., *et al.* ..... (A) 699

Does isoniazid increase the hepatotoxicity of the combination prothionamide-dapsone? Isoprodian Study Group. ..... (O) 536
Human liver microsomal N-hydroxylation of dapsone by cytochrome-P-4503A. Fleming, C. M., *et al.* ..... (A) 676
Immunoreactivity of a mammalian liver component with leprosy sera. Despande, R. G., *et al.* ..... (A) 681

Lucio phenomenon,
[Leprosy reaction in Lucio's phenomenon; treatment with griseofulvin.] Ramirez, M. M. ..... (A) 299

Lupus,
Thalidomide for systemic lupus erythematosus. Bessis, D., *et al.* ..... (A) 518

Lymph node(s),
Mycobacterial spindle cell pseudotumor of lymph nodes. Chen, K. T. K. ..... (A) 318

Lymphocyte(s),
Characterization of circulating lymphocytes by monoclonal antibodies in childhood and adult leprosy. Sehgal, V. N., *et al.* ..... (A) 138
Effect of *in vivo* T lymphocyte subset depletion on mycobacterial infections in mice. Flory, C. M., *et al.* ..... (A) 320
High frequency of cord blood lymphocytes against mycobacterial 65-kDa heat-shock proteins. Fischer, H. P., *et al.* ..... (A) 700
In vivo effects of anti-leprosy drugs on the rat peritoneal macrophages and lymphocyte subpopulations. Sahu, A., *et al.* ..... (A) 686
Mycobacteria and human heat shock protein-specific cytotoxic T lymphocytes in rheumatoid synovial inflammation. Li, S.-G., *et al.* ..... (A) 324
Opportunist mycobacteria express ligands that stimulate production of human V-gamma-9V-delta-2 lymphocytes-T. Hacker, F., *et al.* ..... (A) 683
Quantitation of the soluble E-receptor of human T lymphocytes by rocket electrophoresis in the serum of patients with lepromatous and tuberculoid leprosy. Longo, I. M., *et al.* ..... (A) 135
Role of Th-1 lymphocytes in the development of protective immunity against *M. leprae*; analysis of lymphocyte function by polymerase chain reaction detection of cytokine messenger RNA. Walker, K. B., *et al.* ..... (A) 309
Secreted antigens of *M. tuberculosis*—characterization with lymphocytes-T from patients and contacts after two-dimensional separation. Daugelat, S., *et al.* ..... (A) 698
Supernatants derived from CD8+ lymphocytes activated by mycobacterial fractions inhibit cytokine production; the role of interleukin-6. Sussman, G. and Wadee, A. A. (A) 512
Suppressive effect of circulating immune complexes from leprosy patients on the lymphocyte proliferation induced by *M. leprae* antigens in healthy responders. Tyagi, P., *et al.* ..... (O) 562

Lysozyme,
Use of serum antibody and lysozyme levels for diagnosis of leprosy and tuberculosis. Near, K. A. and Lefford, M. J. ..... (A) 306

Macrophage(s),
Activity *in vitro* of rifabutin, FCE 22807, rifapentine, and rifampin against *M. microti* and *M. tuberculosis* and their penetration into mouse peritoneal macrophages. Dhillon, J. and Mitchison, D. A. ..... (A) 319
CD30 expression by peripheral blood monocytes and hepatic macrophages in a child with miliary tuberculosis. Epstein, M. L., *et al.* ..... (A) 699
Clofazimine crystals in alveolar macrophages from a patient with the acquired immunodeficiency syndrome. Sandler, E. D., *et al.* ..... (A) 297
Comparison of the intracellular activities of clarithromycin and erythromycin against *M. avium* complex strains in J774 cells and in alveolar macrophages from human immunodeficiency virus type 1-infected individuals. Yajko, D. M., *et al.* ..... (A) 708
Effect of antileprosy drugs on superoxide anion production by rat peritoneal macrophage with special reference to light exposed clofazimine. Sahu, A., *et al.* ..... (A) 123

Effect of indomethacin on the modulation of *M. avium* growth in human macrophages by interferon gamma, retinoic acid and 1,25(OH)2-vitamin-D3. DeSousa, J. P. C., *et al.* ..... (A) 681
Effects of activated macrophages on *M. leprae.* Ramasesh, N., *et al.* ..... (A) 137
In vivo effects of anti-leprosy drugs on the rat peritoneal macrophages and lymphocyte subpopulations. Sahu, A., *et al.* ..... (A) 686
Interferon-gamma and macrophage inflammatory proteins (MIP)-1 and (MIP)-2 are involved in the regulation of the T-cell-dependent chronic peritoneal neutrophilia of mice infected with mycobacteria. Appelberg, R. ..... (A) 679
Intracellular growth of *M. avium* in human macrophages is linked to the increased synthesis of prostaglandin E2 and inhibition of the phagosome-lysosome fusions. Rastogi, N., *et al.* ..... (A) 685
Killing of virulent *M. tuberculosis* by reactive nitrogen intermediates produced by activated murine macrophages. Chan, J., *et al.* ..... (A) 310
L-Arginine-dependent macrophage effector functions inhibit metabolic activity of *M. leprae.* Adams, L. B., *et al.* ..... (A) 130
Lipid-laden macrophages in bone marrow of leprosy patients. Sen, P., *et al.* ..... (A) 138
Lipoarabinomannan, a possible virulence factor involved in persistence of *M. tuberculosis* within macrophages. Chan, J., *et al.* ..... (A) 130
M. leprae 65hsp antigen expressed from a retroviral vector in a macrophage cell line is presented to T cells in association with MHC class II in addition to MHC class I. Silva, C. L., *et al.* ..... (A) 511
Macrophage and epithelioid cell nuclear morphology in leprosy. Campbell, G. and Cree, I. A. ..... (A) 680
Mechanisms involved in mycobacterial growth inhibition by gamma interferon-activated bone marrow macrophages: role of reactive nitrogen intermediates. Flesch, I. E. A. and Kaufmann, S. H. E. ..... (A) 132
T-cell mediated cytotoxicity against mycobacterium antigen-pulsed autologous macrophages in leprosy patients. Sasiain, M. D., *et al.* ..... (A) 687

Malawi,
Efficacy of BCG vaccine against leprosy and tuberculosis in Malawi. Ponnighaus, J. M., *et al.* ..... (A) 307

Metabolism,
L-Arginine-dependent macrophage effector functions inhibit metabolic activity of *M. leprae.* Adams, L. B., *et al.* ..... (A) 130
Use of a metabolic inhibitor to reduce dapsone-dependent haemotological toxicity. Coleman, M. D. and Tingle, M. D. ..... (A) 295
Water-soluble complexes of palmitic acid and palmitates for metabolic studies and cultivation trials of *M. leprae.* Kato, L., *et al.* ..... (C) 105

Mice, murine, (see also **Mice, nude**)
Activity *in vitro* of rifabutin, FCE 22807, rifapentine, and rifampin against *M. microti* and *M. tuberculosis* and their penetration into mouse peritoneal macrophages. Dhillon, J. and Mitchison, D. A. ..... (A) 319
Activity of azithromycin against *M. avium* infection in beige mice. Cynamon, M. H. and Klemens, S. P. ..... (A) 698
Antagonism between isoniazid and the combination pyrazinamide-rifampin against tuberculosis infection in mice. Grosset, J., *et al.* ..... (A) 320
Bactericidal activities of single or multiple doses of various combinations of new antileprosy drugs and/or rifampin against *M. leprae* in mice. Ji, B., *et al.* ..... (O) 556
Characterization of the B-cell epitope on hsp65 in the immunized mice and autoimmune patients. Nomaguchi, H., *et al.* ..... (A) 723
Chemotherapeutic efficacy of a newly synthesized benzoxazinorifamycin, KRM-1648, against *M. avium* complex infection induced in mice. Tomioka, H., *et al.* ..... (A) 297
Clarithromycin at very low levels and on intermittent administration inhibits the growth of *M. leprae* in mice. Gelber, R. H., *et al.* ..... (C) 485
Delayed clearance of circulating immune complexes in mice following administration of antileprosy drugs. Kashyap, A., *et al.* ..... (O) 404

Effect of *in vivo* T lymphocyte subset depletion on mycobacterial infections in mice. Flory, C. M., *et al.* ..... (A) 320
Effect of local ultraviolet irradiation on infections of mice with *Candida albicans, M. bovis* BCG, and *Schistosoma mansoni.* Jeevan, A., *et al.* ..... (A) 702
Evidence for an alpha/beta T cell-independent mechanism of resistance to mycobacteria. Bacillus Calmette-Guérin causes progressive infection in severe combined immunodeficient mice, but not in nude mice or in mice depleted of CD4+ and CD8+ T cells. Izzo, A. A. and North, R. J. ..... (A) 507
Immunization of mice with mycobacterial culture filtrate proteins. Hubbard, R. D., *et al.* ..... (A) 321
Immunization of mice with antigen A60 of *M. bovis* BCG. Hubbard, R. D., *et al.* ..... (A) 322
Induction and expression of protective T cells during *M. avium* infections in mice. Appelberg, R. and Pedrosa, J. ..... (A) 313
[Infection and elimination of *M. leprae* in the SCID mouse.] Xabier, M. G., *et al.* ..... (A) 313
Inoculation of foot pads of severe combined immunodeficient mice with *M. leprae.* Ishaque, M. ..... (C) 661
Interferon-gamma and macrophage inflammatory proteins (MIP)-1 and (MIP)-2 are involved in the regulation of the T-cell-dependent chronic peritoneal neutrophilia of mice infected with mycobacteria. Appelberg, R. ..... (A) 679
Killing of virulent *M. tuberculosis* by reactive nitrogen intermediates produced by activated murine macrophages. Chan, J., *et al.* ..... (A) 310
Minimal bactericidal dietary concentration of minocycline for *M. leprae*-infected mice is very low and similar to its minimal inhibitory dietary concentration. Gelber, R. H., *et al.* ..... (C) 276
Morphometric analysis of *M. tuberculosis* infection in mice suggests a genetic influence on the generation of the granulomatous inflammatory response. Orrell, J. M., *et al.* (A) 325
Mouse T cell clones against *M. avium*: identification of clones that modify resistance against atypical mycobacteria infection. Denis, M. ..... (A) 302
[Panteleeva—effectiveness of a liposomal form of rifampicin in the treatment of experimental mouse tuberculosis.]. Yu, N., *et al.* ..... (A) 709
Protection of mice from *M. leprae* infection by T cells and protein vaccines. Gelber, R. H., *et al.* ..... (A) 715
Renal brushborder membrane vesicle study of marker enzymes and uptake of nutrients in *M. leprae* infected mice. Kohli, M., *et al.* ..... (A) 146
Resistance to intravenous inoculation of *M. tuberculosis* H37Rv in mice of different inbred strains following immunization with a leprosy vaccine based on *Mycobacterium w.* Singh, I. G., *et al.* ..... (A) 146
Screening gene expression libraries for epitopes recognized in *M. leprae* by mouse T cells. Villarreal-Ramos, B., *et al.* ..... (A) 688
The activity of amoxicillin plus clavulanic acid against *M. leprae* in mice. Gelber, R. H. ..... (A) 121
Vaccination of mice with a soluble protein fraction of *M. leprae* provides consistent and long-term protection against *M. leprae* infection. Gelber, R. H., *et al.* ..... (A) 303

Mice, nude,
Activity of sparfloxacin against *M. leprae* inoculated into foot pads of nude mice. Gidoh, M. and Tsutsumi, S. ..... (A) 501
Chemotherapy of leprosy in multibacillary nude mice. Hastings, R. C. and Chehl, S. K. (A) 501
Evidence for an alpha/beta T cell-independent mechanism of resistance to mycobacteria. Bacillus Calmette-Guérin causes progressive infection in severe combined immunodeficient mice, but not in nude mice or in mice depleted of CD4+ and CD8+ T cells. Izzo, A. A. and North, R. J. ..... (A) 507

Microbiology,
Gene manipulation in mycobacterium. Konicek, J., *et al.* ..... (A) 311
Multiple forms of O-methyltransferase involved in the microbial conversion of abietic acid into methyl abeitate by *Mycobacterium* sp. Orpiszewski, J., *et al.* ..... (A) 143
Phylogeny of rapidly growing members of the genus *Mycobacterium.* Pitulle, C., *et al.* (A) 704

Minocycline,
A clinical trial of minocycline in lepromatous leprosy. Gelber, R. H., *et al.* ..... (A) 500

Genetic and biochemical analysis of ribosomal proteins of minocycline-susceptible and -resistant *M. smegmatis*. Yamada, T., *et al.* ..... (A) 519
Lepromatous leprosy: nasal manifestations and treatment with minocycline. Lalwani, A. K., *et al.* ..... (A) 505
Minimal bactericidal dietary concentration of minocycline for *M. leprae*-infected mice is very low and similar to its minimal inhibitory dietary concentration. Gelber, R. H., *et al.* ..... (C) 276

Molecular biology,
Binding of a major T-cell epitope of mycobacteria to a specific pocket within HLA-DRw17 (DR3) molecules. Geluk, A., *et al.* ..... (C) 304
Composition and immunogenicity of the polysaccharide components of the thermostable macromolecular antigen group of mycobacterial antigens. Bruneteau, M., *et al.* ..... (A) 512
Genetic vaccines against genetically infective macromolecules? Corcos, M. G. ..... (C) 659
Molecular and immunological analysis of a fibronectin-binding protein antigen secreted by *M. leprae*. Thole, J. E. R., *et al.* ..... (A) 312
Molecular cloning of the alpha-antigen gene from *M. leprae* and its application to serodiagnosis of leprosy. Makino, M. and Suzuki, Y. ..... (A) 721
Mycobacterial heat-shock proteins as carrier molecules. 2. The use of the 70-kDa mycobacterial heat-shock protein as carrier for conjugated vaccines can circumvent the need for adjuvants and bacillis-Calmette-Guérin priming. Barrios, C., *et al.* ..... (A) 695
The 14,000-molecular-weight antigen of *M. tuberculosis* is related to the alpha-crystallin family of low-molecular-weight heat shock proteins. Verbon, A., *et al.* ..... (A) 309

Monocyte(s),
CD30 expression by peripheral blood monocytes and hepatic macrophages in a child with miliary tuberculosis. Epstein, M. L., *et al.* ..... (A) 699
Differential release of interleukin (IL-)-1 alpha, IL-1 beta, and IL-6 from normal human monocytes stimulated with a virulent and an avirulent isogenic variant of *M. avium-intracellulare* complex. Michelini-Norris, M. B., *et al.* ..... (A) 325
Human phagocyte respiratory burst by *M. bovis* BCG and *M. leprae*: functional activation by BCG is mediated by complement and its receptors on monocytes. Launois, P., *et al.* ..... (O) 225
Ultraviolet-irradiated monocytes efficiently inhibit the intracellular replication of *M. avium intracellulare*. Mirando, W. S., *et al.* ..... (A) 509

Morbidity,
Tuberculosis morbidity in the United States: final data, 1990. Jereb, J. A., *et al.* ..... (A) 322

Morphology,
Lack of correlation between colony morphology and lipooligosaccharide content in *M. tuberculosis* complex. Lemassu, A., *et al.* ..... (A) 703
Macrophage and epithelioid cell nuclear morphology in leprosy. Campbell, G. and Cree, I. A. ..... (A) 680

Multidrug therapy (MDT),
About reactivation of the anti-Hansenian programs through early detection of patients and systematic multidrug therapy. Nebout, M. ..... (C) 653
[Adverse, nonsevere side effects seen in leprosy patients implementing multidrug therapy.] Carrazana Hernandez, G. B. and Castano Hernandez, S. T. ..... (A) 120
[An observation of multibacillary cases of leprosy the second year after stopping MDT in Xichang City, Sichuan Province.] Hu, L.-F., *et al.* ..... (A) 676
Comparison of PCR with different clinical forms of leprosy and with multibacillary patients on MDT. Gillis, T. P., *et al.* ..... (A) 716
Duration of multidrug therapy in paucibacillary leprosy patients; experience in the leprosy control program of the All Africa Leprosy and Rehabilitation Training Center (ALERT) in Ethiopia. Becx-Bleumink, M. ..... (O) 436
[Effects of MDT on leprosy in Wuhan area.] Chen, L.-F., *et al.* ..... (A) 120
Impact of multidrug therapy on the treatment and control of leprosy. Chatterjee, B. R. (C) 271
In vitro and *in vivo* interactions of drugs used in multidrug therapy in leprosy. Dhople, A. M., *et al.* ..... (A) 121
Leprosy control through multidrug therapy (MDT). Noordeen, S. K. ..... (A) 119

Multidrug therapy in multibacillary leprosy; experience in an urban leprosy center. Ramesh, V., *et al.* ..... (O) 13
National conference on MDT held in Hangzhou. Ye, G.-Y. ..... (N) 110
[Observation on retreatment with MDT in 657 cases of MB leprosy cured with DDS.] Zhou, D.-H., *et al.* ..... (A) 124
[Observations on two-year therapeutic effect of leprosy MDT of 1482 cases in Jiangsu Province (China).] Lou, H.-Y., *et al.* ..... (A) 296
Occurrence of reactions, their diagnosis and management in leprosy patients treated with multidrug therapy; experience in the leprosy control program of the All Africa Leprosy and Rehabilitation Training Center (ALERT) in Ethiopia. Becx-Bleumink, M. and Berhe, D. ..... (O) 173
Paucibacillary multidrug therapy in leprosy; 7½ years experience. Kaur, S., *et al.* ..... (A) 501
Problems of multidrug therapy. Ramu, G. ..... (A) 503
Relapses among leprosy patients treated with multidrug therapy: experience in the leprosy control program of the All Africa Leprosy and Rehabilitation Training Center (ALERT) in Ethiopia; practical difficulties with diagnosing relapses; operational procedures and criteria for diagnosing relapses. Becx-Bleumink, M. ..... (O) 421
[Results of monitoring 657 ex-patients with MB leprosy in the first year after stop of MDT.] Hu, L.-F., *et al.* ..... (A) 121

Myanmar (Burma),
Lepromin reaction in patients with falciparum malaria. Tin-Shwe and Pe-Than-Myint. (A) 688

Mycobacteria (see also individual species),
A lectin-binding, protease-resistant mycobacterial ligand specifically activates Vgamma9+ and human gamma/delta T cells. Pfeffer, K., *et al.* ..... (A) 307
A rapid microbead method for breaking pathogenic mycobacteria—application in SDS-PAGE and Western blot analysis. Rastogi, N., *et al.* ..... (A) 691
A search for mycobacterial DNA in granulomatous tissues from patients with sarcoidosis using the polymerase chain reaction. Bocart, D., *et al.* ..... (A) 697
Agents of newly recognized or infrequently encountered mycobacterial diseases. Wayne, L. G. and Sramek, H. A. ..... (A) 330
Association of the mycobacterial 30-kDa region proteins with the cutaneous infiltrates of leprosy lesions—evidence for the involvement of the major mycobacterial secreted proteins in the local immune response of leprosy. Rambukkana, A., *et al.* ..... (A) 685
Binding of a major T-cell epitope of mycobacteria to a specific pocket within HLA-DRw17 (DR3) molecules. Geluk, A., *et al.* ..... (C) 304
Cell-mediated immunity to mycobacteria: the effect of cytolysis on parasite viability. Molloy, A., *et al.* ..... (A) 722
Cellular immune responses of mycobacterial heat shock proteins in Nepali leprosy patients and controls. Roche, P. W., *et al.* ..... (O) 36
Cellular oxidative responses and mycobacterial growth inhibition in aerosol and intradermal BCG-immunized guinea-pigs. Lagranderie, M., *et al.* ..... (A) 323
Comparative *in vitro* and *in vivo* activity of fleroxacin and ofloxacin against various mycobacteria. Tomioka, H., *et al.* ..... (A) 146
Composition and immunogenicity of the polysaccharide components of the thermostable macromolecular antigen group of mycobacterial antigens. Bruneteau, M., *et al.* ..... (A) 512
Control and location of acyl-hydrolysing phospholipase activity in pathogenic mycobacteria. Wheeler, P. R. and Ratledge, C. ..... (A) 330
Control of acyl-CoA carboxylase activity in mycobacteria. Wheeler, P. R., *et al.* ..... (A) 312
DNA hybridization analysis of mycobacterial DNA using the 18-kDa protein gene of *M. leprae*. Moudgil, K. D., *et al.* ..... (A) 514
Dendritic cells efficiently immunoselect mycobacterial-reactive T-cells in human blood, including clonable antigen-reactive precursors. Pancholi, P., *et al.* ..... (A) 684
Detection and identification of mycobacteria by amplification of a segment of the gene coding for the 32-kilodalton protein. Soini, H., *et al.* ..... (A) 692
Detection of mycobacterial DNA in sarcoidosis and tuberculosis with polymerase chain reaction. Saboor, S. A., *et al.* ..... (A) 326
Detection of mycobacterial rRNA in sarcoidosis with liquid-phase hybridisation. Mitchell, I. C., *et al.* ..... (A) 325
Development of effective drug combinations for the inhibition of multiply resistant mycobacteria, especially of the *M. avium* complex. Seydel, J. K., *et al.* ..... (A) 706

Diagnosis of mycobacterial infections by PCR and restriction enzyme digestion. Rodrigo, G., *et al.* ..... (A) 705
Disease association of antibodies to human and mycobacterial hsp70 and hsp60 stress proteins. Elsaghier, A., *et al.* ..... (A) 682
Effect of *in vivo* T lymphocyte subset depletion on mycobacterial infections in mice. Flory, C. M., *et al.* ..... (A) 320
Effect of mycobacteria on sensitivity to the cytotoxic effects of tumor necrosis factor. Filley, E. A. and Rook, G. A. W. ..... (A) 132
[Enzymatic release of mycobacteria from the environment.] Thorel, M. F., *et al.* ..... (A) 327
Epidemiology of infection by nontuberculosis mycobacteria; *M. avium, M. intracellulare,* and *M. scrofulaceum* in acid, brown-water swamps of the Southeastern United States and their association with environmental variables. Kirschner, R. A., Jr., *et al.* ..... (A) 323
Evidence for an alpha/beta T cell-independent mechanism of resistance to mycobacteria. Bacillus Calmette-Guérin causes progressive infection in severe combined immunodeficient mice, but not in nude mice or in mice depleted of CD4+ and CD8+ T cells. Izzo, A. A. and North, R. J. ..... (A) 507
Extraction and characterization of mRNA from mycobacteria: implication for virulence gene identification. Patel, B. K. R., *et al.* ..... (A) 144
First International Conference on the Pathogenesis of Mycobacterial Infections: a summary. Rastogi, N., *et al.* ..... (A) 308
Genetic control of innate resistance to mycobacterial infections. Schurr, E., *et al.* ..... (A) 138
High antibody levels to the mycobacterial fibronectin-binding antigen of 30-31 kD in tuberculosis and lepromatous leprosy. Espitia, C., *et al.* ..... (A) 303
IS900-promoted stable integration of a foreign gene into mycobacteria. England, P. M., *et al.* ..... (A) 142
Immunization of mice with mycobacterial culture filtrate proteins. Hubbard, R. D., *et al.* ..... (A) 321
Immunoglobulin-A (IgA) and IgG serum antibodies to mycobacterial antigens in Crohn's disease patients and their relatives. Wayne, L. G., *et al.* ..... (A) 707
Increase of T-cell receptor gamma/delta-bearing T cells in cord blood of newborn babies obtained by *in vitro* stimulation with mycobacterial cord factor. Tsuyuguchi, I., *et al.* (A) 139
Interferon-gamma and macrophage inflammatory proteins (MIP)-1 and (MIP)-2 are involved in the regulation of the T-cell-dependent chronic peritoneal neutrophilia of mice infected with mycobacteria. Appelberg, R. ..... (A) 679
Isolation of cultivable mycobacteria from feces and lungs of armadillos infected with *M. leprae.* Dhople, A. M., *et al.* ..... (O) 244
Lipoarabinomannan; multiglycosylated form of the mycobacterial mannosylphophosphatidylinositols. Chatterjee, D., *et al.* ..... (A) 317
Live but not heat-killed mycobacteria cause rapid chemotaxis of large numbers of eosinophils *in vivo* and are ingested by the attracted granulocytes. Castro, A. G., *et al.* ..... (A) 152
Location of the mycolyl ester substituents in the cell walls of mycobacteria. McNeil, M., *et al.* ..... (A) 143
Lysis of interferon-gamma activated Schwann cell by cross-reactive CD8 + alpha/beta T cells with specificity for the mycobacterial 65 kd heat shock protein. Steinhoff, U., *et al.* ..... (A) 139
Major proteins of mycobacterial strain ICRC and *M. leprae* identified by antibodies in sera from leprosy patients and their contacts. Chiplunkar, S. V., *et al.* ..... (A) 301
Mechanisms involved in mycobacterial growth inhibition by gamma interferon-activated bone marrow macrophages: role of reactive nitrogen intermediates. Flesch, I. E. A. and Kaufmann, S. H. E. ..... (A) 132
Method for high yield preparation in large and small scale of nucleic acids from mycobacteria. Santos, A. R., *et al.* ..... (A) 691
Modulation of expression of delayed hypersensitivity by mycobacterial antigen-85 fibronectin-binding proteins. Godfrey, H. P., *et al.* ..... (A) 682
Modulation of pristane-induced arthritis by mycobacterial antigens. Thompson, S. J., *et al.* ..... (A) 327
Monoclonal antibody epitopes of mycobacterial 65-kD heat-shock protein defined by epitope scanning. Hajeer, A. H., *et al.* ..... (A) 683
Mouse T cell clones against *M. avium*: identification of clones that modify resistance against atypical mycobacteria infection. Denis, M. ..... (A) 302

Mycobacteria and human heat shock protein-specific cytotoxic T lymphocytes in rheumatoid synovial inflammation. Li, S.-G., *et al.* ..... (A) 324
Mycobacteria contain two groEL genes—the second *M. leprae* groEL gene is arranged in an operon with groES. Dewit, T. F. R., *et al.* ..... (A) 690
Mycobacteria contain two groEL genes: the second *M. leprae* groEL gene is arranged in an operon with groES. Rinke de Wit, T. B., *et al.* ..... (A) 514
Mycobacterial brain abscess possibly due to bacille Calmette-Guérin in an immunocompromised child. Coppes, M. J., *et al.* ..... (A) 318
Mycobacterial diseases other than tuberculosis. Wolinsky, E. ..... (A) 708
Mycobacterial heat-shock proteins as carrier molecules. 2. The use of the 70-kDa mycobacterial heat-shock protein as carrier for conjugated vaccines can circumvent the need for adjuvants and bacillis-Calmette-Guérin priming. Barrios, C., *et al.* ..... (A) 695
Mycobacterial induction of activated killer cells—possible role of tyrosine kinase activity in interleukin-2 receptor alpha expression. Blanchard, D. K., *et al.* ..... (A) 680
Mycobacterial protein antigens: a compilation. Young, D. B., *et al.* ..... (A) 312
Mycobacterial research at the N. H. Swellengrebel Laboratory of Tropical Hygiene. Terpstra, W. J. ..... (A) 499
Mycobacterial spindle cell pseudotumor of lymph nodes. Chen, K. T. K. ..... (A) 318
Mycolic acid synthesis—a target for ethionamide in mycobacteria. Quemard, A., *et al.* (A) 691
Nontuberculous mycobacterial keratitis—report of two cases and review of the literature. Bullington, R. H., *et al.* ..... (A) 317
On structural aspects of peptidoglycan of bacterial cell wall with special attention on mycobacteria by computer modeling. Pain, S., *et al.* ..... (A) 311
Opportunist mycobacteria express ligands that stimulate production of human V-gamma-9V-delta-2 lymphocytes-T. Hacker, F., *et al.* ..... (A) 683
Peptide recognition, T-cell receptor usage and HLA restriction elements of human heat-shock protein (hsp)-60 and mycobacterial 65-kDa hsp-reactive T-cell clones from rheumatoid synovial fluid. Quayle, A. J., *et al.* ..... (A) 684
Prevention of adjuvant arthritis in rats by a nonapeptide from the 65-kDa mycobacterial heat shock protein: specificity and mechanism. Yang, X.-D., *et al.* ..... (A) 331
Protein antigens of mycobacteria studied by quantitative immunologic techniques. Harboe, M., *et al.* ..... (A) 304
Refractile mycobacteria in Ramanowsky-stained bone marrow smears; a comparison of acid-fast-stained tissue sections and Romanowsky-stained smears. Torlakovic, E., *et al.* ..... (A) 328
Selection of a human T helper type 1-like T cell subset by mycobacteria. Haanen, J. B. A. G., *et al.* ..... (A) 133
Serological response to purified mycobacterial phosphatidylinositol mannoside in healthy controls and in patients with tuberculosis and leprosy. Mullins, R. J., *et al.* ..... (O) 353
Soluble CD4 suppress the antigen driven proliferative response of certain T cell clones specific for mycobacteria and for peptides by monoclonal heat shock proteins. Gidlund, M., *et al.* ..... (A) 507
Specific inhibition of mRNA accumulation for lymphokines in human T cell line Jurkat by mycobacterial lipoarabinomannan antigen. Chujor, C. S. N., *et al.* ..... (A) 301
Supernatants derived from CD8+ lymphocytes activated by mycobacterial fractions inhibit cytokine production; the role of interleukin-6. Sussman, G. and Wadee, A. A. (A) 512
The significance of proteins actively secreted by *M. tuberculosis* in relation to immunity and complications of mycobacterial diseases. Harboe, M. ..... (SS) 470
The use of radiometric tests in the speciation of mycobacteria—a review. Smid, I., *et al.* ..... (A) 692
WHO Model Prescribing Information; Drugs Used in Mycobacterial Diseases. ..... (B) 117

Mycobacterium aurum,
Cloning and expression of *M. aurum* carotenogenesis genes in *M. smegmatis.* Houssaini-Iraqui, M., *et al.* ..... (A) 321

Mycobacterium avium,
Activity of azithromycin against *M. avium* infection in beige mice. Cynamon, M. H. and Klemens, S. P. ..... (A) 698
Activity of clarithromycin against *M. avium* infection in patients with the acquired immune deficiency syndrome; a controlled clinical trial. Dautzenberg, B., *et al.* ..... (A) 153

Bacteriostatic and bactericidal activities of gentamicin alone and in combination with clarithromycin against *M. avium*. Heifets, L. B., *et al.* ..... (A) 683
Cloning and expression of the gene for the Avi-3 antigen of *M. avium* and mapping of its epitopes. Yamaguchi, R., *et al.* ..... (A) 330
Effect of indomethacin on the modulation of *M. avium* growth in human macrophages by interferon gamma, retinoic acid and 1,25(OH)2-vitamin-D3. DeSousa, J. P. C., *et al.* ..... (A) 681
Epidemiology of infection by nontuberculosis mycobacteria; *M. avium, M. intracellulare,* and *M. scrofulaceum* in acid, brown-water swamps of the Southeastern United States and their association with environmental variables. Kirschner, R. A., Jr., *et al.* ..... (A) 323
Induction and expression of protective T cells during *M. avium* infections in mice. Appelberg, R. and Pedrosa, J. ..... (A) 313
Interleukin-6 is used as a growth factor by virulent *M. avium*: presence of specific receptors. Denis, M. ..... (A) 311
Intracellular growth of *M. avium* in human macrophages is linked to the increased synthesis of prostaglandin E2 and inhibition of the phagosome-lysosome fusions. Rastogi, N., *et al.* ..... (A) 685
Mouse T cell clones against *M. avium*: identification of clones that modify resistance against atypical mycobacteria infection. Denis, M. ..... (A) 302
Susceptibility to infection with *M. avium* is paradoxically correlated with increased synthesis of specific anti-bacterial antibodies. Ferreira, P., *et al.* ..... (A) 155
Transforming growth factor beta (TGF-b1) plays a deterimental role in the progression of experimental *M. avium* infection; *in vivo* and *in vitro* evidence. Denis, M. and Ghadirian, E. ..... (A) 318

***Mycobacterium avium* complex,**
Absence of *M. avium* complex disease in patients with AIDS in Uganda. Morrissey, A. B., *et al.* ..... (A) 325
Activity of antimicrobial agents against *M. avium intracellulare* complex (MAC) strains isolated in Italy from AIDS patients. Fattorini, L., *et al.* ..... (A) 699
CI-960 (PD127391 or AM-1091), sparfloxacin, WIN57273, and isepamicin activity against clinical isolates of *M. avium-intracellulare* complex, *M. chelonae,* and *M. fortuitum*. Barrett, M. S., *et al.* ..... (A) 315
Chemotherapeutic efficacy of a newly synthesized benzoxazinorifamycin, KRM-1648, against *M. avium* complex infection induced in mice. Tomioka, H., *et al.* ..... (A) 297
Clinical and epidemiological importance of typing of *M. avium* complex isolates. Tsang, A. Y., *et al.* ..... (A) 328
Clofazimine: a review of its use in leprosy and *M. avium* complex infection. Garrelts, J. C. ..... (A) 121
Comparison of the intracellular activities of clarithromycin and erythromycin against *M. avium* complex strains in J774 cells and in alveolar macrophages from human immunodeficiency virus type 1-infected individuals. Yajko, D. M., *et al.* ..... (A) 708
Comprehensive approach to identification of serovars of *M. avium* complex. Denner, J. C., *et al.* ..... (A) 319
Development of effective drug combinations for the inhibition of multiply resistant mycobacteria, especially of the *M. avium* complex. Seydel, J. K., *et al.* ..... (A) 706
Differential release of interleukin (IL-)-1 alpha, IL-1 beta, and IL-6 from normal human monocytes stimulated with a virulent and an avirulent isogenic variant of *M. avium-intracellulare* complex. Michelini-Norris, M. B., *et al.* ..... (A) 325
Disseminated *M. avium* complex infection: clinical identification and epidemiologic trends. Havlik, J. A., Jr., *et al.* ..... (A) 320
Extracellular and intracellular activities of sparfloxacin against *M. avium* complex and *M. xenopi*. Gevandan, M. J., *et al.* ..... (A) 701
Gas chromatography-mass spectrometry methods for analysis of secondary alcohols present in the *M. avium* complex. Alugupalli, S., *et al.* ..... (A) 689
Granulomatous prostatitis due to *M. avium* complex. Mikolich, D. J. and Mates, S. M. (A) 326
Survival of patients with acquired immune deficiency syndrome and disseminated *M. avium* complex infection with and without antimycobacterial chemotherapy. Horsburgh, C. R., Jr., *et al.* ..... (A) 156

Mycobacterium bovis (see also **BCG**),
Effect of local ultraviolet irradiation on infections of mice with *Candida albicans, M. bovis* BCG, and *Schistosoma mansoni.* Jeevan, A., *et al.* .....(A) 702
Human phagocyte respiratory burst by *M. bovis* BCG and *M. leprae*: functional activation by BCG is mediated by complement and its receptors on monocytes. Launois, P., *et al.* .....(O) 225
Humoral immune response of tuberculous patients against the three components of the *M. bovis* BCG 85 complex separated by isolectric focusing. Van Vooren, J. P., *et al.* (A) 159
Humoral responses against the 85A and 85B antigens of *M. bovis* BCG in patients with leprosy and tuberculosis. Van Vooren, J. P., *et al.* .....(A) 688
Immunization of mice with the antigen A60 of *M. bovis* BCG. Hubbard, R. D., *et al.* (A) 322
Purification and characterization of an unusually large fatty acid synthase from *M. tuberculosis* var. *bovis* BCG. Kikuchi, S., *et al.* .....(A) 513
Secreted Antigens of Mycobacterium tuberculosis and Mycobacterium bovis BCG by H. G. Wiker .....(B) 665
Serological reactivity to *M. bovis* protein antigens in cattle. Fifis, T., *et al.* .....(A) 319
Serology and leprosy: immunoassays comparing immunoglobulin G antibody responses to 28- and 30-kilodalton proteins purified from *M. bovis.* Pessolani, M. C. V., *et al.* (A) 136
Specific binding of phenolic glycolipid antigens from *M. bovis* BCG with antibodies. Vercellone, A., *et al.* .....(A) 706
The genes coding for the antigen 85 complexes of *M. bovis* BCG are members of a gene family: cloning, sequence determination, and genomic organization of the gene coding for antigen 85-C of *M. tuberculosis.* Content, J., *et al.* .....(A) 153
Thin-layer chromatography systems for the identification of *M. tuberculosis, M. bovis* BCG, *M. kansasii, M. gastri,* and *M. marinum.* Laszlo, A., *et al.* .....(A) 703

Mycobacterium cheloni,
Activities of four macrolides, including clarithromycin, against *M. fortuitum, M. chelonae,* and *M. chelonae*-line organisms. Brown, B. A., *et al.* .....(A) 316
[Activities of polar glycopeptidolipids from *M. chelonae* in the reversal of a chemically induced leucopenia.] Neway, T., *et al.* .....(A) 703
CI-960 (PD127391 or AM-1091), sparfloxacin, WIN57273, and isepamicin activity against clinical isolates of *M. avium-intracellulare* complex, *M. chelonae,* and *M. fortuitum.* Barrett, M. S., *et al.* .....(A) 315
Fatal case of disseminated infection with the turtle bacillus *M. chelonae.* Paul, J., *et al.* (A) 704
Skin, soft tissue, and bone infections due to *M. chelonae chelonae*— importance of prior corticosteroid therapy, frequency of disseminated infections, and resistance to oral antimicrobials other than clarithromycin. Wallace, R. J., *et al.* .....(A) 707
Successful treatment of pulmonary infection due to *M. chelonae*; case report and review. Singh, N. and Yu, V. L. .....(A) 327

Mycobacterium fortuitum,
Activities of four macrolides, including clarithromycin, against *M. fortuitum, M. chelonae,* and *M. chelonae*-like organisms. Brown, B. A., *et al.* .....(A) 316
CI-960 (PD127391 or AM-1091), sparfloxacin, WIN57273, and isepamicin activity against clinical isolates of *M. avium-intracellulare* complex, *M. chelonae,* and *M. fortuitum.* Barrett, M. S., *et al.* .....(A) 315
Characterization of the specific antigenicity of *M. fortuitum.* Besra, G. S., *et al.* .....(A) 696
Interactions of *M. fortuitum* with solid sterol substrate particles. Atrat, P., *et al.* .....(A) 314
Resistance to beta-lactams in *M. fortuitum.* Fattorini, L., *et al.* .....(A) 700

Mycobacterium gastri,
Thin-layer chromatography systems for the identification of *M. tuberculosis, M. bovis* BCG, *M. kansasii, M. gastri,* and *M. marinum.* Laszlo, A., *et al.* .....(A) 703

Mycobacterium intracellulare,
Epidemiology of infection by nontuberculosis mycobacteria; *M. avium, M. intracellulare,* and *M. scrofulaceum* in acid, brown-water swamps of the Southeastern United States and their association with environmental variables. Kirschner, R. A., Jr., *et al.* .....(A) 323
Nucleotide sequence analysis and serologic characterization of the *M. intracellulare* homologue of the *M. tuberculosis* 19-kDa antigen. Nair, J., *et al.* .....(A) 603

Mycobacterium kansasii,

Bacteriostatic and bactericidal activity of anti-tuberculosis drugs against *M. tuberculosis, M. avium, M. intracellulare* complex and *M. kansasii* in different growth phases. Yamori, S., *et al.* ..... (A) 331

Identification of *M. kansasii* by DNA hybridization. Huang, Z. H., *et al.* ..... (A) 157

Thin-layer chromatography systems for the identification of *M. tuberculosis, M. bovis* BCG, *M. kansasii, M. gastri,* and *M. marinum.* Laszlo, A., *et al.* ..... (A) 703

Mycobacterium leprae,

A major T cell antigen of *M. leprae* is a 10-kD heat-shock cognate protein. Mehra, V., *et al.* ..... (A) 305

[A preliminary analysis of antigen components of *M. leprae* with SDS-PAGE.] Li, X.-Y., *et al.* ..... (A) 135

A quantitative basis for sustainable anti-*M. leprae* chemotherapy in leprosy control programs. Almeida, J. G. ..... (E) 255

[A study of subclinical infection with *M. leprae,* the factors influencing the subclinical infection.] Shu, H.-W., *et al.* ..... (A) 139

[A study of subclinical infection with *M. leprae.* (IV) The result of follow-up over three years of the household contacts with leprosy.] Shu, H.-W., *et al.* ..... (A) 687

A unique type of GABA binding by *M. leprae.* Prabhakaran, K., *et al.* ..... (A) 514

Activity of sparfloxacin against *M. leprae* inoculated into foot pads of nude mice. Gidoh, M. and Tsutsumi, S. ..... (A) 501

An experimental study to evaluate the bactericidal activity of ofloxacin against an established *M. leprae* infection. Banerjee, D. K. and McDermott-Lancaster, R. D. ..... (O) 410

Analysis of circulating immune complexes from leprosy patients for *M. leprae* antigens. Sinha, S., *et al.* ..... (O) 396

Antibody responses to the 18-kDa protein of *M. leprae* in leprosy and tuberculosis patients. Roche, P. W., *et al.* ..... (O) 201

Antigens of *M. leprae* in the cerebrospinal fluid of leprosy patients: detection by monoclonal-antibody-based sandwich immunoradiometric assay and avidin/biotin immunoblotting. Patil, S. A., *et al.* ..... (A) 127

Assessing the viability of *M. leprae* by the fluorescein diacetate/ethidium bromide staining technique. Palomino, J. C., *et al.* ..... (A) 144

Avidin-biotin immunoblotting studies on reactivity of leprosy sera with *M. leprae* antigen. Patil, S. A., *et al.* ..... (C) 280

Bactericidal activities of single or multiple doses of various combinations of new antileprosy drugs and/or rifampin against *M. leprae* in mice. Ji, B., *et al.* ..... (O) 556

Cellular immune response to the cell walls of *M. leprae* in leprosy patients and healthy subjects exposed to leprosy. Roche, P. W., *et al.* ..... (A) 686

Characteristics of *M. leprae* Thai-53 strain. Matsuoka, M., *et al.* ..... (A) 722

Clarithromycin at very low levels and on intermittent administration inhibits the growth of *M. leprae* in mice. Gelber, R. H., *et al.* ..... (C) 485

Comparison of polymerase chain reaction technique with other methods for detection of *M. leprae* in tissues of wild nine-banded armadillos. Job, C. K., *et al.* ..... (A) 145

Competency of human-derived *M. leprae* to use palmitic acid in the synthesis of phenolic glycolipid-I and phthiocerol dimycocerosate and to release CO_2 in axenic culture. Shannon, E. J., *et al.* ..... (A) 515

DNA hybridization analysis of mycobacterial DNA using the 18-kDa protein gene of *M. leprae.* Moudgil, K. D., *et al.* ..... (A) 514

Delipidified cell components of *M. leprae* and its applications. Mahadevan, P. R., *et al.* (A) 509

Detection of *M. leprae* in biopsy specimens from leprosy patients by polymerase chain reaction. Yoon, K.-H., *et al.* ..... (A) 727

Detection of a *M. leprae* cell wall antigen in the urine of untreated and treated patients. Sharma, V. K., *et al.* ..... (A) 511

Does Convit vaccine (BCG + *M. leprae*) afford protection against biochemical changes in renal brush border membrane in experimental leprosy? Kohli, M., *et al.* ..... (A) 135

Effect of cutaneous cell-mediated immune response to rIFNgamma on *M. leprae* viability in the lesions of lepromatous leprosy. Damasco, M. H. S., *et al.* ..... (A) 681

Effect of skin test with *M. leprae* soluble antigen on reaction to a subsequent test with the same antigen. Gupte, M. D., *et al.* ..... (O) 54

Effects of activated macrophages on *M. leprae*. Ramasesh, N., *et al.* ..... (A) 137
Enzyme linked immunosorbent assay of a 12-kDa protein of *M. leprae* with sera from leprosy patients. Navalkar, R. G., *et al.* ..... (O) 382
Evaluation of *M. leprae* particle agglutination test, using eluates of filter paper blood spots. Sekar, B. and Anadan, D. ..... (A) 510
Fusidic acid is highly active against extracellular and intracellular *M. leprae*. Franzblau, S. G., *et al.* ..... (A) 296
[GPAT with dried blood specimens for detection of antibody to PGI of *M. leprae*.] Weng, S.-M., *et al.* ..... (A) 679
Hsp 70 synthesis in Schwann cells in response to heat shock and infection with *M. leprae*. Mistry, Y., *et al.* ..... (A) 684
Human phagocyte respiratory burst by *M. bovis* BCG and *M. leprae*: functional activation by BCG is mediated by complement and its receptors on monocytes. Launois, P., *et al.* ..... (O) 225
Immunoprophylactic trial and combined *M. leprae*/BCG vaccine against leprosy: preliminary results. Convit, J., *et al.* ..... (A) 301
Improved method for purification of *M. leprae* from armadillo tissues. Rodde, C., *et al.* ..... (C) 277
[Infection and elimination of *M. leprae* in the SCID mouse.] Xabier, M. G., *et al.* ..... (A) 313
Inoculation of foot pads of severe combined immunodeficient mice with *M. leprae*. Ishaque, M. ..... (C) 661
Interleukin-10 production in response to *M. leprae*: evidence for an immunosuppressive role in leprosy. Sieling, P. A., *et al.* ..... (A) 725
Isolation and structural characteristics of monoclonal antibody-defined cross-reactive phospholipid antigen from *M. tuberculosis* and *M. leprae*. Fournie, J. J., *et al.* ..... (A) 132
Isolation of cultivable mycobacteria from feces and lungs of armadillos infected with *M. leprae*. Dhople, A. M., *et al.* ..... (O) 244
L-Arginine-dependent macrophage effector functions inhibit metabolic activity of *M. leprae*. Adams, L. B., *et al.* ..... (A) 130
Limited T-cell receptor repertoire in the delayed-type hypersensitivity response to *M. leprae*. Wang, X.-H., *et al.* ..... (A) 726
M. leprae 65hsp antigen expressed from a retroviral vector in a macrophage cell line is presented to T cells in association with MHC class II in addition to MHC class I. Silva, C. L., *et al.* ..... (A) 511
M. leprae express extracellular homologs of the antigen 85 complex. Pessolani, M. C. V. and Brennan, P. J. ..... (A) 723
Major proteins of mycobacterial strain ICRC and *M. leprae* identified by antibodies in sera from leprosy patients and their contacts. Chiplunkar, S. V., *et al.* ..... (A) 301
Minimal bactericidal dietary concentration of minocycline for *M. leprae*-infected mice is very low and similar to its minimal inhibitory dietary concentration. Gelber, R. H., *et al.* ..... (C) 276
Modern sensitive techniques for the detection of *M. leprae*. Ayliffe, P. R. ..... (E) 451
Molecular and immunological analysis of a fibronectin-binding protein antigen secreted by *M. leprae*. Thole, J. E. R., *et al.* ..... (A) 312
Molecular cloning of the alpha-antigen gene from *M. leprae* and its application to serodiagnosis of leprosy. Makino, M. and Suzuki, Y. ..... (A) 721
Mycobacteria contain two groEL genes—the second *M. leprae* groEL gene is arranged in an operon with groES. Dewit, T. F. R., *et al.* ..... (A) 690
Mycobacteria contain two groEL genes: the second *M. leprae* groEL gene is arranged in an operon with groES. Rinke de Wit, T. B., *et al.* ..... (A) 514
On the cross-immunoreactivity of the receptor for beta-glucuronidase (BGR) of *M. leprae* with the extracts of beans. Matsuo, E., *et al.* ..... (A) 721
One-carbon requirements of *M. leprae*: need for the folate pathway. Wheeler, P. R. ... (E) 445
Phospholipase activity of *M. leprae* harvested from experimentally infected armadillo tissue. Wheeler, P. R. and Ratledge, C. ..... (A) 144
Polymerase chain reaction amplifying DNA coding to species-specific rRNA of *M. leprae*. Pattyn, S. R., *et al.* ..... (O) 234
Preliminary study of cellular immunity to *M. leprae* protein in contacts and leprosy patients. Rada S., E. M., *et al.* ..... (O) 189

Protection of mice from *M. leprae* infection by T cells and protein vaccines. Gelber, R. H., *et al.* ..... (A) 715
Recognition of *M. leprae* recombinant 18-kDa proteins in leprosy. Hussain, R., *et al.* (O) 368
Relationships between titers of antibodies immunoreacting against glycolipid antigens from *M. leprae* and *M. tuberculosis*, the Mitsuda and Mantoux reactions, and bacteriological loads: implications in the pathogenesis, epidemiology and serodiagnosis of leprosy and tuberculosis. David, H. L., *et al.* ..... (O) 208
Renal brushborder membrane vesicle study of marker enzymes and uptake of nutrients in *M. leprae* infected mice. Kohli, M., *et al.* ..... (A) 146
Role of Th-1 lymphocytes in the development of protective immunity against *M. leprae*; analysis of lymphocyte function by polymerase chain reaction detection of cytokine messenger RNA. Walker, K. B., *et al.* ..... (A) 309
Screening gene expression libraries for epitopes recognized in *M. leprae* by mouse T cells. Villarreal-Ramos, B., *et al.* ..... (A) 688
Sensitization potential and reactogenicity of BCG with and without various doses of killed *M. leprae*. Gupte, M. D., *et al.* ..... (O) 340
Sequence and immunogenicity of the 70-kDa heat shock protein of *M. leprae*. McKenzie, K. R., *et al.* ..... (A) 136
Sero-Immunoreactivity of cloned protein antigens of *M. leprae*. Khan, M. B., *et al.* ..... (O) 195
Species-specific assessment of *M. leprae* in skin biopsies by *in situ* hybridization and polymerase chain reaction. Arnoldi, J., *et al.* ..... (A) 689
Suppressive effect of circulating immune complexes from leprosy patients on the lymphocyte proliferation induced by *M. leprae* antigens in healthy responders. Tyagi, P., *et al.* ..... (O) 562
T-cell responses of leprosy patients and healthy contacts toward separated protein antigens of *M. leprae*. Gulle, H., *et al.* ..... (O) 44
TNF-alpha failed to reverse the *M. leprae*-induced defective chemiluminescence response of human mononuclear cells. Launois, P., *et al.* ..... (A) 305
The activity of amoxicillin plus clavulanic acid against *M. leprae* in mice. Gelber, R. H. ..... (A) 121
The activity of rifabutin against *M. leprae*. Yoder, L. J., *et al.* ..... (A) 124
The antibody repertoire to proteins of *M. leprae*: genetic influences at the antigen and epitope level. Adeleye, T. A., *et al.* ..... (A) 679
The nucleotide sequence of the promoter, 16S rRNA and spacer region of the ribosomal RNA operon of *M. tuberculosis* and comparison with *M. leprae* precursor rRNA. Kempsell, K. E., *et al.* ..... (A) 690
The susceptibility testing of 13 strains of *M. leprae* to rifampicin and the determination of minimal effective dosage. Wang, H., *et al.* ..... (A) 123
The variable C-terminal region of the *M. leprae* 70-kilodalton heat shock protein is the target for humoral immune responses. Davenport, M. P., *et al.* ..... (A) 302
Towards the integration of foreign DNA into the chromosome of *M. leprae*. Eiglmeier, K., *et al.* ..... (A) 142
[UltramicroELISA assay for the detection of human IgM antibodies to *M. leprae*.] Laferte, J., *et al.* ..... (A) 508
Use of synthetic peptides corresponding to sequences of *M. leprae* proteins to study delayed-type hypersensitivity response in sensitized guinea pigs. Estrada-G., I. C. E., *et al.* ..... (O) 18
Vaccination of mice with a soluble protein fraction of *M. leprae* provides consistent and long-term protection against *M. leprae* infection. Gelber, R. H., *et al.* ..... (A) 303
Water soluble palmitic acid-methylated cyclodextrin complex; a substrate oxidized by *M. leprae*. Ishaque, M. ..... (C) 279
Water-soluble complexes of palmitic acid and palmitates for metabolic studies and cultivation trials of *M. leprae*. Kato, L., *et al.* ..... (C) 105

Mycobacterium lepraemurium,
Cyclophosphamide treatment antagonizes the *in vitro* development of *M. lepraemurium*-induced suppressor cell precursors. Gosselin, D., *et al.* ..... (A) 701
Energy generation mechanisms in the *in vitro*-grown *M. lepraemurium*. Ishaque, M. ..... (O) 61
[Energy production in *M. lepraemurium* cultivated *in vitro*.] Ishaque, M. ..... (A) 322

Mycobacterium marinum,
Thin-layer chromatography systems for the identification of *M. tuberculosis, M. bovis* BCG, *M. kansasii, M. gastri,* and *M. marinum.* Laszlo, A., *et al.* ..... (A) 703

Mycobacterium microti,
Activity *in vitro* of rifabutin, FCE 22807, rifapentine, and rifampin against *M. microti* and *M. tuberculosis* and their penetration into mouse peritoneal macrophages. Dhillon, J. and Mitchison, D. A. ..... (A) 319

Mycobacterium paratuberculosis,
Amplification of 16Ss rRNA sequences to detect *M. paratuberculosis.* Vandergiessen, J. W. B., *et al.* ..... (A) 329
M. paratuberculosis binds fibronectin. Valentin-Weigand, P. and Moriarty, K. M. ..... (A) 328
M. paratuberculosis DNA in Crohn's disease tissue. Sanderson, J. D., *et al.* ..... (A) 705

Mycobacterium phlei,
Diagnostic accuracy of a *M. phlei*-absorbed serum enzyme-linked immunosorbent assay for diagnosis of bovine paratuberculosis in dairy cows. Bech-Nielsen, S., *et al.* ..... (A) 315

Mycobacterium psychrophilum,
Adaptation of *M. psychrophilum* (L) to mesophilic growth on water-soluble palmitic acid complex agar media. Kato, L. ..... (C) 662

Mycobacterium scrofulaceum,
Epidemiology of infection by nontuberculosis mycobacteria; *M. avium, M. intracellulare,* and *M. scrofulaceum* in acid, brown-water swamps of the Southeastern United States and their association with environmental variables. Kirschner, R. A., Jr., *et al.* ..... (A) 323
Immunophenotypic analysis of histiocytes involved in AIDS-associated *M. scrofulaceum* infection: similarities with lepromatous lepra. Delabie, J., *et al.* ..... (A) 125

Mycobacterium smegmatis,
Citrate synthase from *M. smegmatis*; cloning, sequence determination and expression in *Escherichia coli.* David, M., *et al.* ..... (A) 154
Cloning and expression of *M. aurum* carotenogenesis genes in *M. smegmatis.* Houssaini-Iraqui, M., *et al.* ..... (A) 321
Fluorescein diacetate and ethidium bromide staining to determine the viability of *M. smegmatis* and *Escherichia coli.* Jayapal, V., *et al.* ..... (A) 143
Genetic and biochemical analysis of ribosomal proteins of minocycline-susceptible and -resistant *M. smegmatis.* Yamada, T., *et al.* ..... (A) 519
Purification and partial characterization of a penicillin-binding protein from *M. smegmatis.* Basu, J., *et al.* ..... (A) 690

Mycobacterium tuberculosis,
Activity *in vitro* of rifabutin, FCE 22807, rifapentine, and rifampin against *M. microti* and *M. tuberculosis* and their penetration into mouse peritoneal macrophages. Dhillon, J. and Mitchison, D. A. ..... (A) 319
Bacteriostatic and bactericidal activity of anti-tuberculosis drugs against *M. tuberculosis, M. avium, M. intracellulare* complex and *M. kansasii* in different growth phases. Yamori, S., *et al.* ..... (A) 331
Beta-Lactamase inhibitors and the inducibility of the beta-lactamase of *M. tuberculosis.* Zhang, S. K., *et al.* ..... (A) 298
Characterization of a DNA probe for detection of *M. tuberculosis* complex in clinical samples by polymerase chain reaction. Altamirano, M., *et al.* ..... (A) 695
Cytokine production induced by *M. tuberculosis* lipoarabinomannan–relationship to chemical structure. Barnes, P. F., *et al.* ..... (A) 680
DNA polymorphisms in strains of *M. tuberculosis* analyzed by pulsed-field gel electrophoresis—a tool for epidemiology. Zhang, Y. S., *et al.* ..... (A) 709
Differentiation of slowly growing mycobacterium species, including *M. tuberculosis,* by gene amplification and restriction fragment length polymorphism analysis. Plikaytis, B. B., *et al.* ..... (A) 704
Does previous BCG vaccination interfere with the serodiagnosis of tuberculosis using *M. tuberculosis*-specific glycolipid antigens? Salem, J. I., *et al.* ..... (C) 87

Dot-ELISA for detection of phenolic glycolipid PGL-Tb1 and diacyl-trehalose antigens of *M. tuberculosis.* Papa, F., *et al.* ..... (A) 326
Heat shock proteins and antigens of *M. tuberculosis.* Young, D. B. and Garbe, T. R. ..(A) 145
Heterogeneity of the repertoire of T cells of tuberculosis patients and healthy contacts to *M. tuberculosis* antigens separated by high-resolution techniques. Schoel, B., *et al.* (A) 326
Identification of B- and T-cell epitopes within the MTP40 protein of *M. tuberculosis* and their correlation with the disease course. Falla, J. C., *et al.* ..... (A) 154
Identification of a novel B-cell epitope of restricted specificity on the hsp 65-kDa protein of *M. tuberculosis.* Rambukkana, A., *et al.* ..... (A) 137
Immunoreactivity of a 120-kDa antigen of *M. tuberculosis.* Barnes, P. F., *et al.* ..... (A) 315
In vitro and *in vivo* activities of sparfloxacin (AT-4140) against *M. tuberculosis.* Ji, B., *et al.* ..... (A) 157
Increase in tumor necrosis factor alpha- and interleukin-6-secreting cells in peripheral blood mononuclear cells from subjects infected with *M. tuberculosis.* Ogawa, T., *et al.* ..... (A) 158
Isolation and structural characteristics of monoclonal antibody-defined cross-reactive phospholipid antigen from *M. tuberculosis* and *M. leprae.* Fournie, J. J., *et al.* ..... (A) 132
Killing of virulent *M. tuberculosis* by reactive nitrogen intermediates produced by activated murine macrophages. Chan, J., *et al.* ..... (A) 310
Lack of correlation between colony morphology and lipooligosaccharide content in *M. tuberculosis* complex. Lemassu, A., *et al.* ..... (A) 703
Lipoarabinomannan of *M. tuberculosis*; capping with mannosyl residues in some strains. Chatterjee, D., *et al.* ..... (A) 317
Lipoarabinomannan, a possible virulence factor involved in persistence of *M. tuberculosis* within macrophages. Chan, J., *et al.* ..... (A) 130
M. tuberculosis-complex specific T-cell stimulation and DTH reactions induced with a peptide from the 38-kDa protein. Vordermeier, H. M., *et al.* ..... (A) 707
Mapping of T helper cell epitopes by using peptides spanning the 19-kDa protein of *M. tuberculosis*: evidence for unique and shared epitopes in the stimulation of antibody and delayed-type hypersensitivity. Ashbridge, K. R., *et al.* ..... (A) 314
Morphometric analysis of *M. tuberculosis* infection in mice suggests a genetic influence on the generation of the granulomatous inflammatory response. Orrell, J. M., *et al.* (A) 325
Nucleotide sequence analysis and serologic characterization of the *M. intracellulare* homologue of the *M. tuberculosis* 19-kDa antigen. Nair, J., *et al.* ..... (A) 603
Purification and characterization of an unusually large fatty acid synthase from *M. tuberculosis* var. *bovis* BCG. Kikuchi, S., *et al.* ..... (A) 513
Pyrazinamide sterilizing activity *in vitro* against semidormant *M. tuberculosis* bacterial populations. Heifets, L. and Lindholm-Levy, P. ..... (A) 701
Rapid, simple method for treating clinical specimens containing *M. tuberculosis* to remove DNA for polymerase chain reaction. Buck, G. E., *et al.* ..... (A) 316
Reduced anti-*M. tuberculosis* antibody response in tuberculosis patients with acquired immunodeficiency syndrome. Figueiredo, J. F. A. and Machado, A. A. ..... (A) 700
Relationships between titers of antibodies immunoreacting against glycolipid antigens from *M. leprae* and *M. tuberculosis,* the Mitsuda and Mantoux reactions, and bacteriological loads: implications in the pathogenesis, epidemiology and serodiagnosis of leprosy and tuberculosis. David, H. L., *et al.* ..... (O) 208
Resistance to intravenous inoculation of *M. tuberculosis* H37Rv in mice of different inbred strains following immunization with a leprosy vaccine based on *Mycobacterium w.* Singh, I. G., *et al.* ..... (A) 146
Secreted Antigens of Mycobacterium tuberculosis and Mycobacterium bovis BCG by H. G. Wiker. ..... (B) 665
Secreted antigens of *M. tuberculosis*—characterization with lymphocytes-T from patients and contacts after two-dimensional separation. Daugelat, S., *et al.* ..... (A) 698
Susceptibility of south Indian strains of *M. tuberculosis* to tuberactinomycin. Selvakumar, N., *et al.* ..... (A) 519
Synthesis of the trisaccharide-protein conjugate of the phenolic glycolipid of *M. tuberculosis* for the serodiagnosis of tuberculosis. Fujiwara, T. ..... (A) 155
The 14,000-molecular-weight antigen of *M. tuberculosis* is related to the alpha-crystallin family of low-molecular-weight heat shock proteins. Verbon, A., *et al.* ..... (A) 309

The catalase peroxidase gene and isoniazid resistance of *M. tuberculosis*. Zhang, Y., *et al.* ..... (A) 709
The genes coding for the antigen 85 complexes of *M. bovis* BCG are members of a gene family: cloning, sequence determination, and genomic organization of the gene coding for antigen 85-C of *M. tuberculosis*. Content, J., *et al.* ..... (A) 153
The nucleotide sequence of the promoter, 16S rRNA and spacer region of the ribosomal RNA operon of *M. tuberculosis* and comparison with *M. leprae* precursor rRNA. Kempsell, K. E., *et al.* ..... (A) 690
The significance of proteins actively secreted by *M. tuberculosis* in relation to immunity and complications of mycobacterial diseases. Harboe, M. ..... (SS) 470
Thin-layer chromatography systems for the identification of *M. tuberculosis, M. bovis* BCG, *M. kansasii, M. gastri,* and *M. marinum*. Laszlo, A., *et al.* ..... (A) 703
Use of polymerase chain reaction for early identification of *M. tuberculosis* in positive cultures. Cormican, M. G., *et al.* ..... (A) 698

Mycobacterium ulcerans,
Postulated epidemiology of *M. ulcerans* infection. Hayman, J. ..... (A) 321
The phenolic mycoside of *M. ulcerans*: structure and taxonomic implications. Daffe, M., *et al.* ..... (C) 310

Mycobacterium w,
Association of HLA antigens with differential responsiveness to *Mycobacterium w* vaccine in multibacillary leprosy patients. Rani, R., *et al.* ..... (A) 308
Histopathological monitoring of an immunotherapeutic trial with *Mycobacterium w.* Mukherjee, A., *et al.* ..... (O) 28
Mycobacterium w vaccine being tried in New Delhi, India. ..... (N) 113
Resistance to intravenous inoculation of *M. tuberculosis* H37Rv in mice of different inbred strains following immunization with a leprosy vaccine based on *Mycobacterium w.* Singh, I. G., *et al.* ..... (A) 146
T-cell responses to fractionated antigens of *Mycobacterium w,* a candidate anti-leprosy vaccine, in leprosy patients. Yadava, A., *et al.* ..... (A) 141

Mycobacterium xenopi,
Extracellular and intracellular activities of sparfloxacin against *M. avium* complex and *M. xenopi*. Gevandan, M. J., *et al.* ..... (A) 701

Nepal,
Cellular immune responses of mycobacterial heat shock proteins in Nepali leprosy patients and controls. Roche, P. W., *et al.* ..... (O) 36

Nerve(s),
An ultrastructural study of Schwann cells in peripheral nerves of leprosy patients. Kumar, V., *et al.* ..... (A) 305
Detection of antibodies to human nerve antigens in sera from leprosy patients by ELISA. Park, J. Y., *et al.* ..... (A) 307
Diagnostic exploration of enlarged peripheral nerves in suspected cases of leprosy; an analysis of 55 cases. Dong, L., *et al.* ..... (A) 505
Early detection of damage to nerves in leprosy. Palande, D. D. and Bowden, R. E. M. (A) 506
Humoral response to nerve glycolipid antigen in sera of leprosy patients. Sahasrabudhe, R. V., *et al.* ..... (C) 488
Immunopathology of nerve involvement in leprosy. Turk, J. L., *et al.* ..... (A) 512
Immunoreactivity of nerve lipid antigens in leprosy. Vemuri, N. and Mukherjee, R. ..(A) 140
Reaction of peripheral nerves to vascular and bacterial injuries. Rasouli, I. and Mehta, L. N. ..... (A) 308

Netherlands, The,
INFOLEP: Leprosy Information Services. ..... (N) 670
Mycobacterial research at the N. H. Swellengrebel Laboratory of Tropical Hygiene. Terpstra, W. J. ..... (A) 499

Neuritis,
Unusual cell of leprous neuritis. Shetty, P. C. and Antia, N. H. ..... (C) 483

Neuropathy,
Perineurial involvement in tuberculoid leprous neuropathy. Kimura, T., *et al.* ..... (A) 719

Neutrophil(s),
Dapsone suppresses integrin-mediated neutrophil adherence function. Booth, S. A., *et al.* ..... (A) 294

Nigeria,
Appraisal of the knowledge and attitude of Nigerian nurses toward leprosy. Awofeso, N. ..... (A) 498

Norway,
A contribution to the history of tuberculosis and leprosy in 19th century Norway. Wood, S. R. ..... (A) 120
Armauer Hansen Jubilee Symposium, October 1992, Bergen, Norway. ..... (SS) 465

Nose,
[A thermoindicative nasal test for detecting allergy to antituberculosis drugs.] Buseva, T. A. and Koryakin, V. A. ..... (A) 152
Lepromatous leprosy: nasal manifestations and treatment with minocycline. Lalwani, A. K., *et al.* ..... (A) 505
Nasal myiasis in leprosy. Husain, S., *et al.* ..... (A) 126

Obituaries,
P. N. Neelan. Desikan, K. V. ..... (Ob) 108
Roy Handel Thangaraj. Fritschi, E. ..... (Ob) 109

Ofloxacin,
An experimental study to evaluate the bactericidal activity of ofloxacin against an established *M. leprae* infection. Banerjee, D. K. and McDermott-Lancaster, R. D. ..... (O) 410
Comparative *in vitro* and *in vivo* activity of fleroxacin and ofloxacin against various mycobacteria. Tomioka, H., *et al.* ..... (A) 146
Ofloxacin for the treatment of leprosy. Ji, B. and Grosset, J. ..... (A) 122

Okinawa,
Immunoepidemiological studies on subclinical infection in leprosy. I. Clinical and immunological findings in schoolchildren and adults in Okinawa. Abe, M., *et al.* ..... (A) 692

Pakistan,
Detection of high titres of *Toxoplasma gondii* antibodies in sera of patients with leprosy in Pakistan. Hussain, R., *et al.* ..... (A) 683

Pathology,
Immunopathogy of nerve involvement in leprosy. Turk, J. L., *et al.* ..... (A) 512

Peroxidase,
The catalase peroxidase gene and isoniazid resistance of *M. tuberculosis.* Zhang, Y., *et al.* ..... (A) 709

Phagocyte(s),
Human phagocyte respiratory burst by *M. bovis* BCG and *M. leprae*: functional activation by BCG is mediated by complement and its receptors on monocytes. Launois, P., *et al.* ..... (O) 225
Reactive oxygen intermediates in the phagocytes from leprosy patients: correlation with reactional states and variation drug treatment. Santos, D. O., *et al.* ..... (C) 92

Phenolic glycolipid(s),
Central nervous system lesions in leprosy—immunohistochemical study using anti-PGL-I antibody. Goto, M., *et al.* ..... (A) 718
Comparison of PGL-I level with AFB numbers in foot pad suspension. Cho, S.-N., *et al.* ..... (C) 96
Competency of human-derived *M. leprae* to use palmitic acid in the synthesis of phenolic glycolipid-I and phthiocerol dimycocerosate and to release CO_2 in axenic culture. Shannon, E. J., *et al.* ..... (A) 515
Distribution of anti-PGL-I and anti-LAM-B antibodies among inhabitants of leprosy-endemic villages in South Sulawesi, Indonesia. Izumi, S., *et al.* ..... (A) 719
Dot-ELISA for detection of phenolic glycolipid PGL-Tb1 and diacyl-trehalose antigens of *M. tuberculosis.* Papa, F., *et al* ..... (A) 326

Evaluation of gelatin particle agglutination assay for the detection of anti-PGL-I antibodies. Comparison with ELISA method and applicability on a large scale study using blood collected on filter paper. Chanteau, S., *et al.* ..... (A) 131
Follow-up of multibacillary leprosy patients using a phenolic glycolipid-I-based ELISA. Do increasing ELISA-values after discontinuation of treatment indicate relapse? Chin-A-Lien, R., *et al.* ..... (A) 507
Prevalence of IgM antibodies to phenolic glycolipid-I among household contacts and controls in Korea and The Philippines. Cho, S.-N., *et al.* ..... (A) 507
Specific binding of phenolic glycolipid antigens from *M. bovis* BCG with antibodies. Vercellone, A., *et al.* ..... (A) 706
Synthesis of the trisaccharide-protein conjugate of the phenolic glycolipid of *M. tuberculosis* for the serodiagnosis of tuberculosis. Fujiwara, T. ..... (A) 155
The pathogenesis of leprosy in the nine-banded armadillo and the significance of IgM antibodies in PGL-I. Job, C. K., *et al.* ..... (A) 515
Use of a different buffer system in the phenolic glycolipid-I ELISA. Sticht-Groh, V., *et al.* ..... (O) 570

Philippines, The,
Prevalence of IgM antibodies to phenolic glycolipid-I among household contacts and controls in Korea and The Philippines. Cho, S.-N., *et al.* ..... (A) 507
Society and leprosy: a study of knowledge, attitudes and practices of Philippine Ilocanos. Valencia, L. B., *et al.* ..... (A) 506

Phospholipid(s),
Control and location of acyl-hydrolysing phospholipase activity in pathogenic mycobacteria. Wheeler, P. R. and Ratledge, C. ..... (A) 330
Isolation and structural characteristics of monoclonal antibody-defined cross-reactive phospholipid antigen from *M. tuberculosis* and *M. leprae*. Fournie, J. J., *et al.* ..... (A) 132
Phospholipase activity of *M. leprae* harvested from experimentally infected armadillo tissue. Wheeler, P. R. and Ratledge, C. ..... (A) 144

Phthiocerol,
Competency of human-derived *M. leprae* to use palmitic acid in the synthesis of phenolic glycolipid-I and phthiocerol dimycocerosate and to release CO_2 in axenic culture. Shannon, E. J., *et al.* ..... (A) 515

Polymerase chain reaction (PCR),
A search for mycobacterial DNA in granulomatous tissues from patients with sarcoidosis using the polymerase chain reaction. Bocart, D., *et al.* ..... (A) 697
Characterization of DNA probe for detection of *M. tuberculosis* complex in clinical samples by polymerase chain reaction. Altamirano, M., *et al.* ..... (A) 695
Comparison of PCR with different clinical forms of leprosy and with multibacillary patients on MDT. Gillis, T. P., *et al.* ..... (A) 716
Comparison of polymerase chain reaction technique with other methods for detection of *M. leprae* in tissues of wild nine-banded armadillos. Job, C. K., *et al.* ..... (A) 145
Detection of *M. leprae* in biopsy specimens from leprosy patients by polymerase chain reaction. Yoon, K.-H., *et al.* ..... (A) 727
Detection of mycobacterial DNA in sarcoidosis and tuberculosis with polymerase chain reaction. Saboor, S. A., *et al.* ..... (A) 326
Diagnosis of mycobacterial infections by PCR and restriction enzyme digestion. Rodrigo, G., *et al.* ..... (A) 705
Polymerase chain reaction amplifying DNA coding to species-specific rRNA of *M. leprae*. Pattyn, S. R., *et al.* ..... (O) 234
Polymerase chain reaction applied to biopsies from paucibacillary leprosy. Pattyn, S. R., *et al.* ..... (C) 482
Rapid, simple method for treating clinical specimens containing *M. tuberculosis* to remove DNA for polymerase chain reaction. Buck, G. E., *et al.* ..... (A) 316
Species-specific assessment of *M. leprae* in skin biopsies by *in situ* hybridization and polymerase chain reaction. Arnoldi, J., *et al.* ..... (A) 689
Suitability of a skin-smear examination needle for leprosy screening by PCR. Sugita, Y., *et al.* ..... (C) 658

The use of the polymerase chain reaction test in the diagnosis of tuberculosis. van Helden, P. D., *et al.* ..... (A) 329
Use of polymerase chain reaction for early identification of *M. tuberculosis* in positive cultures. Cormican, M. G., *et al.* ..... (A) 698

Prostaglandin,
Intracellular growth of *M. avium* in human macrophages is linked to the increased synthesis of prostaglandin E2 and inhibition of the phagosome-lysosome fusions. Rastogi, N., *et al.* ..... (A) 685

Protein(s),
A major T cell antigen of *M. leprae* is a 10-kD heat-shock cognate protein. Mehra, V., *et al.* ..... (A) 305
Antibody responses to the 18-kDa protein of *M. leprae* in leprosy and tuberculosis patients. Roche, P. W., *et al.* ..... (O) 201
Association of the mycobacterial 30-kDA region proteins with the cutaneous infiltrates of leprosy lesions—evidence for the involvement of the major mycobacterial secreted proteins in the local immune response of leprosy. Rambukkana, A., *et al.* ..... (A) 685
Cellular immune responses of mycobacterial heat shock proteins in Nepali leprosy patients and controls. Roche, P. W., *et al.* ..... (O) 36
DNA hybridization analysis of mycobacterial DNA using the 18-kDa protein gene of *M. leprae.* Moudgil, K. D., *et al.* ..... (A) 514
Detection and identification of mycobacteria by amplification of a segment of the gene coding for the 32-kilodalton protein. Soini, H., *et al.* ..... (A) 692
Disease association of antibodies to human and mycobacterial hsp70 and hsp60 stress proteins. Elsaghier, A., *et al.* ..... (A) 682
Enzyme linked immunosorbent assay of a 12-kDa protein of *M. leprae* with sera from leprosy patients. Navalkar, R. G., *et al.* ..... (O) 382
Genetic and biochemical analysis of ribosomal proteins of minocycline-susceptible and -resistant *M. smegmatis.* Yamada, T., *et al.* ..... (A) 519
Heat shock proteins and antigens of *M. tuberculosis.* Young, D. B. and Garbe, T. R. ..(A) 145
Heat-shock proteins and leprosy. Sinha, S. ..... (A) 515
High frequency of cord blood lymphocytes against mycobacterial 65-kDa heat-shock proteins. Fischer, H. P., *et al.* ..... (A) 700
Identification of B- and T-cell epitopes within the MTP40 protein of *M. tuberculosis* and their correlation with the disease course. Falla, J. C., *et al.* ..... (A) 154
Identification of a novel B-cell epitope of restricted specificity on the hsp 65-kDa protein of *M. tuberculosis.* Rambukkana, A., *et al.* ..... (A) 137
[Immunohistochemical study of leprosy skin lesions using S-100 protein and alpha-antichymotrypsin.] Ye, F., *et al.* ..... (A) 689
Interferon-gamma and macrophage inflammatory proteins (MIP)-1 and (MIP)-2 are involved in the regulation of the T-cell-dependent chronic peritoneal neutrophilia of mice infected with mycobacteria. Appelberg, R. ..... (A) 679
Lysis of interferon-gamma activated Schwann cell by cross-reactive CD8 + alpha/beta T cells with specificity for the mycobacterial 65 kd heat shock protein. Steinhoff, U., *et al.* ..... (A) 139
M. tuberculosis-complex specific T-cell stimulation and DTH reactions induced with a peptide from the 38-kDa protein. Vordermeier, H. M., *et al.* ..... (A) 707
Major proteins of mycobacterial strain ICRC and *M. leprae* identified by antibodies in sera from leprosy patients and their contacts. Chiplunkar, S. V., *et al.* ..... (A) 301
Mapping of T helper cell epitopes by using peptides spanning the 19-kDa protein of *M. tuberculosis*: evidence for unique and shared epitopes in the stimulation of antibody and delayed-type hypersensitivity. Ashbridge, K. R., *et al.* ..... (A) 314
Modulation of expression of delayed hypersensitivity by mycobacterial antigen-85 fibronectin-binding proteins. Godfrey, H. P., *et al.* ..... (A) 682
Molecular and immunological analysis of a fibronectin-binding protein antigen secreted by *M. leprae.* Thole, J. E. R., *et al.* ..... (A) 312
Monoclonal antibody epitopes of mycobacterial 65-kD heat-shock protein defined by epitope scanning. Hajeer, A. H., *et al.* ..... (A) 683
Mycobacteria and human heat shock protein-specific cytotoxic T lymphocytes in rheumatoid synovial inflammation. Li, S.-G., *et al.* ..... (A) 324

Mycobacterial heat-shock proteins as carrier molecules. 2. The use of the 70-kDa mycobacterial heat-shock protein as carrier for conjugated vaccines can circumvent the need for adjuvants and bacillis-Calmette-Guérin priming. Barrios, C., *et al.* ..... (A) 695
Mycobacterial protein antigens: a compilation. Young, D. B., *et al.* ..... (A) 312
Peptide recognition, T-cell receptor usage and HLA restriction elements of human heat-shock protein (hsp)-60 and mycobacterial 65-kDa hsp-reactive T-cell clones from rheumatoid synovial fluid. Quayle, A. J., *et al.* ..... (A) 684
Preliminary study of cellular immunity to *M. leprae* protein in contacts and leprosy patients. Rada S., E. M., *et al.* ..... (O) 189
Prevention of adjuvant arthritis in rats by nonapeptide from the 65-kDa mycobacterial heat shock protein: specificity and mechanism. Yang, X.-D., *et al.* ..... (A) 331
Protection of mice from *M. leprae* infection by T cells and protein vaccines. Gelber, R. H., *et al.* ..... (A) 715
Protein antigens of mycobacteria studied by quantitative immunologic techniques. Harboe, M., *et al.* ..... (A) 304
Purification and partial characterization of a penicillin-binding protein from *M. smegmatis.* Basu, J., *et al.* ..... (A) 690
Recognition of *M. leprae* recombinant 18-kDa proteins in leprosy. Hussain, R., *et al.* (O) 368
Sequence and immunogenicity of the 70-kDa heat shock protein of *M. leprae.* McKenzie, K. R., *et al.* ..... (A) 136
Sero-Immunoreactivity of cloned protein antigens of *M. leprae.* Khan, M. B., *et al.* ...(O) 195
Serological reactivity to *M. bovis* protein antigens in cattle. Fifis, T., *et al.* ..... (A) 319
Serology and leprosy: immunoassays comparing immunoglobulin G antibody responses to 28- and 30-kilodalton proteins purified from *M. bovis.* Pessolani, M. C. V., *et al.* (A) 136
Soluble CD4 suppress the antigen driven proliferative response of certain T cell clones specific for mycobacteria and for peptides by monoclonal heat shock proteins. Gidlund, M., *et al.* ..... (A) 507
T-cell responses of leprosy patients and healthy contacts toward separated protein antigens of *M. leprae.* Gulle, H., *et al.* ..... (O) 44
The 14,000-molecular-weight antigen of *M. tuberculosis* is related to the alpha-crystallin family of low-molecular-weight heat shock proteins. Verbon, A., *et al.* ..... (A) 309
The antibody repertoire to proteins of *M. leprae*: genetic influences at the antigen and epitope level. Adeleye, T. A., *et al.* ..... (A) 679
The significance of proteins actively secreted by *M. tuberculosis* in relation to immunity and complications of mycobacterial diseases. Harboe, M. ..... (SS) 470
The variable C-terminal region of the *M. leprae* 70-kilodalton heat shock protein is the target for humoral immune responses. Davenport, M. P., *et al.* ..... (A) 302
Use of synthetic peptides corresponding to sequences of *M. leprae* proteins to study delayed-type hypersensitivity response in sensitized guinea pigs. Estrada-G., I. C. E., *et al.* ..... (O) 18
Vaccination of mice with soluble protein fraction of *M. leprae* provides consistent and long-term protection against *M. leprae* infection. Gelber, R. H., *et al.* ..... (A) 303

Prothionamide,
Does isoniazid increase the hepatotoxicity of the combination prothionamide-dapsone? Isoprodian Study Group. ..... (O) 536

Psoriasis,
Leprosy and psoriasis occurring together. Nigam, P. K., *et al.* ..... (A) 126

Psychosocial,
[Psychopathological aspects in Hansen's disease.] Baconcini, C. ..... (A) 125
Psychosocial aspects of deformed leprosy patients undergoing surgical correction. Ramanathan, U., *et al.* ..... (A) 151
The explanatory model interview catalogue (EMIC)—contribution to crosscultural research methods from a study of leprosy and mental health. Weiss, M. G., *et al.* ..... (A) 678

Puerto Rico,
Leprosy in Puerto Rico: a decade later. Almodovar, P. I. and Figueroa, J. ..... (A) 147

Rat(s),
Effect of antileprosy drugs on superoxide anion production by rat peritoneal macrophage with special reference to light exposed clofazimine. Sahu, A., *et al.* ..... (A) 123

In vivo effects of anti-leprosy drugs on the rat peritoneal macrophages and lymphocyte subpopulations. Sahu, A., *et al.* ..... (A) 686
Inhibition of dapsone-induced methaemoglobinaemia by cimetidine in the presence of thrimethoprim in the rat. Coleman, M. D., *et al.* ..... (A) 295

Reaction, leprosy,
[A leprosy reaction involving the esophagus and the larynx.] Alvardo, M. and Saul, A. (A) 298
[Acute uveitis in the course of reversal reactions.] Spindler, E., *et al.* ..... (A) 129
Leprosy in reaction: a medical emergency. Malin, A. S., *et al.* ..... (A) 126
[Leprosy reaction in Lucio's phenomenon; treatment with griseofulvin.] Ramirez, M. M. ..... (A) 299
Occurrence of reactions, their diagnosis and management in leprosy patients treated with multidrug therapy; experience in the leprosy control program of the All Africa Leprosy and Rehabilitation Training Center (ALERT) in Ethiopia. Becx-Bleumink, M. and Berhe, D. ..... (O) 173
Reactive oxygen intermediates in the phagocytes from leprosy patients: correlation with reactional states and variation drug treatment. Santos, D. O., *et al.* ..... (C) 92
Resolution of type 1 reaction in multibacillary Hansen's disease as a result of treatment with cyclosporine. Frankel, R. I., *et al.* ..... (O) 8
Risk factors for type-1 reactions in borderline leprosy patients. Roche, P. W., *et al.* ..... (A) 128
Serum tumor necrosis factor and interleukin 1 in leprosy and during lepra reactions. Parida, S. K., *et al.* ..... (A) 306
Soluble interleukin-2 receptors: levels in leprosy, and during and after type 1 (lepra) and type 2 (ENL) reactions. Sehgal, B. N., *et al.* ..... (A) 138
Subcorneal pustular dermatosis in type 1 lepra reaction. Pavithran, K. ..... (C) 89
Sulpride and type II reaction. Salafia, A. and Menezes, M. ..... (A) 128

Rehabilitation,
Aspects of rehabilitation in leprosy. Gilbody, J. S. ..... (E) 608
Community-based rehabilitation: an evaluation study. Gershon, W. and Srinivasan, G. R. ..... (A) 517

Relapse(s),
Follow-up of multibacillary leprosy patients using a phenolic glycolipid-I-based ELISA. Do increasing ELISA-values after discontinuation of treatment indicate relapse? Chin-A-Lien, R., *et al.* ..... (A) 507
Relapses among leprosy patients treated with multidrug therapy: experience in the leprosy control program of the All Africa Leprosy and Rehabilitation Training Center (ALERT) in Ethiopia; practical difficulties with diagnosing relapses; operational procedures and criteria for diagnosing relapses. Becx-Bleumink, M. ..... (O) 421
Relapses in multibacillary leprosy patients after stopping treatment with rifampin-containing combined regimens. Marchoux Chemotherapy Study Group. ..... (O) 525
Risk of relapse among non-lepromatous patients released from treatment after dapsone monotherapy. Pandian, T. D., *et al.* ..... (A) 122
Study of the characteristics and causes of relapse amongst leprosy cases in an urban area (Calcutta). Saha, S. P. and Das, K. K. ..... (A) 498

Rifampin,
Abnormal overnight dexamethasone suppression test in subjects receiving rifampin therapy. Kyriazopoulou, V. and Vagenakis, A. G. ..... (A) 677
Activity *in vitro* of rifabutin, FCE 22807, rifapentine, and rifampin against *M. microti* and *M. tuberculosis* and their penetration into mouse peritoneal macrophages. Dhillon, J. and Mitchison, D. A. ..... (A) 319
Antagonism between isoniazid and the combination pyrazinamide-rifampin against tuberculosis infection in mice. Grosset, J., *et al.* ..... (A) 320
Automated high-performance liquid chromatographic method for the determination of rifampicin in plasma. Swart, K. J. and Papgis, M. ..... (A) 503
Bactericidal activities of single or multiple doses of various combinations of new antileprosy drugs and/or rifampin against *M. leprae* in mice. Ji, B., *et al.* ..... (O) 556
Chemoprophylaxis of leprosy with a single dose of 25 mg per kg rifampin in the southern Marquesas; results after four years. Cartel, J.-L., *et al.* ..... (O) 416

Combined chemotherapy including rifabutin for rifampicin and isoniazid resistant pulmonary tuberculosis. Pretet, S., *et al.* ..... (A) 705
Comparative spectrophotometric analysis of rifampicin by chelate formation and charge-transfer complexation. Galal, S. M., *et al.* ..... (A) 500
Displacement of rifampicin bound to serum proteins by addition of levamisole. Perez Gallardo, L., *et al.* ..... (A) 677
Disseminated intravascular coagulopathy associated with rifampicin. Ip, M., *et al.* ..... (A) 322
How effective is monthly rifampin? Almeida, J. G. ..... (C) 81
Intraocular penetration of rifampin in humans. Outman, W. R., *et al.* ..... (A) 677
Intravascular hemolysis and acute renal failure following intermittent rifampin therapy. Gupta, A., *et al.* ..... (O) 185
[Panteleeva—effectiveness of a liposomal form of rifampicin in the treatment of experimental mouse tuberculosis.] Yu, N., *et al.* ..... (A) 709
Relapses in multibacillary leprosy patients after stopping treatment with rifampin-containing combined regimens. Marchoux Chemotherapy Study Group. ..... (O) 525
Role of rifampin and clofazimine ointments in the treatment of leprosy. Venkateswarlu, B., *et al.* ..... (E) 269
Severe thrombocytopenia and intermittent use of rifampin. Nishioka, S. de A., *et al.* ..... (O) 273
The susceptibility testing of 13 strains of *M. leprae* to rifampicin and the determination of minimal effective dosage. Wang, H., *et al.* ..... (A) 123
Treatment of early rheumatoid arthritis with rifampicin. Cox, N. L., *et al.* ..... (A) 318
Update on rifampin drug interactions. Bocherding, S. M., *et al.* ..... (A) 295

Rifamycin,
Chemotherapeutic efficacy of a newly synthesized benzoxazinorifamycin, KRM-1648, against *M. avium* complex infection induced in mice. Tomioka, H., *et al.* ..... (A) 297
In vitro and *in vivo* antileprosy activities of benzoxazinorifamycin (KRM-1648) and clarithromycin. Saito, H., *et al.* ..... (A) 723

Russia, (see **Commonwealth of Independent States),**

Rwanda,
Pulmonary tuberculosis in Kigali, Rwanda—impact of human immunodeficiency virus infection on clinical and radiographic presentation. Batungwanayo, J., *et al.* ..... (A) 696

Sarcoidosis,
A search for mycobacterial DNA in granulomatous tissues from patients with sarcoidosis using the polymerase chain reaction. Bocart, D., *et al.* ..... (A) 697
Detection of mycobacterial DNA in sarcoidosis and tuberculosis with polymerase chain reaction. Saboor, S. A., *et al.* ..... (A) 326
Detection of mycobacterial rRNA in sarcoidosis with liquid-phase hybridisation. Mitchell, I. C., *et al.* ..... (A) 325

Screening,
Double-blind evaluation of BACTEC and Buddemeyer-type radiorespirometric assays for *in vitro* screening of antileprosy agents. Franzblau, S. G., *et al.* ..... (A) 513
Screening gene expression libraries for epitopes recognized in *M. leprae* by mouse T cells. Villarreal-Ramos, B., *et al.* ..... (A) 688
Suitability of a skin-smear examination needle for leprosy screening by PCR. Sugita, Y., *et al.* ..... (C) 658

Senegal,
L'Institut de Leprologie Appliquee de Dakar troisieme cours annuel. ..... (B) 494

Serodiagnosis,
Assessment of the diagnostic value of the native PGLTB1, its synthetic neoglycoconjugate PGLTB0 and the sulfolipid IV antigens for the serodiagnosis of tuberculosis. Chanteau, S., *et al.* ..... (O) 1
Comparison of bis-di-octadecylamide of trehalose dicarboxylic acid (BDA.TDA) with glycolipid SL-IV as ELISA antigens for the serodiagnosis of leprosy. Laszlo, A., *et al.* (O) 376
Does previous BCG vaccination interfere with the serodiagnosis of tuberculosis using *M. tuberculosis*-specific glycolipid antigens? Salem, J. I., *et al.* ..... (C) 87

Evaluation of MLPA test for the serodiagnosis of leprosy. Dhandayuthapani, S., *et al.* (C) 84
Evaluation of synthetic pseudo cord-factor-like glycolipids for the serodiagnosis of tuberculosis. Laszlo, A., *et al.* (A) 702
Molecular cloning of the alpha-antigen gene from *M. leprae* and its application to serodiagnosis of leprosy. Makino, M. and Suzuki, Y. (A) 721
Relationships between titers of antibodies immunoreacting against glycolipid antigens from *M. leprae* and *M. tuberculosis,* the Mitsuda and Mantoux reactions, and bacteriological loads: implications in the pathogenesis, epidemiology and serodiagnosis of leprosy and tuberculosis. David, H. L., *et al.* (O) 208
Synthesis of the trisaccharide-protein conjugate of the phenolic glycolipid of *M. tuberculosis* for the serodiagnosis of tuberculosis. Fujiwara, T. (A) 155

Serum,
An appraisal of enzyme linked immunosorbent assay (ELISA) and serum antibody competition test (SACT) in leprosy. Kanchana, M. A., *et al.* (A) 304
Avidin-biotin immunoblotting studies on reactivity of leprosy sera with *M. leprae* antigen. Patil, S. A., *et al.* (C) 280
Detection of antibodies to human nerve antigens in sera from leprosy patients by ELISA. Park, J. Y., *et al.* (A) 307
Detection of high titres of *Toxoplasma gondii* antibodies in sera of patients with leprosy in Pakistan. Hussain, R., *et al.* (A) 683
Enzyme linked immunosorbent assay of a 12-kDa protein of *M. leprae* with sera from leprosy patients. Navalkar, R. G., *et al.* (O) 382
Expression of a common idiotype PR4 in the sera of patients with leprosy. Zumla, A., *et al.* (A) 141
Humoral response to nerve glycolipid antigen in sera of leprosy patients. Sahasrabudhe, R. V., *et al.* (C) 488
Immunoglobulin-A (IgA) and IgG serum antibodies to mycobacterial antigens in Crohn's disease patients and their relatives. Wayne, L. G., *et al.* (A) 707
Immunoreactivity of a mammalian liver component with leprosy sera. Despande, R. G., *et al.* (A) 681
Major proteins of mycobacterial strain ICRC and *M. leprae* identified by antibodies in sera from leprosy patients and their contacts. Chiplunkar, S. V., *et al.* (A) 301
Quantitation of the soluble E-receptor of human T lymphocytes by rocket electrophoresis in the serum of patients with lepromatous and tuberculoid leprosy. Longo, I. M., *et al.* (A) 135
Serum tumor necrosis factor and interleukin 1 in leprosy and during lepra reactions. Parida, S. K., *et al.* (A) 306
Use of serum antibody and lysozyme levels for diagnosis of leprosy and tuberculosis. Near, K. A. and Lefford, M. J. (A) 306

Skin,
Hyperkeratotic and verrucous skin lesions on lower extremities of leprosy patients. Patki, A. H. and Mehta, J. M. (A) 506
Immune complexes and antibody levels in blisters over human leprosy skin lesions with or without erythema nodosum leprosum. Scollard, D. M., *et al.* (A) 510
[Immunohistochemical study of leprosy skin lesions using S-100 protein and alpha-antichymotrypsin.] Ye, F., *et al.* (A) 689
Skin, soft tissue, and bone infections due to *M. chelonae chelonae*—importance of prior corticosteroid therapy, frequency of disseminated infections, and resistance to oral antimicrobials other than clarithromycin. Wallace, R. J., *et al.* (A) 707
Species-specific assessment of *M. leprae* in skin biopsies by *in situ* hybridization and polymerase chain reaction. Arnoldi, J., *et al.* (A) 689
Suggested new technique for skin biopsy under field conditions. Chaturvedi, R. M. and Kartikeyan, S. (A) 677

Skin smear(s),
Is bacteriological examination by skin smear necessary in all paucibacillary leprosy patients in mass control programmes? Rao, P. S., *et al.* (A) 127
Suitability of a skin-smear examination needle for leprosy screening by PCR. Sugita, Y., *et al.* (C) 658

Skin test(s),
Blastogenic response with autologous plasma and Mitsuda's reaction in leprosy patients and their unaffected sibs. Foss, N. T., *et al.* ..... (A) 132
Effect of skin test with *M. leprae* soluble antigen on reaction to a subsequent test with the same antigen. Gupte, M. D., *et al.* ..... (O) 54
Lepromin reaction in patients with falciparum malaria. Tin-Shwe and Pe-Than-Myint. (A) 688
Relationships between titers of antibodies immunoreacting against glycolipid antigens from *M. leprae* and *M. tuberculosis,* the Mitsuda, and Mantoux reactions, and bacteriological loads: implications in the pathogenesis, epidemiology and serodiagnosis of leprosy and tuberculosis. David, H. L., *et al.* ..... (O) 208

Spain,
Fontilles cursos internacional de leprologia. ..... (N) 292

Stain(s),
Acid-fast and H & E stainings can be combined better than in the TRIFF method. Miko, T. L. and Lucas, S. G. ..... (A) 136
Assessing the viability of *M. leprae* by the fluorescein diacetate/ethidium bromide staining technique. Palomino, J. C., *et al.* ..... (A) 144
Fluorescein diacetate and ethidium bromide staining to determine the viability of *M. smegmatis* and *Escherichia coli.* Jayapal, V., *et al.* ..... (A) 143
Refractile mycobacteria in Ramanowsky-stained bone marrow smears; a comparison of acid-fast-stained tissue sections and Romanowsky-stained smears. Torlakovic, E., *et al.* ..... (A) 328
Significance of neither green nor red (NGR) bacilli in FDA-EB staining. Bhatia, V. N. and Mirmaladevi, B. ..... (A) 142

Subclinical,
[A study of subclinical infection with *M. leprae,* the factors influencing the subclinical infection.] Shu, H.-W., *et al.* ..... (A) 139
Immunoepidemiological studies on subclinical infection in leprosy. I. Clinical and immunological findings in schoolchildren and adults in Okinawa. Abe, M., *et al.* ..... (A) 692

Sulfone(s),
Anticonvulsive effect of dapsone (4,4′-diaminodiphenyl sulfone) on amygdala-kindled seizures in rats and cats. Hamada, K., *et al.* ..... (A) 296

Superoxide,
Effect of antileprosy drugs on superoxide anion production by rat peritoneal macrophage with special reference to light exposed clofazimine. Sahu, A., *et al.* ..... (A) 123

Switzerland,
Report of the First Meeting of the WHO Working Group on Leprosy Control. ..... (N) 114
TDR and IDRC prize for a paper on "Women and Tropical Diseases." ..... (B) 495
TDR needs health education materials. ..... (N) 671
TDR regional linkage grants for research training. ..... (N) 671
TDR Steering Committee deadlines. ..... (N) 673

Tanzania,
Hypoadrenalism in patients with pulmonary tuberculosis in Tanzania: an undiagnosed complication? Mugusi, F., *et al.* ..... (A) 158

Thalidomide,
Thalidomide for systemic lupus erythematosus. Bessis, D., *et al.* ..... (A) 518
Thalidomide for the treatment of chronic graft-versus-host disease. Vogelsang, G. B., *et al.* ..... (A) 330
Thalidomide treatment of chronic graft-versus-host disease. Henry, D., *et al.* ..... (A) 156
Thalidomide's effectiveness in erythema nodosum leprosum is associated with a decrease in CD4+ cells in the peripheral blood. Shannon, E. J., *et al.* ..... (A) 510

The Leprosy Mission (TLM),
Paul Brand new President of TLM International. Hastings, R. C. ..... (N) 673

Therapy (see also **Chemotherapy),**
Abnormal overnight dexamethasone suppression test in subjects receiving rifampin therapy. Kyriazopoulou, V. and Vagenakis, A. G. ..... (A) 677

Ambulatory treatment of multibacillary leprosy with a regiment of 8 months duration. Pattyn, S. R., *et al.* ..... (A) 502
Clarithromycin-ciprofloxacin-amikacin for therapy of *M. avium-M. intracellulare* bacteremia in patients with AIDS. Delalla, R., *et al.* ..... (A) 699
Immunological upgrading with combined immunotherapy and chemotherapy in a lepromatous leprosy patient: a case report. Zaheer, S. A., *et al.* ..... (A) 130
[Influence of tuberculin therapy on the immunologic parameters in adolescents with pulmonary tuberculosis.] Knoring, B. E., *et al.* ..... (A) 323
Intravascular hemolysis and acute renal failure following intermittent rifampin therapy. Gupta, A., *et al.* ..... (O) 185
Patient treatment compliance in leprosy; a critical review. Vadher, A. and Lalljee, M. (E) 587
Prevalence of dementia amongst elderly Japanese with leprosy—apparent effect of chronic drug therapy. McGeer, P. L., *et al.* ..... (A) 678
Relapses in leprosy patients after release from dapsone monotherapy; experience in the leprosy control program of the All Africa Leprosy and Rehabilitation Training Center (ALERT) in Ethiopia. Becx-Bleumink, M. ..... (O) 161
Rick of relapse among non-lepromatous patients released from treatment after dapsone monotherapy. Pandian, T. D., *et al.* ..... (A) 122
Treatment of multibacillary leprosy with a regimen of 13 weeks duration. Pattyn, S. R., *et al.* ..... (A) 502

Throat,
[A leprosy reaction involving the esophagus and the larynx.] Alvardo, M. and Saul, A. (A) 298

Tissue(s),
A search for mycobacterial DNA in granulomatous tissues from patients with sarcoidosis using the polymerase chain reaction. Bocart, D., *et al.* ..... (A) 697
Comparison of polymerase chain reaction technique with other methods for detection of *M. leprae* in tissues of wild nine-banded armadillos. Job, C. K., *et al.* ..... (A) 145
Improved method for purification of *M. leprae* from armadillo tissues. Rodde, C., *et al.* ..... (C) 277
M. paratuberculosis DNA in Crohn's disease tissue. Sanderson, J. D., *et al.* ..... (A) 705
Phospholipase activity of *M. leprae* harvested from experimentally infected armadillo tissue. Wheeler, P. R. and Ratledge, C. ..... (A) 144
Refractile mycobacteria in Ramanowsky-stained bone marrow smears; a comparison of acid-fast-stained tissue sections an Romanowsky-stained smears. Torlakovic, E., *et al.* ..... (A) 328

Training,
A multi-media approach to health education. Friedericks, R. C. ..... (A) 118
An application of the LePSA methodology for health education in leprosy. Lennon, J. L. and Coombs, D. W. ..... (A) 505
Fontilles cursos internacional de leprologia. ..... (N) 292
Heiser Program for Research in Leprosy and Tuberculosis 1993. ..... (N) 496
IAL-sponsored 1991 training workshop on foot care. ..... (N) 112
L'Institut de Leprologie Appliquee de Dakar troisieme cours annuel. ..... (B) 494
Relationship problems between doctor and paramedical professionals working in leprosy with reference to a possible solution. Premkumar, R. and Dave, S. ..... (A) 498
TDR regional linkage grants for research training. ..... (N) 671
The leprosy game; a health education tool. Devasundaram, J. K. ..... (C) 91
[The level of knowledge about leprosy among university students.] Ramirez-Soltero, S., *et al.* ..... (A) 119
The private GP and leprosy: a study. Uplekar, M. W. and Cash, R. A. ..... (A) 129

Transmission,
Can sandflies be the vector for leprosy? Sreevatsa, *et al.* ..... (C) 94
Imported leprosy in the United States, 1987 through 1988—an epidemic without secondary transmission. Mastro, T. D., *et al.* ..... (A) 694

Trial(s),
A clinical trial of minocycline in lepromatous leprosy. Gelber, R. H., *et al.* ..... (A) 500
Activity of clarithromycin against *M. avium* infection in patients with the acquired immune deficiency syndrome; a controlled clinical trial. Dautzenberg, B., *et al.* ..... (A) 153

Histopathological monitoring of an immunotherapeutic trial with *Mycobacterium w.* Mukherjee, A., *et al.* ..... (O) 28
Immunoprophylactic trial with combined *M. leprae*/BCG vaccine against leprosy: preliminary results. Convit, J., *et al.* ..... (A) 301
Leprosy clinical trials of sparfloxacin and clarithromycin. Franzblau, S. G., *et al.* ..... (A) 715
Short-term trial of clofazimine in previously untreated lepromatous leprosy. Jamet, P., *et al.* ..... (O) 542
Water-soluble complexes of palmitic acid and palmitates for metabolic studies and cultivation trials of *M. leprae.* Kato, L., *et al.* ..... (C) 105

Trinidad,
Attitudes toward leprosy in the outpatient population of dermatology clinics in Trinidad. Suite, M. and Gittens, C. ..... (A) 499

Tuberculin,
[Influence of tuberculin therapy on the immunologic parameters in adolescents with pulmonary tuberculosis.] Knoring, B. E., *et al.* ..... (A) 323

Tuberculoid leprosy,
An attempt to produce experimental tuberculoid leprosy in the nine-banded armadillo. Job, C. K., *et al.* ..... (A) 145
Chromoblastomycosis masquerading as tuberculoid leprosy. Pavithran, K. ..... (C) 657
Quantitation of the soluble E-receptor of human T lymphocytes by rocket electrophoresis in the serum of patients with lepromatous and tuberculoid leprosy. Longo, I. M., *et al.* ..... (A) 135

Tuberculosis,
A contribution to the history of tuberculosis and leprosy in 19th century Norway. Wood, S. R. ..... (A) 120
A field evaluation of serological and cellular diagnostic tests for bovine tuberculosis. Wood, P. R., *et al.* ..... (A) 708
[A thermoindicative nasal test for detecting allergy to antituberculosis drugs.] Buseva, T. A. and Koryakin, V. A. ..... (A) 152
Antagonism between isoniazid and the combination pyrazinamide-rifampin against tuberculosis infection in mice. Grosset, J., *et al.* ..... (A) 320
Antibody responses to the 18-kDa protein of *M. leprae* in leprosy and tuberculosis patients. Roche, P. W., *et al.* ..... (O) 201
[Antituberculosis care organization under conditions of a new economic system.] Kucherov, A. L. ..... (A) 158
Antituberculous agents. van Scoy, R. E. and Wilkowske, C. J. ..... (A) 329
[Antituberculous antibodies in enzyme immunoassay in relation to the efficacy of tuberculosis chemotherapy.] Chukanov, V. I., *et al.* ..... (A) 131
Assessment of the diagnostic value of the native PGLTB1, its synthetic neoglycoconjugate PGLTB0 and the sulfolipid IV antigens for the serodiagnosis of tuberculosis. Chanteau, S., *et al.* ..... (O) 1
Association of increased mycobacterium growth inhibitory factor with antituberculous immunity. Chandrasekhar, S. and Perumal, V. K. ..... (A) 152
Bacteriostatic and bactericidal activity of anti-tuberculosis drugs against *M. tuberculosis, M. avium, M. intracellulare* complex and *M. kansasii* in different growth phases. Yamori, S., *et al.* ..... (A) 331
CD30 expression by peripheral blood monocytes and hepatic macrophages in a child with miliary tuberculosis. Epstein, M. L., *et al.* ..... (A) 699
Combined chemotherapy including rifabutin for rifampicin and isoniazid resistant pulmonary tuberculosis. Pretet, S., *et al.* ..... (A) 705
Detection of mycobacterial DNA in sarcoidosis and tuberculosis with polymerase chain reaction. Saboor, S. A., *et al.* ..... (A) 326
Does previous BCG vaccination interfere with the serodiagnosis of tuberculosis using *M. tuberculosis*-specific glycolipid antigens? Salem, J. I., *et al.* ..... (C) 87
Efficacy of BCG vaccine against leprosy and tuberculosis in Malawi. Ponnighaus, J. M., *et al.* ..... (A) 307

Evaluation of lipoarabinomannan for the serological diagnosis of tuberculosis. Sada, E., *et al.* ..... (A) 159
Evaluation of synthetic pseudo cord-factor-like glycolipids for the serodiagnosis of tuberculosis. Laszlo, A., *et al.* ..... (A) 702
Genetics and resistance to tuberculosis—could resistance be enhanced by genetic engineering. Stead, W. W. ..... (A) 706
Heiser Program for Research in Leprosy and Tuberculosis 1993 ..... (N) 496
Heterogeneity of the repertoire of T cells of tuberculosis patients and healthy contacts to *M. tuberculosis* antigens separated by high-resolution techniques. Schoel, B., *et al.* (A) 326
High antibody levels to the mycobacterial fibronectin-binding antigen of 30-31 kD in tuberculosis and lepromatous leprosy. Espitia, C., *et al.* ..... (A) 303
Humoral responses against the 85A and 85B antigens of *M. bovis* BCG in patients with leprosy and tuberculosis. Van Vooren, J. P., *et al.* ..... (A) 688
Hypoadrenalism in patients with pulmonary tuberculosis in Tanzania: an undiagnosed complication? Mugusi, F., *et al.* ..... (A) 158
[Immunogenetic grounds for the development of local forms of primary tuberculosis in children.] Vasilyev, A. V. and Dovgalyuk, I. F. ..... (A) 329
Increased proportions of peripheral blood gamma/delta T cells in patients with pulmonary tuberculosis. Ito, M., *et al.* ..... (A) 701
[Influence of tuberculin therapy on the immunologic parameters in adolescents with pulmonary tuberculosis.] Knoring, B. E., *et al.* ..... (A) 323
Neopterin in tuberculous and neoplastic pleural fluids. Baganha, M. F., *et al.* ..... (A) 299
[Panteleeva—effectiveness of a liposomal form of rifampicin in the treatment of experimental mouse tuberculosis.] Yu, N., *et al.* ..... (A) 709
[Pathomorphological evaluation of therapeutic effect of mycobacteriophages in tuberculosis.] Zemskova, Z. S. and Dorozhkova, I. R. ..... (A) 331
Prevention and control of tuberculosis among homeless persons; recommendations of the Advisory Council for the Elimination of Tuberculosis. ..... (A) 518
Prevention and control of tuberculosis in U.S. communities with at-risk minority populations; recommendations of the Advisory Council for the Elimination of Tuberculosis. ..... (A) 519
Pulmonary eosinophilia in pulmonary tuberculosis. Vijayan, V. K., *et al.* ..... (A) 707
Pulmonary tuberculosis in Kigali, Rwanda—impact of human immunodeficiency virus infection on clinical and radiographic presentation. Batungwanayo, J., *et al.* ..... (A) 696
Radiological features of pulmonary tuberculosis in patients infected with human immunodeficiency virus. Noronha, D., *et al.* ..... (A) 158
Recent trends in the epidemiology of tuberculosis and leprosy. Smith, P. G. ..... (A) 517
Reduced anti-*M. tuberculosis* antibody response in tuberculosis patients with acquired immunodeficiency syndrome. Figueiredo, J. F. A. and Machado, A. A. ..... (A) 700
Relationships between titers of antibodies immunoreacting against glycolipid antigens from *M. leprae* and *M. tuberculosis,* the Mitsuda and Mantoux reactions, and bacteriological loads: implications in the pathogenesis, epidemiology and serodiagnosis of leprosy and tuberculosis. David, H. L., *et al.* ..... (O) 208
Role of TNFalpha in the pathogenesis of leprosy and tuberculosis. Kaplan, G. ..... (A) 719
Serological response to purified mycobacterial phosphatidylinositol mannoside in healthy controls and in patients with tuberculosis and leprosy. Mullins, R. J., *et al.* ..... (O) 353
Synthesis of the trisaccharide-protein conjugate of the phenolic glycolipid of *M. tuberculosis* for the serodiagnosis of tuberculosis. Fujiwara, T. ..... (A) 155
The use of the polymerase chain reaction test in the diagnosis of tuberculosis. van Helden, P. D., *et al.* ..... (A) 329
Time course of anti-SL-IV immunoglobulin-G antibodies in patients with tuberculosis and tuberculosis-associated AIDS. Martin-Casabona, N., *et al.* ..... (A) 324
Tuberculosis morbidity in the United States: final data, 1990. Jereb, J. A., *et al.* ..... (A) 322
[Use of dimephosphone in a pathogenetic therapy of experimental tuberculosis.] Alexandrova, A. E., *et al.* ..... (A) 151
Use of serum antibody and lysozyme levels for diagnosis of leprosy and tuberculosis. Near, K. A. and Lefford, M. J. ..... (A) 306
Vaccination against tuberculosis and leprosy. Kaufmann, S. H. E. and Young, D. B. ..(A) 508

Turkey,
International Leprosy Seminar, Istanbul, Turkey. ....(N) 495

Uganda,
Absence of *M. avium* complex disease in patients with AIDS in Uganda. Morrissey, A. B., *et al.* ....(A) 325

U.K.,
New Director for LEPRA. ....(N) 293
Prevention of Blindness in Leprosy. ....(N) 114
Robert Cochrane Fund for Leprosy. ....(N) 674

Ulcer(s),
Squamous cell carcinoma in chronic ulcers in leprosy: a review of 38 consecutive cases. Richardus, J. H. and Smith, T. C. ....(A) 128

Urine,
Comparison of a urine spot test and blood tests as indicators of patient compliance. Yoder, L. J., *et al.* ....(A) 124
Detection of a *M. leprae* cell wall antigen in the urine of untreated and treated patients. Sharma, V.K., *et al.* ....(A) 511

U.S.A.,
American Association for the Advancement of Science (AAAS). ....(N) 495
Epidemiology of infection by nontuberculosis mycobacteria; *M. avium, M. intracellulare,* and *M. scrofulaceum* in acid, brown-water swamps of the Southeastern United States and their association with environmental variables. Kirschner, R. A., Jr., *et al.* ....(A) 323
Federal funded and private sector sources of HD treatment. ....(N) 114
Frist elected President of ILEP. ....(N) 674
Hansen's disease cases in 1991. ....(N) 114
Heiser Program for Research in Leprosy and Tuberculosis 1993. ....(N) 496
Imported leprosy in the United States, 1987 through 1988—an epidemic without secondary transmission. Mastro, T. D., *et al.* ....(A) 694
International Medical Services for Health (INMED). ....(N) 115
Jacobson new Carville Director. Hastings, R. C. and Goodman, D. D. ....(N) 674
Leprosy in Puerto Rico: a decade later. Almodovar, P. I. and Figueroa, J. ....(A) 147
"The Star" completes 50 years. ....(N) 293
Tuberculosis morbidity in the United States: final data, 1990. Jereb, J. A., *et al.* ....(A) 322
Video available on health workers and blindness prevention in leprosy. ....(N) 115

U.S.S.R. (see **Commonwealth of Independent States),**

Vaccine(s), Vaccination,
Association of HLA antigens with differential responsiveness to *Mycobacterium w* vaccine in multibacillary leprosy patients. Rani, R., *et al.* ....(A) 308
Does Convit vaccine (BCG + *M. leprae*) afford protection against biochemical changes in renal brush border membrane in experimental leprosy? Kohli, M., *et al.* ....(A) 135
Does previous BCG vaccination interfere with the serodiagnosis of tuberculosis using *M. tuberculosis*-specific glycolipid antigens? Salem, J. I., *et al.* ....(C) 87
Efficacy of BCG vaccine against leprosy and tuberculosis in Malawi. Ponnighaus, J. M., *et al.* ....(A) 307
Genetic vaccines against genetically infective macromolecules? Corcos, M. G. ....(C) 659
Immunoprophylactic trial with combined *M. leprae*/BCG vaccine against leprosy: preliminary results. Convit, J., *et al.* ....(A) 301
Mycobacterial heat-shock proteins as carrier molecules. 2. The use of the 70-kDa mycobacterial heat-shock protein as carrier for conjugated vaccines can circumvent the need for adjuvants and bacillis-Calmette-Guérin priming. Barrios, C., *et al.* ....(A) 695
Mycobacterium w vaccine being tried in New Delhi, India. ....(N) 113
Protection of mice from *M. leprae* infection by T cells and protein vaccines. Gelber, R. H., *et al.* ....(A) 715
Resistance of intravenous inoculation of *M. tuberculosis* H37Rv in mice of different inbred strains following immunization with a leprosy vaccine based on *Mycobacterium w.* Singh, I. G., *et al.* ....(A) 146

T-cell responses to fractionated antigens of *Mycobacterium w*, a candidate anti-leprosy vaccine, in leprosy patients. Yadava, A., *et al.* ..... (A) 141
Vaccination against tuberculosis and leprosy. Kaufmann, S. H. E. and Young, D. B. .. (A) 508
Vaccination of mice with a soluble protein fraction of *M. leprae* provides consistent and long-term protection against *M. leprae* infection. Gelber, R. H., *et al.* ..... (A) 303
Vaccines against leprosy. Gupte, M. D. ..... (A) 516

Vanuatu,
Modification of multidrug treatment of leprosy in Vanuatu. Reeve, P. A., *et al.* ..... (C) 655

Vitamin(s),
Effect of indomethacin on the modulation of *M. avium* growth in human macrophages by interferon gamma, retinoic acid and 1,25(OH)2-vitamin-D3. DeSousa, J. P. C., *et al.* ..... (A) 681
The protective effect of vitamin E on the hemolysis associated with dapsone treatment in patients with dermatitis herpetiformis. Prussick, R., *et al.* ..... (A) 297

World Health Organization (WHO),
Report of the First Meeting of the WHO Working Group on Leprosy Control. ..... (N) 114
WHO Model Prescribing Information; Drugs Used in Mycobacterial Diseases. ..... (B) 117

Zambia,
Clinical observations on leprosy patients with HIV-1 infection in Zambia. Vreeburg, A. E. M. ..... (A) 506